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Abstract 
 
Osteoarthritis (OA) is a common disease characterised by the progressive loss of the 
articular cartilage of synovial joints. It is multifactorial and polygenic. Candidate gene-
based association studies and genome-wide association scans (GWAS) have been used 
to identify OA risk alleles with over 10 regions of the human genome so far reported as 
harbouring OA susceptibility.  
Expression quantitative trait loci (eQTLs) demonstrate a correlation between 
gene expression levels and DNA polymorphism, the assumption being that the 
polymorphism resides within a regulatory element of the gene. The functional 
polymorphism can be cis-acting (within or close to the gene) or trans-acting (located a 
distance from the gene).  
It has become apparent for many common diseases that the majority of risk 
alleles are eQTLs rather than polymorphisms that alter amino acid sequences.  
The aim of this thesis was to investigate whether genes proximal to or 
harbouring OA-associated polymorphisms identified by GWAS are subject to cis-
regulation, which could therefore be contributing to the association signal.  
The expression levels of the genes were analysed in joint tissues from OA 
patients who had undergone joint replacement. Overall gene expression was measured 
by quantitative PCR whilst allelic expression was assessed using assays that can 
distinguish mRNA output from each allele of a transcript SNP. The functional effect of 
SNPs was tested in vitro using luciferase reporter assays.  
Expression analysis of genes at the OA-associated chromosome 7q22 locus 
identified HBP1 as the likely target of the OA susceptibility mapping to this region. 
Expression analysis of SMAD3 and GNL3 identified eQTLs active in OA joint tissues 
for both genes, whilst luciferase reporter assays identified two 3´UTR SNPs as potential 
mediators of the SMAD3 eQTL.  
Overall, this thesis demonstrates that OA tissues are subject to a range of 
regulatory elements that can influence disease during development or ageing.   
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Chapter 1: General Introduction 
  
1.1 Introduction to Osteoarthritis 
 
Osteoarthritis (OA) affects nearly 9 million people in the UK, over half of which are 
affected by OA of the knee (1). In 2012 an estimated 2.3 million working days were lost 
to musculoskeletal disorders of the lower limbs, the most common of which is OA (2). 
In the same year, over 200,000 people claimed incapacity or severe disablement benefit 
for musculoskeletal disorders (3) and over 160,000 joint replacement surgeries took 
place (4). As a result of these factors, OA is of considerable economic burden to the 
UK.  
OA is characterised by progressive destruction of articular cartilage, but it affects the 
entire joint, including the synovial membrane, joint capsule, ligaments, muscles, 
tendons and subchondral bone, and can occur at any site but is most common in the 
hand, knee, hip and foot (5). In 2013 it was estimated that 4.71 million people in the UK 
had knee OA, 2.12 million had hip OA, 1.77 million had foot and ankle OA, and 1.56 
had hand and wrist OA (6). The eventual destruction of cartilage results from a failure 
of chondrocytes to maintain a homeostatic balance between matrix synthesis and 
degradation (7). Clinical manifestations of OA include pain, stiffness and impairment of 
joint motion, which lead to disability and finally, the need for joint replacement (5).  
 
1.2 Disease Definition and Diagnosis 
 
OA is not a single disease entity but comprises a heterogeneous group of syndromes 
with differing underlying pathophysiological mechanisms (8). All the tissues of the joint 
are involved in OA (9), although the articular cartilage and the adjacent bone often 
show the most prominent changes (10). OA can be divided into primary and secondary 
forms; primary or idiopathic OA is defined as a condition developing in previously 
undamaged joints in the absence of an apparent triggering event, and secondary OA is 
caused by well-recognised predisposing conditions (10). These conditions include: 
anatomic abnormalities, such as congenital dislocation of the hip; trauma, such as joint 
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fracture; inflammatory disorders, such as septic arthritis; and metabolic disorders, such 
as haemochromatosis (11).  
The epidemiological criteria for OA are based upon radiographically observed 
changes originally described by Kellgren and Lawrence in 1957 (12). The criteria are 
appearance of osteophytes, narrowing of the space between the joint resulting from the 
loss of articular cartilage, subchondral bone sclerosis, and cysts (11, 13-15). Studies 
have shown that there are many asymptomatic people with advanced radiographic OA 
and many others with severe symptoms but minimal pathology, so as the severity of OA 
pathology has little to do with the severity of the symptoms there are no strict diagnostic 
criteria for OA (16). The American College of Rheumatology has produced 
classification criteria based on differentiating OA from other rheumatic diseases, stating 
that ‘anyone over the age of 50 with regional joint pain, short-lasting ‘gelling’ of joints 
and crepitus should be considered to have OA’ (17). The initial clinical diagnosis of OA 
is usually made by general practitioners, predominantly on symptoms of pain, stiffness 
after inactivity, swelling and associated functional impairment (14, 15). Radiography is 
used to define OA for epidemiological studies and is the usual method of diagnosis, 
however inconsistencies in the descriptions of radiographic features of OA have led to 
studies being performed using criteria that are conflicting (11). Magnetic resonance 
imaging (MRI) has the advantage over radiography of being able to image all the 
structures within the OA joint, thereby improving our understanding of the association 
between structural changes and clinical symptoms, but MRI remains largely for use in 
research studies rather than clinical practice (18). Ultrasound has also provided greater 
insight into OA pathology than radiographic methods, although it does not assess 
cartilage surfaces as efficiently as MRI and cannot assess the subchondral bone (19).  
 
1.3 Management and Treatment of OA 
 
Since the relationship between the severity of radiographic changes seen in OA patients 
and the severity of their symptoms is weak, decisions about management of disease are 
usually not made on the severity of the pathology but on the degree of pain, disability 
and distress felt by the individual (16). Current treatments for OA focus on pain relief 
(symptom modifying drugs), rather than treating the cause of the disease (20, 21), since 
as yet there are no licenced treatments that can stop the progression of structural 
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changes within the joint (structure modifying drugs; 18). Current guidelines, set down 
by Osteoarthritis Research Society International (OARSI) and National Institute for 
Health and Care Excellence (NICE) for the treatment of OA, recommend a combination 
of both pharmacological and non-pharmacological treatments (22, 23). Pharmacological 
treatments include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, 
corticosteroid injections and paracetamol. Non-pharmacological treatments include 
physiotherapy, splints, acupuncture and the use of a walking aid or brace (18). Current 
established treatments such as opioids, NSAIDs such as Ibuprofen, and 
Cyclooxygenase-2 (COX-2) inhibitors, are limited by side effects (22, 24), although 
COX-2 inhibitors have fewer gastrointestinal side effects in comparison to Ibuprofen (5, 
16). Due to the adverse side effects of most pain-relieving drugs, there is a distinct lack 
of safe treatments for those with OA pain (18). Another issue facing many symptom-
modifying drugs is their lack of efficacy, as demonstrated by intra-articular 
corticosteroid injections, the effectiveness of which is short-lived (25). Anti-synovial 
analgesic agents and antibodies against tumour necrosis factor (TNF)-α have however 
shown good efficacy for some OA patients (26). In addition to this, Duloxetine, a 
serotonin-noradrenaline reuptake inhibitor also shows a significant improvement in pain 
and function for people with painful knee OA who are already taking NSAIDs (27). 
While the presence of cartilage damage from the earliest stages of OA is undisputed, it 
seems unusual that this should result in pain, as healthy cartilage is aneural (5, 18). A 
number of studies have demonstrated that nerve and vascular in-growth occurs in 
damaged areas of OA cartilage at the osteochondral junction (28), which may explain 
the pain in OA. Increased nerve growth factor (NGF) expression has been observed in 
these vascular channels, and may offer a target for treatment by a novel class of drugs, 
the anti-NGFs, such as Tanezumb, which has demonstrated good analgesic efficacy and 
improvement in function in a study of people with knee OA (29).  
Glucosamine and chondroitin are commonly used dietary supplements that are 
claimed to reduce the symptoms and retard the progression of OA (30). Another 
naturally occurring agent is hyaluronic acid, a glycosaminoglycan that makes up the 
viscous component of synovial fluid and acts as a lubricant and shock absorber (16). 
Injections of hyaluronic acid have been shown to improve the biomechanical function in 
OA (31).  
Although there are currently no drugs available with proven structure-modifying 
efficacy in OA (18, 21, 32) there has been some research using Strontium ranelate, an 
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osteoporosis treatment, which can reduce bone resorption as well as increasing bone 
formation, and has been shown to cause a significant reduction in both joint space 
narrowing and pain (33, 34). Another study looking at Calcitonin, a thyroid hormone, in 
knee OA, showed improved knee function and increased cartilage volume compared to 
a placebo, although side effects were common (35).  
Of the non-pharmacological treatments for OA, exercise is one of the most 
frequently recommended (16). Muscle strengthening and aerobic exercises have both 
been shown to lead to a moderate decrease in pain (36, 37). Other non-pharmacological 
approaches for treating cartilage damage, such as micro-fractures, abrasions or 
chondrocyte implantation require a regenerative response from the patient, and healing 
is often incomplete leaving cartilage susceptible to the degradation processes that lead 
to OA (38). One surgical treatment, joint distraction, has been effectively applied to 
treat OA. Joint distraction is based upon the theory that OA cartilage has some 
reparative activity when the damaged cartilage is no longer subject to mechanical 
loading (39). The joint is unloaded using an external frame which partially transfers the 
load through the frame rather than the bone, eliminating mechanical contact between the 
degenerating cartilage surfaces, preventing further wear and tear, whilst the pressure 
changes in the synovial fluid essential for the nutrition of cartilage are maintained (39, 
40). Joint distraction has been used successfully in ankle OA, demonstrating decreased 
subchondral bone density that persisted for at least 2 years (41), and has been shown to 
reverse tissue structure damage in patients with knee OA who demonstrated decreased 
exposed bone area and joint space width (JSW) due to an increase in cartilage thickness 
(42).  The side effects of joint distraction are stiffness of the joint, and the potential for 
pain or infection at the points at which the frame is affixed (43).  
At the end stage of OA replacement of joints by endoprotheses is the last 
possible curative approach (20). However, there are many problems with total joint 
replacements including morbidity, and the need for revisions, resulting in an estimated 
15% of patients being unsatisfied following joint replacement (44). Despite all the 
available therapies many people treated for OA still live with significant symptoms (5, 
18).  
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1.4 Normal Structure and Function of the Synovial Joint 
 
The function of the synovial joint is to facilitate articulation where two skeletal 
elements meet (45).  Synovial joints are made up of articular cartilage, subchondral 
bone, ligament, tendon, synovial fluid, and fat pad and meniscus in the knee, enclosed 
in a sleeve of dense fibrous connective tissue known as the joint capsule (46). The ends 
of the opposing skeletal elements at the synovial joint are covered with a layer of 
articular cartilage that provides a low-friction, wear-resistant surface for load-bearing 
and smooth movement of the joints (9, 47).  
 
1.4.1 Articular Cartilage 
The articular cartilage is composed of a sparse population of cells named chondrocytes 
(7). Chondrocytes make up only 5% of the tissue and are relatively metabolically 
inactive due to the aneural and avascular nature of cartilage (5, 45) Chondrocytes are 
responsible for the synthesis and maintenance of the extra cellular matrix (ECM; 13). 
The ECM is composed of a high concentration of highly sulphated proteoglycans, 
mainly the large chondroitin-sulfate proteoglycan, aggrecan, which attaches to 
hyaluronic acid via link protein to form large aggregates (8, 20; Figure 1.1A). These are 
entangled in a dense network of type II collagen fibrils together with other collagens, 
predominantly type IX and type XI, and a large amount of water (8, 7).  The 
composition of ECM gives articular cartilage its ability to function as a cushion, 
absorbing the impact of excessive loads (13, 47). Under compressive forces, water 
molecules are forced from the matrix until the repulsive forces between the 
proteoglycan molecules balance the load (9). On removing the load, the hydrophilic 
aggregates rehydrate, restoring the elasticity of the articular cartilage (8). This ability to 
support compressive forces is due to the stratified nature of articular cartilage (48), 
which is divided into four zones (Figure 1.1B): the superficial zone, the middle zone, 
the deep zone and the calcified cartilage zone  (7, 8). Each zone is characterised by its 
organisation of the chondrocytes and collagen network, and by the composition and 
type of the proteoglycans (20). The superficial zone is at the surface of the articular 
cartilage, in contact with the synovial fluid. Here the chondrocytes are elongated and 
orientated with the collagen fibres parallel to the surface, the proteoglycan content is 
low and the water content is high. In the middle zone, the largest of the zones, 
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comprising 40-60% of the total articular cartilage, the chondrocytes are larger, more 
rounded in shape and randomly distributed throughout the collagen network. The 
chondrocytes of the deep zone are similar in size and shape to the middle zone, but are 
arranged with the collagen fibres in columns perpendicular to the surface. In the deep 
zone, collagen is at its thickest, the proteoglycan content is high and the chondrocytes 
are very sparse and hypertrophic. The deep zone is separated from the layer of calcified 
cartilage that sits above the subchondral bone by a ‘tidemark’ (7, 8, 14).  
 
Figure 1.1. The structure of aggrecan and the cartilage extracellular matrix. A) The 
structure of aggrecan. Aggrecan is comprised of monomers non-covalently bound to a 
hyaluronic acid backbone. The small glycoprotein link protein helps to stabilize 
aggregate formation. The side chains are mostly chondroitin sulfate, but also include 
keratan sulfate. B) The chondrocyte and collagen composition of the four zones of 
articular cartilage: the superficial zone, the middle zone, the deep zone and the calcified 
cartilage zone. Figure reproduced with kind permission of Andrew Waugh. 
 
1.4.2 Subchondral Bone 
Subchondral bone is the term used for the region encompassing the subchondral bone 
plate, consisting of the relatively non-porous and poorly vascularised cortical bone, and 
the richly vascularised subchondral trabecular bone beneath it (49-51). As articular 
cartilage has no intrinsic vasculature or lymphatic system, it therefore relies on the 
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richly vascularised adjacent tissues, the subchondral trabecular bone and synovial 
membrane to provide nutrients that are essential for maintaining the health of the 
chondrocyte and articular cartilage (52, 53). 
        Bone is a specialised tissue made up of several components including: osteoblasts, 
which are responsible for bone formation; osteoclasts, which are responsible for 
degradation of bone matrix; non-collagenous substances such as proteoglycans; and a 
collagenous component of which type I collagen is the major constituent (51). In the 
adult skeleton, bone is in a state of dynamic equilibrium between bone formation and 
resorption, which is perfectly balanced i.e. bone resorption by osteoclasts, is exactly 
compensated by an equal amount of new bone deposition by osteoblasts (54). Following 
remodelling is the process of mineralisation (49). The mechanical properties of bone are 
dependent on the mineral content, and the degree of mineralisation is highly dependent 
on the rate of bone formation and remodelling (50).  
 
1.4.3 Synovium  
The synovial joint capsule consists of dense fibrous connective tissue that forms a 
sleeve around the articulating bones providing a seal that keeps synovial fluid in 
position around the cartilage (46). The synovial membrane lines the joint capsule and 
consists of two layers, a lining layer directly next to the joint space, named the intima, 
and an outer layer that merges with the fibrous capsule, named the subsynovial or sub-
intima (51). The cells of the synovial membrane secrete the synovial fluid components, 
which contribute to the unique functional properties of articular surfaces and modulate 
chondrocyte activity (53). The synovial cells consist mainly of two main types: type A, 
macrophage-like synoviocytes and type B, the synovial fibroblasts (51). These cells 
produce two important synovial fluid components, proteoglycan 4, also known as 
lubricin, and hyaluronic acid (55). Together these two molecules reduce friction by 
providing boundary lubrication at the articular surface (53). The synovial membrane 
also functions as a semi-permeable membrane allowing the removal of the products of 
chondrocyte metabolism and matrix turnover (55). 
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1.4.4 Infrapatellar Fat Pad 
The main role of the infrapatellar fat pad (IPFP) is to facilitate the distribution of 
synovial fluid and distribute mechanical forces through the knee (56). The IPFP is 
composed of a fibrous scaffold upon which adipose tissue is embedded (57). It is 
located in the space between the patellar tendon, the femoral condyles and the tibial 
plateau and its surface is covered by a layer of synovial membrane (58). Adipose tissue 
can function as an endocrine organ actively secreting cytokines such as TNFα and 
interleukin 6 (IL-6) in humans (58).  
 
1.4.5 Meniscus 
The menisci are fibrocartilaginous wedge shaped discs that are positioned on the tibial 
plateau and act as functional extensions of the tibia (59, 60). The meniscus is composed 
of a solid phase of collagen and ECM and a fluid phase consisting of water and 
electrolytes (59). Compressive forces facilitate the flow of fluid in and out of the 
meniscus lubricating the joint, providing nutrition and dissipating the compressive 
energy, making the meniscus is an integral part of the biomechanical system of the knee 
(51, 59).  
 
1.4.6 Ligaments and Tendons 
Ligament and tendons are viscoelastic structures with unique mechanical properties. 
Tendons serve primarily to transfer the pull of muscles to bone while ligaments connect 
one bone to another (61). Both ligaments and tendons are pliant and flexible, allowing 
natural movements of bones but are strong enough to sustain high tensile forces and 
offer resistance (62). Ligaments and tendons are composed of tightly packed collagen 
fibre bundles, mainly collagen I, and proteoglycan threads interspersed with fibroblasts 
and orientated in a parallel fashion to provide stability to joints (63, 64). There are four 
major ligaments in the knee: the medial and lateral collateral ligaments and the anterior 
and posterior cruciate ligaments (63). There are also ligaments providing peripheral 
attachments between the tibial plateau and both menisci preventing the menisci from 
being extruded from the joint during compression (60).  
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1.5 Development of the Synovial Joint  
 
Long bones of the limbs are formed through a process named endochondral ossification, 
which consists of four stages (65; Figure 1.2). Initially, epithelium-mesenchymal 
interactions induce the existing mesenchymal cells to aggregate and form a densely 
packed cell condensation at the sites where bones will form (66, 38). The condensed 
mesenchymal cells then proliferate, followed by differentiation into hypertrophic 
chondrocytes, forming the cartilaginous anlagen of the future bones, which is then 
vascularised by the invasion of blood vessels from the perichondrium (66). Finally 
osteoblasts are transported into the cartilage by the blood vessels and replace the 
cartilage with mineralised trabecular bone (20, 65-69). This centre of mineralised bone 
splits into two opposite growth plates, where the maturation of cartilage continues and 
chondrocyte proliferation causes bone growth, separating the growth plates by an 
increasing amount of space that eventually becomes filled by bone marrow (68).  
                                 
 
Figure 1.2 The stages of endochondral ossification. A) In the cartilage model the 
mesenchymal cells form a condensation. B) Cells proliferate and differentiate into 
hypertrophic chondrocytes and die as matrix calcifies. C) Newly formed osteoblasts 
cover the shaft in a layer of bone and the medullary cavity is invaded by blood vessels. 
D) The bone of the shaft thickens as osteoblasts replace cartilage with mineralised bone. 
E) The mature bone, with the remnants of the epiphyses. Figure reproduced with kind 
permission of Andrew Waugh. 
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The development of the joint is dependent on signalling from: members of the Wnt 
signalling pathway such as WNT4, which regulates growth and differentiation of the 
chondrocytes (70); members of the hedgehog signalling pathway such as Indian 
hedgehog (IHH), which controls chondrocyte proliferation and maturation (71); Notch 
signalling, which is essential for chondrocyte proliferation and for the normal 
progression of hypertrophic chondrocyte differentiation into bone in the developing 
skeleton (72); and transforming growth factor β (TGF-β) signalling.  
 
1.6 TGF-β  Pathway 
 
The TGF-β superfamily of secreted growth and differentiation factors consists of over 
30 ligands that have regulatory roles both during embryogenesis and in adult 
homeostasis (73). The superfamily comprises amongst others, TGF-βs 1, 2 and 3, and 
members of the bone morphogenic protein (BMP) and growth differentiation factor 
(GDF) subfamilies (74). TGF-β signals are conveyed through type I and type II 
receptors that are transmembrane serine/threonine kinases (74). The type I receptor 
family comprises seven activin-like kinases (ALK1-7), whilst the type II receptor 
family has four members (BMPRII, ActRIIA, ActRIIB and TβRII; 73,74). 
         During the first stage in skeletal development, chondroprogenitor cells begin to 
upregulate expression of TGF-β and fibronectin, which in turn upregulates expression 
of the cell-cell adhesion molecules N-cadherin and neural cell adhesion molecule (N-
CAM; 75), initiating cell condensation and cartilage differentiation (57, 76). BMPs are 
also required for the initiation of chondrocyte differentiation by inducing SOX9 
expression (69). Progressing from condensation to differentiation of chondroblasts or 
osteoblasts requires down-regulation of N-CAM expression, resulting in cells being 
released from strong interactions with each other (75). The subsequent transition from 
proliferating chondroblasts to chondrocytes and hypertrophic chondrocytes is regulated 
via BMPs interacting with IHH, which induces Parathyroid hormone (PTH) and PTH-
related protein (PTHrP), which in turn act via negative feedback to regulate IHH, so 
controlling the size of the condensation (67, 69). Undifferentiated mesenchymal stem 
cells (MSCs) produce an ECM rich in collagen type I, hyaluronan, tenascin and 
fibronectin (66). In the third stage of the differentiation of MSCs into chondrocytes, 
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TGF-β promotes chondrocytes to change this ECM composition and they begin 
producing articular cartilage specific collagen II and aggrecan (66). During 
endochondral bone formation, BMP signalling is required for the commitment of MSCs 
toward the osteoblast lineage (69), specifically BMP2, which stimulates the osteogenic 
differentiation of MSCs by inhibiting their differentiation into the myoblastic lineage 
(73). In the final stage of skeletal development, BMP2 induces expression of key 
osteogenic transcription factors in osteoblast precursor cells, like RUNX2, and 
osteoblast markers such as alkaline phosphatase, promoting the mineralisation of the 
bone matrix (73).  
 
1.7 Pathobiology of OA 
 
OA is pathologically characterised by damage to the articular cartilage, changes in 
subchondral bone, synovitis and capsular thickening (15; Figure 1.3). In primary OA 
there is an imbalance between the biological properties resisting cartilage wear and 
mechanical stress, which results in the breakdown of the ECM (14). The articular 
cartilage becomes fibrillated, in that cracks develop along the surface, and at later stages 
of the disease fibrocartilage forms, possibly as a consequence of unsuccessful attempts 
by chondrocytes to repair the damaged tissue (77). Finally osteophytes, which are 
irregular bony outgrowths capped with cartilage, form at the periphery of the joint 
surface (14). The similarities in the pathologic progression of OA between patients, 
even when the initiating events are different, indicates that there may be a common 
molecular sequence of events underlying OA progression (77).  
 
1.7.1 OA Cartilage 
The earliest indication of pathological change is at the articular cartilage surface, which 
becomes rough and yellowish in colour and fibrillations become visible where 
chondrocytes cluster together as a result of increased cell proliferation (5, 8, 77). 
Cartilage is progressively lost until in the later stages the eburnated subchondral bone 
plate is visible (8; Figure 1.3). Gradual loss of proteoglycans also occurs at the surface 
region of articular cartilage and this is followed by type II collagen degradation, 
resulting in disruption of the integrity of the collagen network, allowing hyperhydration 
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of articular cartilage and loss of tensile strength in the cartilage matrix as the lesion 
progresses (5, 9, 77). The loosening of the collagen network results in further loss of 
proteoglycans, leading to mechanical overload, which in turn further damages and 
loosens the collagen network (14). It is this loosening of the collagen network that 
causes the hyperhydration of the cartilage giving the soft swollen macroscopic 
appearance that is visible early in OA (14).  Chondrocytes appear unable to compensate 
fully for this proteoglycan loss even in the presence of increased synthesis, resulting in 
net loss of matrix (7). With the loss of the matrix components the cartilage is no longer 
able to function properly (13). 
 
 
Figure 1.3 Structure of the synovial joint under normal and osteoarthritic conditions. 
Figure reproduced with kind permission of Andrew Waugh.  
 
 23 
The chondrocyte has clinical importance in the context of the pathogenesis of OA as 
cartilage matrix turnover is mediated by a multitude of factors that act on the 
chondrocytes and which could lead to repair, remodelling or catabolic processes (5). At 
a certain point these processes are altered, resulting in matrix changes including 
abnormal biochemical pathways that contribute to cartilage degradation (7). The gradual 
self-destruction of the matrix is induced as the chondrocytes respond to catabolic 
mediators such as IL-1 or to fragments of matrix components including fibronectin, 
collagen and hyaluronan (13). Synthesis of cartilage components is dependent on a 
number of growth factors including insulin-like growth factor 1 (IGF-1) and TGF-β 
(32). These factors have been seen to induce changes in chondrocyte metabolism or 
induce mechanisms leading to matrix degradation (20). In an attempt by the 
chondrocytes to initiate repair, new aggrecan, which has a composition more similar to 
juvenile cartilage than adult, with decreased keratan-sulfate content and increased 
chondroitin-4-sulfate relative to chondroitin-6-sulfate, is synthesised (78). This new 
aggrecan forms aggregates that are retained in cartilage during the early phases of OA, 
but in later stages they diffuse into the synovial fluid (79). Degradative proteinases 
secreted by the chondrocytes such as the matrix metalloproteinases (MMPs), enzymes 
that catalyse both collagen and proteoglycan degradation, and which are responsible for 
matrix turnover and have an increased concentration in OA cartilage (80). Collagenases 
(MMP1), gelatinases (MMP2) and stromelysin (MMP3) are synthesised by 
chondrocytes and their activity can be upregulated by certain stimuli, for example 
cytokines such as IL-1, hormones, and mechanical or growth factors (81). Multiple 
members of the MMP family acting in unison are responsible for the degradation of the 
collagen fibrils, which result in the irreversible fibrillation of the articular cartilage in 
the OA joint (7). In the early phases of OA, MMP13 is predominantly expressed in the 
lower-middle and deep layers of cartilage, whereas aggrecanases are expressed in the 
superficial zone (7). An increase in expression of cartilage degrading proteinases and 
matrix proteins such as these, suggests that chondrocytes attempt to repair the damaged 
cartilage (77). Another protease that attacks the proteoglycan monomer is Oncostatin M 
(OSM), a member of the IL-6 family, which plays a role in the articular tissue (82). It is 
the only member of this cytokine family to cause proteolytic release of proteoglycans 
and collagen from human articular cartilage (7).  
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1.7.2 OA Bone 
Changes in subchondral bone are closely involved in disease progression. Subchondral 
bone changes are often seen on radiographs in patients with established OA. 
Increasingly data suggests that subchondral bone lesions may precede cartilage 
alterations and that it is the site causing the most significant pathophysiological events 
occurring in cartilage, rather than as a consequence of cartilage damage (32). Cartilage 
thins with advancing age as a result of the slow but progressive advance of the 
ossification front (48). As the cartilage breaks down, changes occur in the underlying 
bone, which thickens with the formation of bony outgrowths from the calcified cartilage 
layer and the bone surface (21; Figure 1.3).  Increased bone mineral density (BMD), is 
associated with increased risk of incident OA (83) but some longitudinal studies have 
shown that decreased BMD is associated with progression of OA (84), implying that 
increased BMD, although a risk factor for OA, may protect against disease progression 
once it is established (85). 
 
1.7.3 OA Synovium 
The synovium becomes inflamed as a result of excessive catabolism of articular 
cartilage, causing the release of matrix breakdown products including chondroitin and 
keratin sulfate peptides, proteoglycan fragments, type II collagen peptides and 
chondrocyte membranes into the synovial fluid, all of which are antigenic and can elicit 
an inflammatory response in the synovial membrane (9). As soon as degradation occurs, 
the inflammatory mediators are either rapidly diffused into the synovial fluid or they act 
on chondrocytes to cause further catabolism by creating a positive amplification loop 
leading to more protease production, as well as cytokines and other inflammatory 
factors (7). Among the mediators responsible for the progression of the disease, 
evidence points to the proinflammatory cytokine IL-1β as being the most important 
factor responsible for the catabolic process in OA, as it reduces expression of type II 
collagen (86) and increases production of MMPs (87, 88). Other proinflammatory 
cytokines include TNF-α, which is present in OA but only at severe end stage disease, 
and Nitric oxide (NO) generated by the inducible NO synthase (iNOS), which has been 
shown to be involved in the promotion of cartilage catabolism in OA through a number 
of mechanisms (7). For example, it can inhibit the major anabolic processes such as the 
synthesis of cartilage matrix macromolecules and enhance catabolic processes such as 
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MMP activity (7). Other major inflammatory factors involved in OA pathophysiology 
are the prostaglandins, synthesised from arachidonic acid via the actions of the COX 
enzymes (89). The most abundant of these is prostaglandin E2 (PGE2), which, in 
addition to exacerbating joint inflammation, can potentiate the effects of other 
mediators of inflammation, affect cartilage remodelling directly, and contribute to 
cartilage damage by promoting MMP production (7).   
 
1.7.4 OA Infrapatellar Fat Pad  
Inflammation plays an important role in the aetiopathogenesis of OA, and the IPFP 
secretes adipokines, cytokines, and growth factors that are capable of altering cartilage 
and synovium (57). The adipokine IL-6 is increased in the IPFP of OA patients 
compared to their subcutaneous adipose tissue (90), and it has been shown to induce the 
release of MMPs in vitro (91). In addition to this human OA IPFP contains significant 
protein levels of vascular endothelial growth factor (VEGF) and the cytokine TNF-α 
which both contribute to OA (58). 
 
1.7.5 OA Meniscus 
OA menisci are often dark yellow/light brown in colour and have calcium deposited on 
roughened, cracked and frayed surfaces (92; Figure 1.3). Microscopically, OA meniscus 
ECM shows fine fibrillations, a loss of structure due to swelling of the tissue, large 
variation in proteoglycan content with some areas high in proteoglycan and others 
devoid of it, and abnormal cell clustering close to meniscal tears and frays (92). 
Meniscal extrusion can also occur in the OA joint, where the meniscus is pushed out 
and extends beyond the tibial plateau, and is caused by articular changes such as joint 
space narrowing (93).  
 
1.7.6 OA Ligaments and Tendons 
Joint space narrowing caused by loss of cartilage causes laxity of the ligaments and 
tendons reducing their joint restraining abilities and contributing to the progression of 
OA (94).  
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1.8 Risk Factors 
 
OA is a complex disease that is likely the result of a combination of risk factors. These 
risk factors can be divided into two categories: systemic risk factors such as age and 
gender, or local risk factors such as injury or occupation (15, 95).  
 
1.9 Systemic Risk Factors 
1.9.1 Age 
Age is the strongest risk factor for both the prevalence and incidence of OA in all joints 
(32, 96, 97) and it is estimated that radiological evidence of OA is found in 70% of 
those over 65 years of age (97). The increase in prevalence of OA with age can be 
attributed to the many age-related changes that occur in the joint including: mechanical 
stress on cartilage that may arise from local factors such as altered gait; increased joint 
laxity caused by muscle weakness (98); and changes in proprioception, which is the 
perception of position and movement of a joint (99). Chondrocytes also undergo age-
related changes including decreased synthesis, decreased responsiveness to anabolic 
growth factors, and synthesis of smaller and less uniform proteoglycans (98) all 
contributing to the chondrocytes inability to protect itself from biomechanical stress 
(95).  
 
1.9.2 Sex 
Gender has been associated with OA in a joint-specific manner (96). Knee OA is more 
common in females than in males, and although hip OA is slightly more common in 
men there is an increased prevalence of OA in all joints in post-menopausal women (13, 
32, 98, 100).  This high incidence of OA in women who have undergone menopause has 
been attributed to oestrogen deficiency (85, 98), as adult articular chondrocytes have 
oestrogen receptors, and it has been demonstrated that oestrogen can have an effect on 
proteoglycan synthesis (101). In addition to this, the Framingham study reported that 
post-menopausal women taking oestrogen have a decreased prevalence and incidence of 
radiographic OA (102). However many studies have failed to detect functional 
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oestrogen receptors in chondrocytes (101) and the findings of case-control studies of 
oestrogen use in women with OA have been inconsistent (85).  
 
1.9.3 Ethnicity 
Different ethnic populations have been shown to have differences in prevalence of OA; 
in the Johnston County study it has been demonstrated that African-Americans have a 
higher prevalence of knee OA than Caucasians but a lower prevalence of hand OA 
(103). The Beijing osteoarthritis study showed that Chinese men and Caucasian men 
have a similar prevalence of knee OA whereas Chinese women have a significantly 
higher prevalence of both radiographic and symptomatic knee OA than Caucasian 
women from the Framingham study (104). However, in contrast the same study looking 
at severe radiographic OA and a study of radiographic hip OA both demonstrated lower 
prevalence in Chinese populations compared to Caucasian populations (104, 105).  
 
1.9.4 Joint Deformity and Injury  
Developmental defects that affect the composition of the joint or the alignment angle of 
the hip, knee and ankle, can affect the weight distribution of the joint and may make an 
individual more likely to develop OA than people with structurally normal joints (5, 21, 
95, 106).  Any defect that affects joint stability, such as muscle weakness, or articular 
cartilage surface fractures, can also lead to development of OA (85, 95). Anterior 
cruciate ligament injury also leads to joint laxity, which leaves the knee more 
susceptible to meniscal tears, and surgery to treat meniscal tears has been shown to 
significantly increase the long-term risk of developing OA (95, 107).  
 
1.10 Local Risk Factors 
 
1.10.1 Obesity 
Obesity is strongly linked to both the development and progression of OA, particularly 
in the knee but also in the hip and the hand (32, 95, 108). The increase in mechanical 
stress across load-bearing joints in obese individuals has been thought to account for 
 28 
this risk (98). Overloading of the joints could lead to failure of the ligaments and 
structural support leading to joint misalignment and knee deformities that accelerate 
cartilage degeneration and sclerosis of the subchondral bone (32, 85, 98, 109). Although 
this is probably the primary factor accounting for progression of OA in obese 
individuals (98), it does not account for the difference in risk for the non-weight-bearing 
joints such as the hands, wrist and shoulder (108, 109), or for the fact that women are 
more susceptible to the risks of OA associated with obesity than men (32). It is because 
of these incongruities that metabolic pathways are also thought to be involved in the 
risk from obesity (98). It is hypothesised that excess fat may have a metabolic effect on 
cartilage (109), however some studies have not supported this and controlling for 
hypertension, diabetes, high serum cholesterol and high uric acid levels did not reduce 
the risk of OA (110). It has also been suggested that the association between obesity and 
OA may be partially mediated by the inflammatory effects of adipokines such as leptin, 
adiponectin and resistin, produced by the excess fat (111).  
 
1.10.2 Sports and Exercise 
Epidemiological studies have shown that participation in high-level intense sport is 
associated with increased risk of lower limb OA (32, 95).  However studies have shown 
that individuals who participate in lower-impact recreational activity, such as jogging 
do not have an increased risk of OA provided the joint is biomechanically normal (32, 
112). This probably reflects the fact that normal moderate movement and loading of the 
joint is required to maintain healthy cartilage (48, 112).  
 
1.10.3 Occupation 
Occupations involving repetitive tasks such as kneeling, bending, squatting and 
climbing stairs, overworking the joints and fatiguing the muscles, have been shown to 
increase the incidence of knee OA (32, 85, 95). Whilst manual labour jobs that require 
heavy lifting such as farming have been associated with increased incidence of hip OA 
(32). 
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1.11 Genetic Contribution to OA 
 
OA is a multifactorial disease with a clear genetic component (113) that was first 
reported as far back as the 1940s (114). Following this several twin studies were carried 
out in which monozygotic twins demonstrated a consistently higher concordance for 
OA than dizygotic twins (115), giving the first estimate of the heritability of OA; that is 
the extent to which genetic variation determines variation of a disease or trait (116). 
These studies translated into heritability estimates of 39% for OA of the knee and 60% 
for OA of the hip (96).  
 
1.11.1 Linkage Analysis 
Genetic linkage is the co-segregation of characteristics, such as a phenotype or allele in 
a family, because their determinants are not separated by recombination (116, 117). 
Families that have at least one sibling pair affected by primary OA are analysed to see if 
these alleles are segregating with incidence of OA (118, 119). Linkage studies often 
suffer from several shortcomings, including: analysis of relatively small sized cohorts; 
genotyping only a proportion of the variants within a gene; and late onset of disease 
meaning that often no parents are available for extended family studies (14). The most 
significant result from linkage studies has been the identification of the region in 
chromosome 14q harbouring deiodinase, iodothyronine, type II (DIO2; 120), which 
mediates thyroid hormone signalling, important in skeletogenesis (119). The common 
DIO2 haplotype containing the minor allele of rs225014 and the major allele of 
rs12885300 was shown to be associated with female hip OA (OR 1.79, P < 2.02x10-5; 
120).   
 
1.11.2 Candidate Gene Studies 
Candidate genes are chosen based on prior knowledge of OA, and since our knowledge 
of the aetiology of OA is poor, and the power of small cohorts is generally low, these 
studies have yielded inconsistent results (14, 118). Initial candidate genes focused on 
several cartilage ECM structural genes i.e. the type II, IV, V, VI and XI collagen genes 
on the basis that they code for regulators of joint formation maintenance (119), and 
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some studies focussed on genes that are important in bone homeostasis such as VDR, 
encoding the vitamin D receptor gene (121) and ESR1, which codes for the oestrogen 
receptor α gene (122), as subchondral sclerosis and increased bone density appears 
early in OA. Genes encoding inflammatory cytokines have also been widely 
investigated, based on the inflammation of the synovium in OA and the possible 
autocrine and paracrine role of cytokines synthesised by chondrocytes; in particular the 
IL1 cluster which contains members of the IL1 family including IL1A, IL1B, IL1R1, 
IL1R2 IL1RN (encoding IL-1α, IL-1β, IL-1 receptors type 1 and 2, and IL-1 receptor 
antagonist, respectively; 14, 123, 124, 125), Some of the reasons for a lack of 
consistency in replication of candidate gene studies are: difference in case ascertainment 
and phenotype criteria; difference in ethnicity; the sites of OA studied; the sex of the 
patients; and the occurrence of false positives in the initial studies or false negatives in 
the replication study (126). Insufficient power due to sample size, which can cause 
over-estimation of genetic effects, is one likely source of false positives in initial studies 
(127). Heterogeneity in control ascertainment may also explain some inconsistent 
results across study populations, as what constitutes an appropriate control population 
for OA genetics studies remains unclear; for example, genes important in OA pain may 
be detected using controls with asymptomatic OA but genes important in joint structural 
changes may only be detected when the controls have no OA. Additionally, because of 
the late onset and high prevalence of OA, individuals who are considered to be controls 
at one time-point may subsequently develop OA and become cases in later studies 
(127).  
        There is only one candidate gene to have reached genome-wide significance 
(GWS; P < 5x10-8); GDF5 coding for growth differentiation factor 5, part of the TGF-β 
superfamily (128). GDF5 mutations cause a variety of rare inherited skeletal dysplasias 
such as chondrodysplasia grebe type and brachydactyly type C (118) and common 
functional variation, affecting transcription of this gene is significantly associated with 
OA in both Europeans and Asians (P < 5x10-8; 119).  
 
1.11.3 Genome Wide Association Studies 
Genome wide association studies (GWAS) involve a hypothesis-free, systematic screen 
of large case-control cohorts with dense maps of millions of polymorphic markers (119, 
129). GWAS has been made possible by advances in high-throughput SNP genotyping 
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methods, the completion of the Human Genome Project and databases such as HapMap 
with extensive information about the linkage disequilibrium (LD) structure of 
chromosomes (116), as the genotypes of the SNPs missing from an array can by 
imputed, or predicted, from the LD relationship with SNPs on the array (130). However, 
GWAS are also subject to drawbacks such as lack of defined patient stratification 
criteria, as OA associations are often to a particular joint rather than to several different 
joints (119), the need for a large number of subjects and the need for replication of 
positive associations (116). In recent years a few such studies have overcome these 
drawbacks to successfully identify OA-associated loci with GWS (P < 5x10-8):  
 
7q22 
A region on chromosome 7q22 encompassing six different genes, PRKAR2B, COG5, 
GPR22, HBP1, DUS4L and BCAP29 was found to be associated with knee and/or hand 
OA in a Dutch Caucasian population with an odds ratio (OR) of 1.14 (P = 8x10-8; 131). 
NCOA3 
A meta-analysis comprising the largest study of hip OA to date identified a locus near 
nuclear receptor co-activator 3 (NCOA3) that is associated with OA (OR = 1.8, P = 
7.9x10-9;). NCOA3 recruits histone acetyltransferases and methyltransferases for 
chromatin remodeling, and is involved in the co-activation of nuclear receptors for 
many hormones that have been implicated in skeletal metabolism such as thyroid 
hormone and vitamin D3 (113).  
DOT1L 
A GWAS analysing cartilage thickness in hip OA identified a SNP in disruptor of 
telomeric silencing 1-like (DOT1L) histone H3 methyltransferase associated with larger 
JSW (OR = 1.10, P =  4.8x10-10) and with a decreased risk of hip OA but not at a GWS 
level (OR = 1.14, P = 1.5x10-4; 132). A meta-analysis then demonstrated that the SNP 
was associated with increased risk of hip OA (OR = 1.10, P = 8.1x10-8; 133) 
MCF2L 
In a European cohort a SNP in MCF.2 cell-line-derived transforming sequence-like 
(MCF2L) was found to be associated with OA (OR 1.17, P = 2.1x10-8). MCF2L 
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regulates nutrophin-3, a member of the nerve growth factor family, which are known to 
be effective in the treatment of pain in knee OA (134).  
arcOGEN 
In the largest GWAS to date, eight novel signals, five of which were GWS and three 
that were approaching it were identified (135).  The most significant signal, after 
replication was on chromosome 3p marked by two SNPs in perfect LD with each other 
in glycosyltransferase 8 Domain Containing 1 (GLT8D1; OR = 1.09, P = 7.24x10-11) 
and Guanine Nucleotide Binding Protein-Like 3 (GNL3; OR = 1.09, P = 5.13x10-9). The 
two SNPs were significant in all joints, whereas the remaining four GWS signals (Table 
1.1) were significant only in hip OA.  
 
Table 1.1 The five genome-wide significant signals from the arcOGEN GWAS.  
 
SNP Chromosome Nearest Gene Stratum Odds ratio P-value 
rs6976/ 
rs11177 
3 GLT8D1/ 
GNL3 
All joint 1.12 (1.08-1.16) 7.24x10-11 
rs4836732 9 ASTN2 Female hips 1.20 (1.13-1.27) 6.11x10-10 
rs9350591 6 FILIP1/ 
SENP6 
All hips 1.18 (1.12-1.25) 2.42x10-9 
rs835487 12 CHST11 All hips 1.13 (1.09-1.18) 1.64x10-8 
rs10492367 12 KLHDC5/ 
PTHLH 
All hips 1.14 (1.09-1.20) 1.48x10-8 
 
         Interestingly there is no overlap between genes and regions identified by linkage 
scans and those found by GWAS (116). For example, GDF5 which is the only 
candidate gene found to be robustly associated with OA, has not been identified in any 
of the GWAS so far (131). 
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1.12 Expression Quantitative Trait Loci 
 
Ideally the loci identified by GWAS would implicate functional variants and disease 
pathways that could be experimentally studied in follow-up functional studies, such as 
non-synonymous SNPs that change the amino acid sequence or truncate the protein, or 
insertions/deletions that can interrupt splicing sites, changing the mRNA isoform (136). 
However the OA-associated SNPs identified by GWAS will not usually be the causal 
variants. Instead the surrounding genomic regions of high LD with the associated SNPs 
will most likely contain the causal variants with biological function (137). Most of these 
SNPs fall into non-coding regions of the genome according to the GWAS catalogue 
(138). Projects such as the Encyclopedia of DNA Elements (ENCODE) have collected 
and annotated genomic features, which are valuable for the prioritisation of SNPs (137). 
Among the genomic features catalogued in this database are, DNase I hypersensitivity 
sites, which are markers of accessible chromatin indicating regulatory roles in the 
transcription process (136), transcription start sites, enhancers, repressors and promoter 
regions (139). In addition to these regions it has been demonstrated that trait-associated 
SNPs will often alter gene expression rather than alter the protein (140). By treating 
gene expression as a quantitative trait it is possible to correlate genotypes of disease-
associated SNPs with transcriptional levels of the genes (141). Regions that demonstrate 
a correlation between expression levels and genotype at trait-associated SNPs are 
known as expression quantitative trait loci (eQTLs). Polymorphisms that regulate 
eQTLs can be cis-acting SNPs (within or close to the gene) or trans-acting (located a 
distance from the gene or on a different chromosome; 142). Variants can regulate 
expression post-transcriptionally in 3#UTR regions by altering microRNA binding sites 
(143), by altering polyadenylation sites resulting in transcripts with different 3#UTR 
lengths (143, 144) or by altering splice sites causing the splicosome to either employ the 
next available legitimate splice site, known as exon skipping, or select the next best, 
pseudo splice site in the surrounding sequence, known as cryptic splice-site utilisation 
(145). This alternative splicing can affect gene expression by removing or inserting 
regulatory elements controlling translational efficiency, mRNA stability or localisation 
(143, 146). Once an eQTL is identified there has been a good level of success 
pinpointing the nearest regulatory element (147), but in the majority of cases, however, 
it is unclear whether such variants are of direct functional significance, as opposed to 
simply being in LD with another as yet unidentified SNP in the vicinity (148).   
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1.13 Aims of this Study  
 
The overall aim of this study is to analyse the expression of genes from a number of OA 
susceptibility loci to identify eQTLs and regulatory variants. Each of the chapters in this 
study further explores a locus identified as being associated with OA. Initially, for each 
locus, the allelic output of a gene was measured in synovial joint tissues, working under 
the hypothesis that if one allele produces significantly more mRNA than the other 
allele, then a cis-regulatory polymorphism is present. Where possible the results were 
further analysed in order to identify the precise regulatory variants affecting the 
expression of genes at the locus.  
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Chapter 2: Materials and Methods 
 
2.1 Tissue Samples 
 
Cartilage (Cn) was obtained from patients undergoing either total hip replacement 
(THR) surgery, total knee replacement (TKR) surgery or from trauma patients 
presenting with a neck-of-femur fracture (NOF). Additionally a number of synovial 
joint tissues were obtained; infrapatellar fat pad (Fp), meniscus (Me), patellar tendon 
(Te), anterior cruciate ligament (Li), synovium (Sy), and cancellous bone (Bn). Ethical 
approval for the collection of these tissues was granted by local ethics committees from 
both Oxford and Newcastle upon Tyne and informed consent was obtained from each 
donor. Patient details can be found in the appendix (Table A1).   
 
2.2 Tissue Grinding 
 
On the day of surgery tissue samples were removed from the joint, washed in 
phosphate-buffered saline (PBS; Lonza, Slough, UK) and snap frozen at -80°C. The 
frozen tissue was placed into a grinding vial, pre-cooled in liquid nitrogen, with a 
grinding ball and ground to a powder using a Retsch mixermill 200 (Retsch Ltd, 
Castleford, UK). Samples we subjected to 90 seconds of grinding at a frequency of 20 
Hz, cooling the vials in liquid nitrogen between each cycle, until completely 
powderised. The ground tissue was then stored at -80°C.  
 
2.3 Nucleic Acid Extraction and Quantification 
 
Genomic DNA (gDNA) and RNA were extracted simultaneously from the ground tissue 
using a protocol adapted from the Omega EZNA DNA/RNA isolation Kit (Omega Bio-
Tek, Georgia, USA). Between 0.25-0.30g of ground tissue was combined with 700 µl of 
GTC lysis buffer (Omega) mixed with 14 µl of β-mercaptoethanol (BME; Sigma-
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Aldrich, Gillingham, UK). The sample was then thoroughly homogenised and 
centrifuged at 11700 rpm for 5 minutes. To extract DNA from the tissue the resulting 
supernatant was passed through a Hi-bind DNA column (Omega), and to extract RNA 
from the tissue the supernatant was mixed with 1 volume of ice-cold 70% ethanol made 
up with diethylpyrocarbonate (DEPC)-treated H2O (Invitrogen, Life Technologies, 
Paisley, UK), and passed through a Hi-bind RNA column (Omega). The DNA and RNA 
columns were washed with DNA wash buffer or RNA wash buffer I (Omega) 
respectively, centrifuged at 10300rpm for 1 minute and the filtrate discarded. The DNA 
and RNA columns were further washed with buffer HB or RNA wash buffer II (Omega) 
respectively, centrifuged at 10300 rpm, and the filtrate discarded. The column-bound 
DNA was eluted with elution buffer (Omega) and the column-bound RNA was eluted 
with DEPC-treated H2O (Invitrogen). The concentration of the nucleic acids was 
determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, USA). To the RNA, 3 µl of RNaseOUT recombinant ribonuclease 
inhibitor (40 U/µl; Invitrogen) was added to prevent degradation, and along with the 
DNA was centrifuged using the DNA 120 SpeedVac system (Thermo Scientific, 
Epsom, UK). The pellets were resuspended in DEPC-treated H2O (Invitrogen) to a final 
concentration of 50 ng/µl for DNA and 250 ng/µl for RNA. DNA was stored at -20°C 
and RNA at -80°C until required.  
 
2.4 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
 
RNA extracted from patient tissue was reverse transcribed to synthesise complementary 
DNA (cDNA). Prior to RT-PCR a DNase step was carried out to remove any remaining 
gDNA from the sample. Four microlitres of RNA suspended in DEPC-treated H2O 
(Invitrogen) were mixed with 1 µl of 10X TURBO DNase buffer (Ambion, Life 
Technologies) and 1 µl of TURBO DNase enzyme (2 U/µl; Ambion) and incubated at 
37°C for 30 minutes. Following this, 1.8 µl of ethylenediaminetetraacetic acid (EDTA; 
100mM; Sigma) was added and incubated at 75°C for 10 minutes.  
RT-PCR was carried out with the SuperScript First-Strand Synthesis System 
(Invitrogen). The DNase-treated RNA was mixed with 1 µl of random primers (50 
ng/µl; Invitrogen), 1µl of dNTPs (10 mM each dATP, dCTP, dGTP, dTTP; Invitrogen) 
and 1 µl of DEPC-treated H2O (Invitrogen) and incubated at 65°C for 5 minutes 
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followed by incubation on ice for 1 minute.  Four microlitres of 5X first-strand buffer 
(250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2; Invitrogen), 4 µl of MgCl2 (25 
mM; Life Technologies), 2 µl of dithiothreitol (DTT; 0.1 M; Invitrogen), and 1 µl of 
RNaseOUT recombinant ribonuclease inhibitor (40 U/µl; Invitrogen) were then added 
and incubated at 25°C for 1 minute. Following this step, 1 µl of SuperScript II reverse 
transcriptase enzyme (200 U/µl; Invitrogen) diluted 1:3 with DEPC-treated H2O 
(Invitrogen) was added. This mix was then incubated at 25°C for 10 minutes, 42°C for 
50 minutes and 70°C for 15 minutes. Finally 1 µl of RNase H (5 U/µl; New England 
Biolabs; NEB, Hitchin, UK) diluted 2:3 with H2O (Sigma) was added and the product 
was incubated at 37°C for 20 minutes.  
Quality and integrity of the cDNA was assessed using primers specific for the gene 
HBP1 that concurrently amplify both gDNA and cDNA producing different fragment 
sizes. Primer sequences can be found in the appendix (Table A2). PCR products were 
electrophoresed through a 2% weight/volume agarose gel containing ethidium bromide 
(10 mg/ml; Sigma) at a concentration of 1 µl/100 ml agarose and UV visualised using a 
G:BOX gel doc system (Syngene, Cambridge, UK). Samples that produced the correct 
sized band for the cDNA fragment and no gDNA fragment were taken forward for 
analysis.   
 
2.5 Polymerase Chain Reaction (PCR) 
 
PCR was carried out in 15 µl reactions containing 0.5 µl of cDNA or 50 ng of DNA, 
0.075 µl of each amplimer (100 µM; Sigma), 1.5 µl of 10X PCR buffer (500 mM KCl, 
100 mM Tris-HCl pH 8.3; Life Technologies), 0.8 µl, 1.2 µl or 1.8 µl of 25mM MgCl2 
(Life Technologies) to a concentration of 1 mM, 2 mM or 3 mM respectively, 0.375 µl 
of dNTPs (10 mM each dATP, dCTP, dGTP, dTTP; Bioline, London, UK), 0.08 µl of 
AmpliTaq Gold DNA Polymerase (5 U/µl; Life Technologies), and made up to 15 µl 
with H2O (Sigma). Thermocycling conditions were an initial denaturation at 96°C for 
14 minutes, followed by 35 cycles of 96°C for 30 seconds, annealing for 30 seconds at 
temperatures between 55°C and 65°C depending on the specific conditions required for 
the amplimers, extension at 72°C for 1 minute/kb then a final extension at 72°C for 5 
minutes. Primers and reaction conditions are listed in the appendix (Table A2). PCR 
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products were electrophoresed through a 2% agarose gel stained with ethidium bromide 
(10 mg/ml; Sigma).  
 
2.6 Gene Expression Analysis using Real Time Quantitative PCR (qPCR) 
 
Gene expression analysis was carried out using ready-made assays consisting of specific 
primer-probe mixes (Integrated DNA Technologies: IDT, Leuven, Belgium) or a 
combination of primers (Sigma) and probes custom designed using the real time PCR 
Assay Design Tool (IDT). Primer and probe sequences are listed in the appendix (Table 
A3). The pre-designed primer-probe mixes were dissolved in IDTE buffer (10mM Tris, 
0.1mM EDTA pH 8.0) and amplifications were performed in triplicate in 10 µl 
reactions containing 5 µl of TaqMan Gene Expression Master Mix (Life Technologies), 
1 µl of 10X primer-probe mix (IDT) specific to each gene, 1.5 µl of H2O (Sigma) and 
2.5 µl of cDNA at a dilution of 1:20 with DEPC-treated H2O. Reactions for custom-
designed primers and probes were also carried out in a final volume of 10 µl containing 
0.2 µl of both forward and reverse primer (10 mM; Sigma), 0.1 µl of custom-designed 
probe (IDT), 5 µl of TaqMan Gene Expression Master Mix (Life Technologies), 2 µl of 
H2O (Sigma), and 2.5 µl of cDNA in a 1:20 dilution. Cycling conditions were 50°C for 
2 minutes, 95°C for 10 minutes, 95°C for 15 seconds repeated for 40 cycles and 60°C 
for 1 minute. The cycles were performed on a 7900HT Fast Real-Time PCR system 
(Life Technologies). Gene expression was measured relative to the housekeeping genes 
HPRT1, GAPDH and Human 18S ribosomal RNA (rRNA).  
 
2.7 Statistical Analysis of Real-Time qPCR 
 
Analysis of these data was carried out using Sequence Detection Systems Version 2.4 
(Life Technologies). Differences in the threshold cycle (Ct) value were calculated using 
the equation 2-ΔCt where ΔCt is the difference between the mean Ct of the three 
housekeeping genes HPRT1, GAPDH and 18S, and the Ct of the gene of interest. 
GraphPad Prism Software Version 5.0 (GraphPad) was used to generate graphs and to 
perform statistical analysis. The 2-ΔCt values were then grouped together according to 
the genotype at the associated SNP in question and plotted on a graph. Mann-Whitney 
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U tests were used to determine a statistical difference between two genotypic groups. 
Kruskal-Wallis tests were used to determine a statistical difference between three 
genotypic groups. A P ≤ 0.05 was considered significant.  
 
2.8 Restriction Fragment Length Polymorphism (RFLP) Analysis 
 
PCR was performed in a total reaction volume of 15 µl as previously described (section 
2.5). Primers and reaction conditions are listed in the appendix (Table A4). For the 
restriction digests 10 µl of PCR product were digested for 3 hours at the appropriate 
temperature with 5 µl of digestion mixture containing 5 units of the specific restriction 
enzyme, 1.5 µl of enzyme buffer (10X; NEB), 0.15 µl of bovine serum albumin (BSA; 
100X; NEB) if required, and H2O (Sigma). Enzymes, buffers and reaction conditions 
are listed in the appendix (Table A5). Digested products were electrophoresed through 
3% agarose gels stained with ethidium bromide (10 mg/ml; Sigma) and scored 
following UV visualisation. 
 
2.9 Database Search for Polymorphisms 
 
BROAD Institute, single nucleotide polymorphism (SNP) annotation and proxy search 
version 2.2 (SNAP; http://www.broadinstitute.org/mpg/snap/) was used to query the 
pairwise LD between two SNPs, and to identify transcript SNPs in high LD with 
associated SNPs that could be used as proxies.  In addition to this, HapMap genome 
browser (http://hapmap.ncbi.nlm.nih.gov), Ensembl 
(http://www.ensembl.org/index.html), the University of California, Santa Cruz (UCSC) 
genome browser (http://genome.ucsc.edu), RegulomeDB (http://www.regulomedb.org) 
and Mutation Taster (http://www.mutationtaster.org) were used to select SNPs for 
analysis. All SNPs investigated in this study are listed in the appendix (Table A6).  
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2.10 Allelic Expression Imbalance (AEI) Analysis using a SNaPshot Multiplex Kit 
 
To analyse the differences in mRNA output from the two copies of a gene, allelic 
expression imbalance (AEI) analysis was carried out on patients who were heterozygous 
for transcript SNPs used as markers for the associated SNPs. RT-PCR was performed as 
previously described (section 2.4) to synthesise cDNA from the extracted RNA. This 
cDNA was then PCR amplified using primers specific for the region encompassing the 
SNP. Primer sequences and reaction conditions are listed in the appendix (Table A7). 
For each cDNA and gDNA sample amplifications were carried out in 15 µl reactions as 
previously described (section 2.5) with 10 technical replicates. Five microlitres of these 
PCR products were incubated with 0.15 µl Exonuclease I (ExoI; 20,000 U/ml; NEB), 
0.65 µl of Exonuclease I Reaction Buffer (1X; 67 mM Glycine-KOH, 6.7 mM MgCl2, 
10 mM β-ME, pH 9.5; NEB) and 0.7 µl of H2O (Sigma) at 37°C for 1 hour then 
inactivated at 80°C for 20 minutes. Following this the samples were further incubated 
with 1 µl of shrimp alkaline phosphatase (SAP; 1 U/µl; GE Healthcare, Little Chalfont, 
UK) at 37°C for 1 hour then inactivated at 75°C for 15 minutes. These products were 
then used as a template in the single base extension (SBE) reaction using a SNaPshot 
Multiplex Kit (Life Technologies). SBE utilises a primer that anneals immediately 
adjacent to the SNP of interest. SBE primer sequences are listed in the appendix (Table 
A8). The primer is extended into the polymorphic site using fluorescently labelled 
dideoxynucleotides (ddNTPs). Each ddNTP has a different fluorescent tag allowing the 
3130xl Genetic Analyzer (Life Technologies) to discriminate between the two alleles. 
SBE reactions were carried out in a total reaction volume of 3 µl containing 1.2 µl of 
ExoI/SAP-treated PCR product, 1.5 µl of SNaPshot Multiplex Kit reaction mix (Life 
Technologies), 0.1 µl of SBE (100 µM; Sigma), and 0.2 µl of H2O (Sigma). Positive 
and negative SNaPshot Multiplex Kit controls were carried out in a total reaction 
volume of 10 µl containing 5 µl of SNaPshot reaction mix, 1 µl of control primer, 2 µl 
of control DNA was added to the positive control only and the volumes made up to 10 
µl with H2O (Sigma). Thermocycling conditions were 25 cycles at 96°C for 10 seconds, 
50°C for 5 seconds and 60°C for 30 seconds. Finally, following this reaction, extension 
products were incubated with 1 µl of SAP (1 U/µl; GE Healthcare) at 37°C for 1 hour 
then inactivated at 80°C for 20 minutes.  One microlitre of this final product was 
combined with 9 µl of GS120 LIZ size standard (Life Technologies) at a 1:100 dilution 
with HiDi Formamide (Life Technologies). These products were separated by capillary 
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electrophoresis through a 36 cm capillary array with POP-7 polymer (Life 
Technologies) at 60°C using a 3130xl Genetic Analyzer (Life Technologies). These data 
were analysed using GeneMapper 4.0 software (Life Technologies), which produces 
electropherograms of the peak heights for the two alleles.  
 
2.11 AEI Analysis using Taqman Real-Time qPCR Genotyping Assays 
 
Quantitative real time PCR genotyping assays are standard real time assays containing 
probes specific for each of the alleles, labelled with either FAM or VIC dye. Real time 
PCR was carried out in a 10 µl reaction containing 5 µl of TaqMan Universal Master 
Mix II no UNG (Life technologies), 0.25 µl of TaqMan assay (40X; Life technologies), 
0.75 µl of H2O (Sigma) and either 20 ng of gDNA or 4 µl of cDNA at 1:20 dilution with 
DEPC-treated H2O (Invitrogen). Samples were amplified using an ABI PRISM 7900HT 
Sequence Detection System (Life Technologies) under the thermocycling conditions 
50°C for 2 minutes, 95°C for 10 minutes followed by 40 cycles of 92°C for 15 seconds 
and 60°C for 1 minute. Reactions were carried out with five technical replicates for both 
gDNA and cDNA.  
 
2.12 Statistical Analysis of AEI Data 
 
For SNaPshot, the peak heights produced by the GeneMapper 4.0 software (Life 
Technologies) are proportional to the amount of each allele present and allelic ratios 
were calculated with the formula (peak height allele 1)/(peak height allele 2). For 
TaqMan, allelic ratios were calculated using the formula (2-FAM Ct)/(2-VIC Ct). For all 
methods the average peak height ratio for gDNA (gDNA), which represents a 1:1 ratio 
was used to normalise the cDNA peak height ratios using the formula; normalised 
allelic ratio = cDNA average allelic ratio/ gDNA average allelic ratio. A particular 
patient sample was considered to demonstrate AEI if following a two-tailed Mann-
Whitney U Test, the difference in the normalised allelic ratio versus the gDNA allelic 
ratio generated a P ≤ 0.05. Statistical analysis was carried out using GraphPad Prism 5.0 
software (GraphPad Software Inc. La Jolla, USA). For each assay a standard curve 
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experiment using mixtures of known amounts of homozygous gDNA was carried out to 
verify that differences in allelic output could be accurately measured.  
 
2.13 Functional Analysis of the SMAD3 3"UTR 
 
2.13.1 Construction of SMAD3 3"UTR Luciferase Reporter Plasmids 
To generate the constructs for use in the luciferase reporter gene assays, gDNA was 
PCR amplified using gene-specific primers containing restriction sites at the 5" ends of 
both primers. Primer sequences and restriction enzymes are listed in the appendix 
(Tables A9 and A10). PCR was carried out in 50 µl reactions containing 1 µl of 50X 
Titanium Taq DNA polymerase (Clontech, Oxford, UK), 5 µl of 10X Titanium Taq 
PCR buffer (400 mM Tricine-KOH pH 8.0, 160 mM KCl, 35 mM MgCl2, 37.5 µg/ml 
BSA; Clontech), 1 µl of dNTPs (10 mM each dATP, dCTP, dGTP, dTTP; Bioline), 1 µl 
of each primer (100 µM; Sigma), 12.5 µl of Betaine solution (5M; Sigma), 26.5 µl of 
H2O (Sigma) and 100 ng of DNA. Thermocycling conditions were an initial denaturing 
step at 95°C for 1 minute, followed by 35 cycles of 95°C for 30 seconds and annealing 
at 68°C for 1 minute, then a final extension at 68°C for 3 minutes. After PCR 
amplification the PCR product was purified using the QIAquick PCR purification kit 
(Qiagen) following the manufacturer’s protocol.  
The purified PCR product was then doubled digested in a 50 µl reaction with 25 units of 
SpeI (10,000 U/ml; NEB) and 25 units of HindIII (20,000 U/ml; NEB) for amplicons 1 
and 3 or 25 units of MluI (10,000 U/ml; NEB) and 25 units of SacI (20,000 U/ml) for 
amplicon 2, and 5 µl of restriction buffer (10X; NEB), made up to 50 µl with H2O 
(Sigma).  The reaction mix was incubated overnight at 37°C. The digested products 
were then further purified using the QIAquick PCR purification kit (Qiagen) according 
to the manufacturer’s protocol.  
In preparation of cloning 5 µg of p-MIR-REPORT miRNA expression reporter vector 
(Promega, Southampton, UK) was double-digested as previously described, with SpeI 
(NEB) and HindIII (NEB) for amplicon 1 and 3, and MluI (NEB) and SacI (NEB) for 
amplicon 2.  The digested products were electrophoresed through a 0.8% agarose gel 
stained with ethidium bromide (10 mg/ml; Sigma). The digested vectors were excised 
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from the gel and purified using the QIAquick gel extraction kit (Qiagen) according to 
the manufacturer’s instructions.  
The purified PCR fragments were then ligated into the purified pMIR-REPORT vector 
by incubating 17 µl of DNA in a ratio of 4:1 (PCR fragments: plasmid), 400 units of T4 
DNA ligase (400,000 U/ml; NEB) and 2 µl of 10X T4 DNA ligase reaction buffer (50 
mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT pH 7.5; NEB), at 16°C 
overnight.  
 
2.13.2 Bacterial Cell Transformation 
Two microlitres of the ligated construct were transformed into one 50 µl vial of One 
Shot Mach1 T1 phage-resistant chemically competent E.coli cells (Invitrogen) by 
incubating the mixture on ice for 20 minutes and heat shocking the cells at 42°C for 30 
seconds followed by incubation on ice for a further 2 minutes. The transformed cells 
were placed at 37°C in a shaking incubator at 200 rpm for 1 hour with 200 µl of super 
optimal broth with catabolite repression (SOC) medium (2% tryptone, 0.5% yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose; 
Invitrogen). After incubation this mixture was spread onto two Lysogeny broth (LB; 
Sigma) Bacto™ agar (BD Biosciences, Oxford, UK) plates containing ampicillin (100 
mg/ml; Sigma), 50 µl on one plate and 100 µl on the other. Plates were incubated 
overnight at 37°C.  
Ten colonies were picked from each plate and each one added to a 1.5 ml centrifuge 
tube containing 15 µl of LB (Sigma) and ampicillin (100 mg/ml; Sigma) to a final 
concentration of 100 µg/ml. This mixture was then amplified using the same PCR 
primers and conditions used to amplify the original inserts. Clones displaying the 
correct size PCR product were then grown overnight by adding 10 µl of the colony 
mixture to a 15 ml centrifuge tube containing 3.5 ml LB (Sigma) and 3.5 µl of 
ampicillin (100 mg/ml; Sigma), and incubating at 37°C in a shaking incubator at 200 
rpm. Glycerol stocks were also made from the positive colonies by adding 200 µl of the 
colony mixture to 200 µl of glycerol (Sigma), with storage at -80°C.  
Plasmid DNA was purified from the overnight bacterial cultures using a Qiagen 
Plasmid Mini Kit (Qiagen) according to the manufacturer’s instructions. Ten microlitres 
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of the purified plasmid DNA was then sent to Source Bioscience (Nottingham, UK) to 
be Sanger sequenced. Sequencing primers are listed in the appendix (Table A11).  
One plasmid with the correct DNA sequence was grown overnight. Briefly, 10 µl of the 
bacterial culture glycerol stock was added to 5 ml of LB containing 5 µl of ampicillin 
(100 mg/ml; Sigma) and incubated at 37°C in a shaking incubator at 200 rpm for 4 
hours. This was then added to 250 ml of LB (Sigma) and grown overnight at 37°C in a 
shaking incubator at 200 rpm. The DNA was then purified using a Qiagen plasmid maxi 
kit (Qiagen) according to the manufacturer’s instructions.  
 
2.13.3 SW1353 Cell Culture 
SW1353 human chondrosarcoma cells were cultured in complete growth medium made 
up of Dulbecco’s modified Eagle medium (DMEM)/F-12 (1:1; Life Technologies), 
supplemented with 10% fetal bovine serum (FBS; Life Technologies), 2mM L-
glutamine (Sigma), and 100 U/ml penicillin, 100 µg/ml streptomycin (Sigma). SW1353 
cells were maintained in 10 ml of this complete growth medium in 75 cm2 cell culture 
flasks (Corning, USA), at 37°C in a humidified 5% CO2 incubator. Cells were passaged 
at 80% confluence using standard tissue culture techniques.  
 
2.13.4 MG63 Cell Culture 
MG63 human osteosarcoma cells were cultured in DMEM (Life Technologies) 
supplemented with 10% FBS (Life Technologies), 100 U/ml penicillin, 100 µg/ml 
streptomycin (Sigma). The cells were maintained in 10 ml of this complete growth 
medium in 75 cm2 cell culture flasks (Corning), at 37°C in a humidified 5% CO2 
incubator. Cells were passaged at 80% confluence using standard tissue culture 
techniques.  
 
2.13.5 Transfection of Cells with SMAD3 3"UTR pMIR-REPORT miRNA Expression 
Vector Construct 
Both SW1353 and MG63 cells were seeded at a density of 17,500 cells/well in a 48-
well cell culture plate (Corning) with 300 µl of complete growth medium. Once cells 
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had reached 80% confluence they were transfected, with a master mix containing 1.65 
µl of ExGen 500 in vitro transfection reagent (Fermentas, Thermo Scientific), 500 ng of 
the SMAD3 3"UTR luciferase reporter construct and 15 ng of pRL Renilla luciferase 
control reporter vector (Promega) made up to 30 µl with 0.9M NaCl. This was 
incubated at room temperature for 10 minutes, the media was removed from the wells, 
and 30 µl of the master mix was added to each well followed by 270 µl of medium. The 
plate was incubated at 37°C in a humidified 5% CO2 incubator. For each construct, 
transfections were performed using three different passages each with 6 biological 
replicates. 
 
2.13.6 Luciferase Reporter Assay 
Medium was removed from the cells and the wells were washed twice with 500 µl of 
non-sterile PBS (Lonza). Sixty-five microlitres of 1X passive lysis buffer (PLB; 
Promega) was added to each well. The plates were incubated on a rocker at room 
temperature for 20 minutes and stored at -20°C for at least 4 hours until the PLB froze.  
Once the PLB was frozen the plate was removed and defrosted on a rocker at room 
temperature for 10-15 minutes.  The cell lysate was assayed for firefly luciferase 
activity by transferring 20 µl of the cell lysate to a luminometer plate, adding 50 µl of 
Luciferase Assay Reagent II (Promega) to each well and reading the luciferase activity 
using a MicroLumatPlus Luminometer (Berthold Technologies, Hertfordshire, UK). 
Following this step 50 µl of Stop and Glo Reagent (Promega) was added to each well 
and the Renilla luciferase activity was measured as a control for transfection efficiency. 
The experiment was performed using three biological replicates with six technical 
replicates for each.  
 
2.13.7 Statistical Analysis of Luciferase Activity 
Relative luciferase activity was measured by calculating the ratio of the firefly 
luciferase readings to the Renilla luciferase readings to account for differences in 
transfection efficiency. Luciferase activity of the constructs containing the 
polymorphisms was compared to the luciferase activity of constructs containing the 
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wild-type (WT) alleles. Statistical comparison was performed on the average of the six 
technical and three biological repeats using the two-tailed Student’s t-test. 
 
2.13.8 Site-Directed Mutagenesis 
Site-directed mutagenesis of the SMAD3 3"UTR amplicon 3-pMIR-REPORT miRNA 
expression vector construct was performed using the QuikChange II Site-Directed 
Mutagenesis Kit (Agilent, Cheshire, UK). Primers sequences are listed in the appendix 
(Table A12).  Mutagenesis was carried out in 50 µl reactions containing 5 µl of 10X 
reaction buffer (Agilent), 50 ng of DNA, 1.25 µl of both primers (100 µM; Sigma), 1 µl 
of dNTP mix (Agilent), and 1 µl of PfuUltra HF DNA polymerase (2.5 U/µl; Agilent) 
made up to 50 µl with H2O (Sigma).  Thermal cycling conditions were 95°C for 30 
seconds, followed by 18 cycles of 95°C for 30 seconds, 55°C for 1 minute and 68°C for 
7 minutes, then cooling at 37°C for 2 minutes. To digest the non-mutated parental 
product, 1 µl of the DpnI restriction enzyme (10 U/µl; Agilent) was added and 
incubated at 37°C for 1 hour. One microlitre of the digested product was then 
transformed into 50 µl of XL1-Blue Supercompetent cells (Agilent) by placing on ice 
for 30 minutes, heat shocking for 45 seconds at 42°C and incubating on ice for a further 
2 minutes. The cells were then added to 200 µl of SOC medium (Invitrogen), 
transferred to a 15 ml centrifuge tube and incubated in a shaking incubator at 37°C for 1 
hour at 250 rpm. Following incubation, 250 µl of the cells were plated onto an 
ampicillin plate treated with 40 µl of 5-bromo-4-chloro-indolyl-β-D-galactopyranoside 
(X-gal; 40 mg/ml; Sigma) in dimethyl sulfoxide (DMSO; Sigma) and incubated 
overnight at 37°C. Ten white colonies were selected for PCR amplification as 
previously described. Three positive colonies were sent away to Source Bioscience for 
Sanger sequencing. Sequencing primers are listed in the appendix (Table A11).   
 
2.14 Database Search of miRNA Binding Sites 
 
PolymiRTS (http://compbio.uthsc.edu/miRSNP), TargetScan 
(http://www.targetscan.org/), MiRBase (http://www.mirbase.org/), PicTAR 
(http://pictar.mdc-berlin.de/) and miRWalk (http://www.umm.uni-
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heidelberg.de/apps/zmf/mirwalk/) were used to identify sequence variations in putative 
miRNA binding sites and to predict binding sites for miRNAs encompassing 
rs12595334 and rs3743342.  
 
2.15 Cell Culture of Vascular Smooth Muscle Cells (VSMCs) 
 
VSMC (a kind gift from Drs Aida Bertoli-Avella and Ingrid van de Laar, Rotterdam) 
from aortic tissue were cultured in complete smooth muscle cell basal medium (Lonza) 
supplemented with 5 % FBS (Lonza), 0.1% human recombinant epidermal growth 
factor (rhEGF; Lonza), 0.1% human recombinant insulin, 0.2% human recombinant 
fibroblast growth factor B (hrFGF-B; Lonza), and 500 µl of GA-100 (gentamicin 
sulphate/amphotericin-B; Lonza). Cells were maintained in 10 cm tissue culture dishes 
coated in 0.1% gelatin, in a humidified 5% CO2 incubator. Cells were passaged at 80% 
confluence.  
 
2.16 Haplotype Analysis by Cloning 
 
2.16.1 PCR of VSMC DNA 
DNA and RNA were extracted from vascular smooth muscle cells and cDNA was 
synthesised as previously described in sections 2.3 and 2.4. Primers were designed to 
amplify a cDNA fragment containing the SNPs to be haplotyped. Primer sequences are 
listed in the appendix (Table A13). PCR was carried out in 50 µl reactions containing 2 
µl of cDNA, 0.25 µl of each primer (100 µM; Sigma), 5 µl of 10X PCR buffer II  (Life 
Technologies), 4 µl of MgCl2  (25mM; Life Technologies), 1.25 µl of dNTPs (10 mM 
each dATP, dCTP, dGTP, dTTP; Bioline), and 0.27 µl of AmpliTaq Gold DNA 
Polymerase (5 U/µl; Life Technologies), made up to 50 µl with H2O (Sigma). 
Thermocycling conditions were an initial denaturation at 96°C for 14 minutes, followed 
by 35 cycles of 96°C for 30 seconds, annealing at 70°C for 30 seconds, and extension at 
72°C for 1 minute then a final extension at 72°C for 7 minutes. 
 
 48 
2.16.2 Cloning  
Cloning was carried out using the TOPO TA Cloning Kit (Invitrogen). Briefly, 1 µl of 
PCR product was incubated at room temperature for 30 minutes with 1 µl of salt 
solution (1.2 M NaCl, 0.06 M MgCl2; Invitrogen), 3 µl of H2O (Sigma), and 1 µl of 
pCR 4-TOPO vector (Invitrogen).   
 
2.16.3 Transforming Competent Cells 
Two microlitres of the TOPO Cloning reaction were added to one 50 µl vial of One 
Shot Mach1 cells (Invitrogen) and incubated on ice for 20 minutes. The cells were then 
heat shocked at 42°C for 30 seconds followed by incubation on ice for a further 2 
minutes. The transformed cells were incubated in a shaking incubator at 37°C for 1 hour 
at 200 rpm with 200 µl of SOC medium (Invitrogen). This broth was then spread onto 
two room temperature LB (Sigma) agar plates containing ampicillin (100 mg/ml; 
Sigma), 50 µl on one plate and 100 µl on the other. Plates were incubated overnight at 
37°C.  
 
2.16.4 Analysing Transformants 
Three colonies were picked for each patient and PCR amplified as previously described. 
Clones displaying the correct size PCR product were then grown overnight and sent to 
Source Bioscience to be DNA sequenced. Primer sequences are listed in the appendix 
(Table A11). The WT and mutated construct sequences were compared using the 
Clustal Omega alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/).  
 
2.17 Bioinformatic Analysis of Protein Prediction Databases 
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SNPs3D (http://www.snps3d.org) 
and the Craig J. Venter Institute’s SIFT database (http://sift.jcvi.org), were used to 
predict the structural and functional effects of the non-synonymous rs11177 SNP, on 
human protein.  
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2.18 siRNA Knockdown  
 
2.18.1 Cartilage Digestion and HAC Culture 
Articular cartilage was removed from the joint using a scalpel blade either on the day of, 
or up to 24 hours after total joint replacement surgery. The removed cartilage was 
washed thoroughly in PBS, cut very finely with a scalpel, transferred to a 50 ml 
centrifuge tube and weighed. Cartilage was digested by incubating with 4 ml/g of 
hyaluronidase (type I-S from bovine testes; Sigma) in PBS (Lonza) to a concentration of 
1 mg/ml. The enzyme was filter-sterilised on to the cartilage and placed at 37°C for 30 
minutes. The cartilage was washed twice with PBS (Lonza) and incubated with 4 ml/g 
of filter-sterilised trypsin (type III from porcine pancreas; Sigma), in PBS (Lonza) to a 
concentration of 2.5 mg/ml, at 37°C for 30 minutes. The cartilage was then washed with 
DMEM (Life Technologies) supplemented with 10% FBS (Life Technologies), 2 mM 
L-glutamine (Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin (Sigma) and 50 
U/ml nyastatin (Sigma) to inactivate the trypsin. The cartilage was then incubated in a 
shaking incubator at 35°C overnight with 3 ml/g of bacterial collagenase (type I from 
Clostridium histolyticum; Sigma) in DMEM (Life Technologies) to a concentration of 
2.5 mg/ml. The supernatant was removed and centrifuged at 1100 rpm for 10 minutes to 
collect the cells. The cell pellet was then washed with PBS (Lonza) and resuspended in 
serum containing DMEM (Life Technologies). The cells were counted in a 1:10 dilution 
with PBS (Lonza) using a haemocytometer. Cells were seeded at a density of 3 million 
cells/ 75 cm2 tissue culture flask (Corning) in 10 ml DMEM (Life Technologies) 
supplemented with 10% FBS (Life Technologies), 2 mM L-glutamine (Sigma), 100 
U/ml penicillin and 100 µg/ml streptomycin (Sigma), and 50 U/ml nyastatin (Sigma). 
Cells were passaged after 10-12 days.  
 
2.18.2 Human MSC Culture 
Human bone marrow stem cells from human bone marrow mononuclear cells taken 
from the iliac crest of young Caucasian donors between the ages of 19-24 (Lonza) were 
isolated by adherence to 75cm2 tissue culture flasks (Corning) over 24 hours. Patient 
details are listed in the appendix (Table A1). Remaining cells were then expanded in 
monolayer culture in MSC basal medium (Lonza) supplemented with 50 ml MSC 
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growth supplement (Lonza), 10 ml L-glutamine (Lonza), 500 µl GA-100 (gentamicin 
sulphate amphotericin-B; Lonza), and 5 ng/ml fibroblast growth factor-2 (FGF2; R&D 
Systems Europe Ltd, Abingdon, UK). Cultures were maintained in a humidified 5% 
CO2 incubator at 37°C. Cells were split 1:6 once they had reached 80% confluence.  
 
2.18.3 siRNA Transfection for Gene Expression Analysis 
Once the HACs and MSCs (Lonza) had become 80% confluent they were passaged 
using 0.25% 1X trypsin-EDTA (Life Technologies). The cells were seeded at a density 
of 10,000 cells/well in 96-well culture plates (Corning), with 200 µl of serum-positive 
DMEM (Life Technologies) for HACs, and serum-positive MSC growth medium for 
MSCs. Empty wells surrounding the cells were filled with 200 µl PBS to minimise 
evaporation. After 24 hours HACs and MSCs were transfected with 0.5 µl of GNL3 
siRNA (20 µM; Sigma) and 0.26 µl of DharmaFECT transfection reagent 1 (Thermo 
Scientific) made up to 30 µl with serum-free DMEM (Life Technologies). Cells 
transfected with non-targeting siRNA (20 µM; Sigma), untransfected cells treated with 
serum-free medium and cells treated with transfection reagent only were used as 
controls. siRNA sequences are listed in the appendix (Table A14). Firstly, the required 
amount of siRNA (GNL3 or non-targeting), and the required amount of transfection 
reagent were each mixed with serum-free medium and incubated at room temperature 
for 5 minutes before combining the siRNA with the transfection reagent. The reaction 
mixture containing siRNA, transfection reagent and serum-free medium was then 
incubated at room temperature for 20 minutes. Each transfection condition was carried 
out in 6 biological replicates. Plates were incubated in a humidified 5% CO2 incubator 
for 48 hours then lysed and reverse transcribed into cDNA for gene expression analysis.  
 
2.18.4 Cell Lysis and Reverse Transcription 
Medium was removed from the wells and the cells were washed with PBS (Lonza). The 
cells were placed on ice and 30 µl of Cells-to-cDNA II Cell Lysis Buffer (Ambion) was 
added to each well. The cells were mixed and centrifuged and the suspension was 
transferred to a 96-well PCR plate. The cell suspension was heated to 75°C for 15 
minutes following which 8 µl was transferred to a fresh 96-well PCR plate.  The mix 
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was then incubated with 1 µl of random primers (0.2 µg/µl; Invitrogen) and 3 µl of 
dNTP mix (10 mM each of dATP, dCTP, dGTP and dTTP; Bioline) at 70°C for 5 
minutes. The RNA was then reverse transcribed by adding 4 µl of First-strand Buffer 
(5X; Invitrogen), 0.5 µl of SuperScript II RT enzyme (200 U/µl; Invitrogen), 2 µl of 
DTT (0.1 M; Invitrogen) and 1.5 µl of DEPC-treated H2O (Invitrogen). The 
thermocycling conditions were 42°C for 50 minutes then 75°C for 15 minutes. When 
the reverse transcription was complete the cDNA product was diluted in 50 µl of H2O 
(Sigma) and stored at -20°C until required.  
 
2.18.5 siRNA Transfection for Western Blot Analysis  
HACs and MSCs (Lonza) were seeded at a density of 300,000 cells/well in 6-well 
culture plates (Corning), with 2 ml of serum positive DMEM (Life Technologies) for 
HACs, and serum-positive MSC growth medium for MSCs. After 24 hours HACs and 
MSCs were transfected as previously described with 5 µl of GNL3 siRNA (20 µM; 
Sigma), 6.5 µl of DharmaFECT transfection reagent 1 (Thermo Scientific) made up to 
500 µl with serum-free medium. Cells transfected with non-targeting siRNA (20 µM; 
Sigma), untransfected cells treated with serum-free medium and cells treated with 
transfection reagent only were used as controls. siRNA sequences are listed in the 
appendix (Table A14). Cells were incubated in a humidified 5% CO2 incubator for 48 
hours then lysed. Each condition was carried out on three biological replicates each with 
six technical replicates.  
 
2.18.6 Protein Extraction  
Medium was aspirated from the wells and the cells were washed with PBS (Lonza). The 
plate was placed on ice and 120 µl of protein lysis buffer was added, consisting of 50 
mM Tris-HCl (Sigma), 50 mM sodium fluoride (NaF; Sigma), 10 mM sodium 
orthovanadate (Na3VO4; Sigma), 0.5 mM sodium pyrophosphate (Na4P2O7; Sigma), 1 
mM ethyleneglycoltetraacetic acid (EGTA; Sigma), 0.0146g EDTA (Sigma), 10 mM 
glycerol phosphate (Sigma), 10 % glycerol (Sigma), 10 ml Triton X-100 (Sigma), 1X 
complete inhibitor cocktail (Roche, Indiana, USA), 1 µM microcystin-LR (Sigma), and 
made up to 50 ml with deionised H2O. The cells were scraped in the protein lysis buffer 
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using a cell scraper (Corning) and the lysate was transferred to a 1.5 ml centrifuge tube. 
The cell lysate was incubated on ice for 20 minutes and mixed by flicking after 10 
minutes. Following this the tubes were centrifuged at 13,000 rpm at 4°C for 10 minutes 
and the supernatant containing the protein was transferred to a fresh 1.5 ml centrifuge 
tube and stored at -80°C until required.  
 
2.18.7 Protein Quantification using Bradford Ultra 
To ensure equal protein loading in Western blot analysis, the amount of protein was 
quantified using a standard curve of BSA (2 mg/ml; Thermo Scientific) from 0 to 1.5 
mg/ml in protein lysis buffer. Each of the proteins to be measured were diluted 1:10 
with protein lysis buffer and 20 µl added to two wells of a microtitre plate (Corning). To 
the protein, 300 µl of Bradford Ultra (Expedeon, Harsdon, UK) was added and the 
absorbance at 595 nm was measured using a Tecan microplate reader (Tecan, Reading, 
UK). The absorbance values were used to plot a BSA standard curve and the equation y 
= mx + b from the graph was used to calculate the volume of protein where y is the 
absorbance and x is the protein concentration.  
 
2.19 Western Blotting 
 
2.19.1 Gel Preparation 
A 12% separating gel was made, consisting of 3.6 ml of acrylamide bis-acrylamide 
(40%; NBS Biologicals, Huntingdon, UK), 3 ml of lower buffer (pH 8.8; 1.5 M Tris, 
0.4% w/v sodium dodecyl sulphate; SDS; Sigma), 5.4 ml of deionised H2O, 30 µl of 
ammonium persulphate (APS; 20%; Sigma) and 20 µl of N, N, N", N"-
tetramethylethylenediamine (TEMED; Sigma). The space between the glass plates was 
filled with 6 ml of the separating gel and 1 ml of propan-2-ol was added to the top to 
prevent evaporation of the gel. After 30 minutes a 4.5% stacking gel was made 
consisting of 1.35 ml of acrylamide bis-acrylamide (40%; Sigma), 3 ml of upper buffer 
(pH 6.8; 0.5M Tris, 0.4% w/v SDS; Sigma), 7.65 ml of deionised H2O, 30 µl of APS 
(20%) and 20 µl of TEMED (Sigma). The propan-2-ol was removed, the top of the gel 
was washed with deionised H2O, 3 ml of stacking gel was added to the top of the gel 
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and the comb was inserted. After 15 minutes the comb was removed from the set 
stacking gel and the glass plates were placed into a gel tank (Bio-Rad, Hertfordshire, 
UK) with running buffer (1X; pH 8) made up of 5.86 g glycine (Sigma), 20 g SDS 
(Sigma) and 60.6 g Tris base (pH 7-9; Sigma) in 2 L deionised H2O. For loading, 10 µg 
of the sample was mixed with 4 µl of Laemmli buffer (5X; 0.1M Tris-HCl; Sigma; 0.35 
M SDS; Sigma; 20% (v/v) glycerol; Sigma; 0.01% (v/v) bromophenol blue; Sigma; 5% 
(v/v) BME; Sigma) and made up to 20 µl with H2O (Sigma). Samples were boiled at 
95°C for 5 minutes to denature the proteins. The protein was loaded and 
electrophoresed at 100 V for 15 minutes at room temperature increasing to 150 V for 1 
hour.  
 
2.19.2 Electrophoretic Transfer of the Proteins to PVDF Membrane 
A piece of polyvinylidene fluoride (PVDF; GE Healthcare) and four pieces of blotting 
paper (GE Healthcare) were cut to the same size as the gel. The blotting paper was 
soaked for 5 minutes in transfer buffer consisting of 5.86 g glycine (Sigma) 0.65 g SDS 
(Sigma) 11.62 g Tris base (pH 7-9; Sigma) 400 ml methanol (100%) made up to 2 L 
with deionised H2O. The PVDF membrane was soaked for 3 minutes in methanol 
(100%). The gel had finished plates were carefully removed and the stacking gel 
discarded. The separating gel was then soaked in transfer buffer for 3 minutes. The 
blotting paper, membrane and gel were assembled on a semi-dry transfer machine (Bio-
Rad); two pieces of blotting paper then the membrane followed by the gel and the 
remaining two pieces of blotting paper. Air bubbles were removed with a roller, and the 
proteins were transferred to the membrane at 80 mA per gel for 1 hour 15 minutes.  
 
2.19.3 Blocking 
Once the proteins were completely transferred, the membrane was blocked for 30 
minutes in 20 ml Tris-buffered saline-Tween (TBS-T; pH 7.4; 12.1 g Tris; Sigma; 90 g 
NaCl; Sigma; 10 ml 10X Tween-20; Sigma made up to 1 L with deionised H2O) with 
5% milk powder (Marvel, Hertfordshire, UK).  
 
 
 54 
2.19.4 Incubation with Antibody 
The membranes were incubated on a rocker overnight at 4°C with anti-nucleostemin 
rabbit polyclonal antibody (Abcam, Cambridge, UK; 1:2000) in TBS-T with 5% milk 
powder (Marvel), or anti-β-actin mouse polyclonal antibody (1:10,000; Sigma) in TBS-
T with 5% milk powder (Marvel), as a control. The membranes were then incubated on 
a rocker at room temperature for 1 hour with polyclonal goat anti-rabbit secondary 
antibody or polyclonal goat anti-mouse (1:2000; 0.25 g/L; Dako, Ely, UK) in TBS-T 
with 5% milk. Following this the membranes were washed with TBS-T for 30 minutes, 
changing the buffer every 5 minutes.  
 
2.19.5 Detection 
Membranes incubated with anti-GNL3 were detected using Enhanced 
Chemiluminescent reagent (ECL) prime (GE Healthcare) and membranes incubated 
with anti-β-actin were detected using ECL (GE Healthcare). The membranes were 
incubated at room temperature for 5 minutes with 1 ml of ECL or ECL prime reagents 1 
and 2 in a 1:1 ratio. The membrane was exposed 5 times at 20-second intervals using a 
G:BOX gel doc system (Syngene). If the protein was undetectable after this exposure 
time then the exposure time was increased to 1-minute or 5-minute intervals.  
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Chapter 3: Gene Expression Analysis of the Osteoarthritis Susceptibility Locus 
Mapping to Chromosome 7q22 
 
 
3.1 Introduction 
 
A GWAS of hip, knee and hand OA was performed on female Dutch Caucasian OA cases 
and controls from the Rotterdam study (131). The GWAS tested 500,510 SNPs and 
identified 18 SNPs at 12 loci with associations to OA. The 12 loci were tested in 12 further 
studies of hip, knee and hand cases as well as controls. Only one locus reached GWS after 
replication; a locus on 7q22 that was associated with knee and/or hand OA, with an OR of 
1.14 and a P-value of 8 x 10-8 for the G allele of SNP rs3815148 within intron 12 of COG5. 
A subsequent study of knee cases and controls from 8 additional European cohorts to those 
originally investigated in the Dutch report generated more significant evidence for 
association of OA to the 7q22 locus (149). This meta-analysis identified an additional 
signal at 7q22 with an OR of 1.17 and a P-value of 9.2 x 10-9 for the G allele of SNP 
rs4730250 within intron 3 of DUS4L. 
    The 7q22 locus contains six genes in a 500kb region of high LD with pair-wise r2 and D! 
values between rs3815148 and rs4730250, of 0.82 and 1.0, respectively. In physical order 
the six genes from within the association signal are: PRKAR2B, HBP1, COG5, GPR22, 
DUS4L, and BCAP29 .  
 
3.1.1 PRKAR2B 
The cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) is a 
serine/threonine kinase consisting of two catalytic subunits and a regulatory subunit dimer 
made up of RI and RII subunits. Activation of PKA occurs when two cAMP molecules 
bind the regulatory dimer, releasing the active catalytic subunits and allowing them to 
phosphorylate specific substrate proteins on serine and threonine residues (150-152). Both 
the catalytic and the regulatory subunits exist as multiple isoforms: Cα, Cβ, Cγ, RIα, RIβ, 
RIIα and RIIβ (150). PRKAR2B encodes the RIIβ regulatory subunit of PKA. PRKAR2B 
has limited expression in most tissues but is abundantly expressed in the brain and in brown 
and white adipose tissue (153, 154). Activation of white adipose tissue is decreased in RIIβ 
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knockout mice whereas activation of brown adipose is increased, leading to an increased 
metabolic rate, which protects against diet-induced obesity (153-155). Overexpression 
studies of the RIIβ regulatory subunit in cancer cell lines have shown that increased RIIβ 
results in growth arrest, differentiation and maturation of the cells (152). 
RIIβ has also been implicated in the autoimmune disease systemic lupus erythematosus 
(SLE). Deficient PKA activity in the T cells is estimated to affect 37% of SLE patients and 
is associated with a significant increase in RIIβ levels (156). It is possible that RIIβ acts as 
a negative regulator of T cell activation as it was demonstrated to bind cAMP response 
element-binding protein (CREB) in vitro leading to inhibition of CREB transcription 
activity and CRE-dependent transcription in T cells (156).  
  
3.1.2 HBP1 
HBP1 is a member of the high mobility group (HMG) box transcription factors and is one 
of few transcriptional repressors within this family (157, 158). Other HMG box 
transcription factor members include lymphoid enhancer factor (LEF) and T cell factor 
(TCF), which are transcription factors activating oncogenes such as Cyclin D1 and c-Myc, 
via the Wnt/β catenin pathway (158).  HBP1 has been shown to be a negative regulator of 
the Wnt/β-catenin pathway (159) through binding TCF4 and preventing subsequent binding 
of TCF4 to its target genes (160).  
It has been shown that HBP1 interacts with proteins of the retinoblastoma (RB) family, 
which are growth suppressor proteins with a role in cell cycle regulation (161, 162). HBP1 
is the target of RB in the establishment of terminal differentiation and a large increase in 
HBP1 mRNA has been seen during terminal differentiation (163) indicating that HBP1 has 
a role in the progression of the cells through the cell cycle (158). RB along with another 
tumour suppressor gene, p53, is an important factor in both replicative and premature 
senescence. RB binding is essential for HBP1-induced premature senescence triggered by 
either RAS or p38 mitogen-activated protein kinase (MAPK) signalling (159).  
HBP1 has also been implicated in the regulation of superoxide production whereby 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase catalyses the reduction of 
O2 to the superoxide anion O2-. NADPH oxidase comprises cytoplasmic regulatory subunits 
p47phox, p67phox and p40phox that combine with a membrane complex containing a 
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catalytic subunit. HBP1 has been demonstrated to bind to and repress the gene for the 
p47phox subunit reducing cell cycle progression, and superoxide levels (164).  
 
3.1.3 COG5 
The conserved oligomeric Golgi (COG) complex is essential for Golgi structure (165). 
Mammalian COG is a large complex consisting of eight polypeptides (COG1-8; 166). 
These eight subunits are divided into two lobes COG1- 4 and COG5-8 bridged by a 
interaction of COG1 and 8; COG5 encodes the COG5 subunit.  Mutations in COG genes 
can cause congenital disorders of glycosylation (CDG; 165), which can cause milder 
phenotypes such as psychomotor retardation, language delay and dysmorphism, or more 
severe phenotypes such as hormonal disorders, coagulopathies, multiple organ failure and 
skeletal malformations (166, 167). Mutations within COG5 have been shown to cause the 
milder phenotypes (166). Around 70% of all proteins are glycosylated and these 
glycoproteins have a key role in metabolism including correct protein folding, cell 
recognition, and cell adhesion (166). The Golgi apparatus is a hub for membrane trafficking 
pathways and plays a key role in the secretion of glycoproteins, glycolipids and 
proteoglycans (168). Vesicular trafficking of proteins and lipids through the Golgi requires 
that vesicles recognize and fuse to the membrane compartments (169). It is thought that the 
COG complex acts as a tether for this vesicular transport through the Golgi compartments 
(167).  
 
3.1.4 GPR22 
GPR22 is referred to as an orphan G protein-coupled receptor as the natural ligand remains 
undiscovered (170). However, GPR22 mRNA has been shown to be expressed in the 
cardiac myocytes and coronary arteries and the protein couples to receptor Gi/Go, which 
suggests a role in cardiac contractile function (170, 171). Increased Gi protein expression 
during heart failure has been associated with the decreased contractile response to 
activation of the β-adrenergic pathway, and this, coupled with the fact that GPR22 
knockout mice have increased susceptibility to heart failure, indicates that there may be a 
role for GPR22 in the transition process from hypertrophy to heart failure (170). 
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3.1.5 DUS4L 
DUS4L, also known as PP35, encodes dihydrouridine synthase 4-like. Dihydrouridine is 
one of the most common modified nucleosides (172), and is formed by the reduction of the 
carbon-carbon double bond by dihydrouridine synthases, mostly at the D loop of tRNAs. 
Functionally they may protect the tRNA against degradation as it has been demonstrated 
that tRNAs degrade significantly faster when there are no dihydrouridines present (173). 
DUS4L/PP35 has also been linked to Fanconi anaemia (FA), an autosomal recessive 
immunodeficiency, after being shown to interact with the FA complementation group A 
(FANCA) protein. Amongst the characteristics of FA are skeletal abnormalities and growth 
retardation (174).  
  
3.1.6 BCAP29 
BCAP29, or BAP29, codes for a 29kDa B cell receptor-associated protein. BCAP29 forms a 
complex with the closely related BCAP31 (175, 176). BCAP29 and BCAP31 both possess 
a dilysine motif (KKXX) at the C terminus, which is required for localisation of proteins to 
the endoplasmic reticulum (ER; 177-179) so it is thought that the BCAP29/BCAP31 
complex is involved in the process of protein exportation from the ER (179). Immature B 
cells express only IgM antigen receptors and, once they leave the bone marrow they mature 
and begin to express both IgM and IgD (176). The antigen receptor on mature B cells 
(BCR) comprises one membrane bound immunoglobulin (mIg) for example IgM or IgD 
and an Igα/Igβ heterodimer (178). It has been demonstrated in mice that when co-
expressed with BCAP29/31, the transmembrane form of the IgD BCR is not exported to the 
surface in the absence of the Igα/Igβ heterodimer, however when there is no 
BCAP29/BCAP31 complex the incomplete BCR is exported to the surface (179). It was 
therefore concluded that BCAP29/BCAP31 complexes are involved in the ER retention of 
mIg molecules in the absence of Igα/Igβ (178).  
 
The Dutch 7q22 association report investigated the expression of PRAKR2B, HBP1, 
COG5 and DUS4L in cultured synovial fibroblasts and chondrocytes, where they detected 
abundant HBP1 and COG5 expression but very low expression levels of PRKAR2B, 
DUS4L and GPR22 (131). In their discovery of the 7q22 OA susceptibility locus, Kerkhof 
and colleagues noted that GPR22 harbored a common SNP that was associated with GPR22 
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expression in transformed lymphoblast cell lines. Whether this is relevant to the pathology 
of OA or simply a coincidence reflecting the existence of cell-type specific eQTLs was not 
resolved. Based upon this, they performed immunohistochemistry on joints from normal 
and osteoarthritic mice and on osteophytes from mice with instability-induced OA. GPR22-
positive chondrocytes were found in the osteophytes of the mice with OA but not in normal 
mice chondrocytes (131). Evangelou et al. analysed the expression of all six genes in 
chondrocyte pellet cultures compared to monolayer cultures and observed that HBP1, 
COG5, DUS4L, and BCAP29 were all expressed at higher levels in pellet cultures, which 
replicate the environment seen in articular cartilage, whereas PRKAR2B and GPR22 
showed no difference in expression between pellet cultures and monolayer (149). They also 
analysed expression in zebrafish to explore possible roles of these genes during 
embryogenesis and detected expression of all six genes. The overall conclusion from these 
expression studies was that all of the genes showed near universal expression patterns in the 
tissues examined, except GPR22, which was only seen to be expressed in cultured 
chondrocytes and in cartilage from mice with instability-induced OA (131).  
  
 
3.2 Aim 
The aim of this chapter is to assess whether the six genes are subject to cis-acting 
regulatory polymorphisms that are active in joint tissues, which could contribute to the 
association signal.  
 
 
3.3 Results 
 
3.3.1 Expression of the Genes in Human Synovial Joint Tissues. Each gene was analysed 
for expression in joint tissues by standard qualitative PCR (Chapter 2, section 2.5). Five of 
the six genes were expressed in all joint tissue cDNAs tested (Figure 3.1), with the 
exception being GPR22. This gene was not expressed in any joint tissue but was expressed 
in heart, which was used as a positive control for its expression. Subsequently, expression 
was tested by Real-Time qPCR (Chapter 2, section 2.6-7). Again, all genes demonstrated 
expression except for GPR22 (Figure 3.2).  
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Figure 3.1.  Expression analysis of the six chromosome 7q22 genes by standard 
qualitative PCR. The analysis was performed on pooled cDNA synthesized from RNA 
extracted from OA knees. The tissues analysed were fat pad (Fp), meniscus (Me), tendon 
(Te), ligament (Li), cartilage (Cn) and synovium (Sy). The housekeeping gene HPRT1 was 
included to confirm the integrity of each cDNA sample. Heart cDNA from a cDNA library 
was used as a positive control for the GPR22 primers.
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Figure 3.2. Column graphs of expression levels of the six 7q22 genes by Real-Time qPCR in: OA cartilage (Cn), cartilage from a patient 
who had undergone surgery for a neck of femur fracture (NOF), ligament (Li), meniscus (Me), tendon (Te), synovium (Sy), fat pad (Fp), 
osteophyte (Os) and cancellous bone (Bn). The reactions were carried out in triplicate using cDNA from three different individuals. The 
results were normalized against the 18S housekeeping gene. There is no expression of GPR22 in synovial joint tissues. Heart cDNA was 
used as a positive control for the GPR22 assay. The error bars represent the standard error of the mean. 
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3.3.2 Quantitative Comparison of the Expression of the Genes between the Cartilage 
from OA and NOF Patients. Expression of the six genes was compared between cartilage 
from OA patients who had undergone a THR and control cartilage from patients who had 
undergone hip surgery due to a NOF fracture (Figure 3.3). GPR22 was not expressed in any 
of the over 100 cartilage samples tested but it was expressed in heart. Therefore we can 
conclude that GPR22 is not expressed at detectable levels in the patient samples used. As 
already noted, in the discovery of the 7q22 locus, the investigators were able to detect 
expression of GPR22 in RNA isolated from cultured chondrocytes (131). It is known that 
the culturing of cells can alter the expression pattern of genes (180) so it is therefore 
possible that this previous report on the expression of GPR22 reflects an artefact of the use 
of cultured cells. Based on the cartilage results, and on the lack of expression of GPR22 in 
the other joint tissues tested, it was decided to exclude this gene from subsequent 
experiments. Significant reductions in expression in OA cartilage relative to control 
cartilage were seen for all five of the remaining genes. Next, expression of the genes in 
cartilage of patients who had undergone TKR was compared with expression of the genes 
in cartilage from patients who had undergone THR (Figure 3.4). A significant reduction in 
expression of PRKAR2B (P = 0.04), COG5 (P = 0.003) and BCAP29 (P = 0.03) in hip 
cartilage compared to knee cartilage was observed. Conversely, a significant reduction in 
expression of DUS4L in knee cartilage was observed compared to hip cartilage (P < 
0.0001).  Having observed that GPR22 was not detectable in our tissue samples, that the 
five remaining genes showed reduced expression in OA cartilage, and that four of the five 
(PRKAR2B, COG5, BCAP29, and DUS4L) showed significantly different expression levels 
between OA hip cartilage and OA knee cartilage, the samples were analysed for a 
correlation between expression levels and genotype at the associated SNP to ascertain 
whether the 7q22 association signal could be operating by modulating expression of one or 
more of the five genes in joint tissues from patients undergoing total joint replacement 
(TJR).  
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Figure 3.3 Columnar scatter plots of the quantitative expression of the five genes between 
cDNA from OA hip cartilage and cDNA from control hip cartilage. The control cartilage 
was collected from patients who had undergone surgery for a NOF fracture. n is the number 
of patients studied. The horizontal lines in each plot represent the mean and the standard 
error of the mean. P-values were calculated using a Mann-Whitney U test.
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 Figure 3.4 Columnar scatter plots of the quantitative expression of the five genes between 
cDNA from OA hip cartilage and cDNA from OA knee cartilage. n is the number of 
patients studied. The horizontal lines in each plot represent the mean and the standard error 
of the mean. P-values were calculated using a Mann-Whitney U test. 
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3.3.3 Quantitative Expression of PRKAR2B, HBP1, COG5, DUS4L and BCAP29 in 
Cartilage, Fat Pad, and Synovium Stratified by Genotype at the Associated SNPs. To 
initially determine whether one or more of the five genes harboured cartilage eQTLs that 
correlated with the OA association signal, overall levels of expression of each gene were 
quantified in cartilage samples and the data were stratified by genotype at the two OA 
associated SNPs, rs3815148 and rs4730250 (Chapter 2, section 2.8). None of the OA 
patients tested were homozygous for the minor allele of either SNP. This is a reflection of 
the relatively low minor allele frequencies of the two SNPs; in HapMap CEU rs3815148 
has a GG frequency of 4.4% whilst rs4730250 has a GG frequency of 3.5%. The analysis 
therefore involved a comparison between individuals that were homozygous for the major 
allele and those that were heterozygous. HBP1 demonstrated a significant difference in 
expression between the two genotypic groups for rs3815148 (P = 0.02; Figure 3.5) and 
rs4730250 (P = 0.003; Figure 3.6). In both instances there was reduced expression of the 
gene in individuals who carried the OA-associated G alleles at the SNPs. When the analysis 
was repeated on the TKR cases only, HBP1 again demonstrated a significant difference in 
expression in cartilage between the two genotypic groups for rs3815148 (Figure 3.7) and 
for rs4730250 (Figure 3.8), and once again it was the OA associated G alleles that 
correlated with reduced expression.  
          The P-values were however more significant in this TKR analysis compared to the 
combined analysis, with P-values of 0.004 for rs3815148 and 0.0002 for rs4730250. This 
clearly aligns with the fact that the 7q22 OA association signal is particularly relevant to 
knee OA (131, 149). COG5 also demonstrated a significant difference for rs4730250 in the 
TKR analysis (Figure 3.8), but the P-value was 100-fold less significant than that seen for 
HBP1 (0.02 versus 0.0002), whilst COG5 was not significant for rs3815148 (P = 0.99; 
Figure 3.7). All but one of the THR patients were homozygous TT for rs3815148 and 
homozygous AA for rs4730250, so no genotype comparisons could be made for the THR 
patients. Fat pad and synovial tissue was also collected from a number of TKR patients, 
providing the opportunity to assess whether any of the five genes harboured eQTLs 
relevant to these two joint tissues. As with the cartilage analysis, in fat pad there were no 
homozygotes for the minor allele of either of the associated SNPs.  
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Figure 3.5 Columnar scatter plots of the quantitative gene expression of the 7q22 genes in 
cDNA from OA hip and OA knee cartilage, with patients stratified by genotype at the 
associated SNP rs3815148. n is the number of patients studied. Due to the absence of GG 
homozygotes at rs3815148, the analysis was between TT homozygotes and G-allele carriers 
(TG). The horizontal lines in each plot represent the mean and the standard error of the 
mean. P-values were calculated using a Mann-Whitney U test.  
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Figure 3.6 Columnar scatter plots of the quantitative gene expression of the 7q22 genes in 
cDNA from OA hip and OA knee cartilage, with patients stratified by genotype at the 
associated SNP rs4730250. n is the number of patients studied. Due to the absence of GG 
homozygotes at rs4730250, the analysis was between AA homozygotes and G-allele 
carriers (AG). The horizontal lines in each plot represent the mean and the standard error of 
the mean. P-values were calculated using a Mann-Whitney U test.  
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Figure 3.7 Columnar scatter plots of the quantitative gene expression of the 7q22 genes in 
OA knee cartilage cDNA, with patients stratified by genotype at the associated SNP 
rs3815148. n is the number of patients studied. Due to the absence of GG homozygotes at 
rs3815148, the analysis was between TT homozygotes and G-allele carriers (TG). The 
horizontal lines in each plot represent the mean and the standard error of the mean. P-values 
were calculated using a Mann-Whitney U test. 
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Figure 3.8 Columnar scatter plots of the quantitative gene expression of the 7q22 genes in 
OA knee cartilage cDNA, with patients stratified by genotype at the associated SNP 
rs4730250. n is the number of patients studied. Due to the absence of GG homozygotes at 
rs4730250, the analysis was between AA homozygotes and G-allele carriers (AG). The 
horizontal lines in each plot represent the mean and the standard error of the mean. P-values 
were calculated using a Mann-Whitney U test. 
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The DUS4L expression levels in fat pad stratified by rs3815148 approached significance (P 
= 0.07; Figure 3.9), and a significant difference in expression for DUS4L was observed 
between the two genotypic groups for rs4730250 (P = 0.04, Figure 3.10). In both cases the 
OA associated G alleles correlated with reduced expression. In the analysis of synovium, 
only one of the patients was a GG homozygote for rs3815148 and rs4730250. This person 
was combined with the TG (rs3815148) and AG (rs4730250) heterozygotes and a 
comparison was made between carriers of the G allele at each SNP and non-carriers. 
Carriage of the OA associated G allele at rs3815148 correlated with significantly reduced 
expression of HBP1 (P = 0.02, Figure 3.11), whilst the data for rs4730250 approached 
significance for this gene (P = 0.07: Figure 3.12).   
This analysis demonstrated that carriers of the OA-associated G allele at both 
rs3815148 and rs4730250 show reduced HBP1 expression levels in cartilage, that carriers 
of the G allele at rs3815148 show reduced HBP1 expression levels in synovium, and that 
carriers of the OA-associated G allele at rs4730250 show reduced DUS4L expression in fat 
pad. Both HBP1 and DUS4L are therefore subject to cis-regulatory eQTLs that correlate 
with the OA association signal at 7q22. To further investigate these eQTLs the relative 
allelic expression levels of HBP1 and DUS4L were then measured in various joint tissues.  
 
3.3.4 AEI Analysis in Joint Tissues. As both rs3815148 and rs4730250 are intronic SNPs, 
AEI was measured using two transcript SNPs in high LD with the associated SNPs; the 
HBP1 SNP rs7794598 and the DUS4L SNP rs711442 (Chapter 2, section 2.9; LD values 
can be found in Table 3.1, and SNP details in the appendix, Table A6). AEI was measured 
using SNaPshot (Chapter 2, section 2.10) and for each transcript SNP, individuals who 
were heterozygous for the SNP and heterozygous for one or both of the associated SNPs 
were studied. This enabled the assessment of whether the OA associated alleles at 
rs3815148 and rs4730250 correlated with increased or decreased allelic expression of the 
two genes. If this were the case, AEI would be observed in a compound heterozygote. 
Individuals who were heterozygous for the transcript SNP but homozygous for one or both 
of the associated SNPs were also studied. This allowed for the direct assessment of whether 
HBP1 or DUS4L were subject to a cis-eQTL that was acting independently of the 
association signal.     
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Figure 3.9 Columnar scatter plots of the quantitative gene expression in fat pad cDNA 
from OA knees, with patients stratified by genotype at the associated SNP rs3815148. n is 
the number of patients studied. Due to the absence of GG homozygotes at rs3815148, the 
analysis was between TT homozygotes and G-allele carriers (TG). The horizontal lines in 
each plot represent the mean and the standard error of the mean. P-values were calculated 
using a Mann-Whitney U test.  
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Figure 3.10 Columnar scatter plots of the quantitative gene expression in fat pad cDNA 
from OA knees, with patients stratified by genotype at the associated SNP rs4730250. n is 
the number of patients studied. Due to the absence of GG homozygotes at rs4730250, the 
analysis was between AA homozygotes and G-allele carriers (AG). The horizontal lines in 
each plot represent the mean and the standard error of the mean. P-values were calculated 
using a Mann-Whitney U test.  
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Figure 3.11. Columnar scatter plots of the quantitative gene expression in synovium cDNA 
from OA knees, with patients stratified by genotype at the associated SNP rs3815148. n is 
the number of patients studied. Due to the low frequency of GG homozygotes at rs3815148 
the analysis was between TT homozygotes and G-allele carriers (TG and GG). The 
horizontal lines in each plot represent the mean and the standard error of the mean. P-values 
were calculated using a Mann-Whitney U test.  
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Figure 3.12. Columnar scatter plots of the quantitative gene expression in synovium cDNA 
from OA knees, with patients stratified by genotype at the associated SNP rs4730250. n is 
the number of patients studied. Due to the low frequency of GG homozygotes at rs4730250 
the analysis was between AA homozygotes and G-allele carriers (AG and GG). The 
horizontal lines in each plot represent the mean and the standard error of the mean. P-values 
were calculated using a Mann-Whitney U test. 
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Table 3.1 The two transcript SNPs used for AEI analysis and their pair-wise D′ and r2 
values relative to the two associated SNPs rs3815148 and rs4730250. 
 
Gene Transcript 
SNP 
Alleles MAF1 Pairwise linkage disequilibrium 
relative to rs3815148 relative to rs4730250 
D′  r2 D′ r2 
HBP1 rs7794598 C/T 0.219 1 1 1 0.82 
DUS4L rs711442 C/T 0.469 0.59 0.10 1 0.21 
1Minor allele frequency in Europeans (HapMap CEU) 
 
 
HBP1 
AEI analysis was carried out on a number of different joint tissues taken from twenty 
patients (Table A1). Twelve of the twenty were heterozygous for both rs7794598 and 
rs4730250, whilst all twenty were heterozygous for rs7794598 and rs3815148. This is a 
reflection of the fact that rs7794598 and rs4730250 are in complete linkage disequilibrium 
(D′ = 1.0, r2 = 0.82; Table 3.1), whilst rs7794598 and rs3815148 are in perfect linkage 
disequilibrium (D′ = 1.0, r2 = 1.0). The G allele of rs4730250 will reside on a haplotype 
carrying the T allele of rs7794598, as will the G allele of rs3815148. Seventeen of the 
twenty patients demonstrated a significant AEI (P < 0.05; Figure 3.13 and Table 3.2), and 
these significant imbalances observed operated in both directions, that is, in eight patients 
(26, 45, 52, 55, 62, 128, 148 and 189) the C-allele at rs7794598 produced more transcript 
than the T-allele whilst the opposite was the case for nine patients (26, 28, 33, 82, 86, 92, 
134, 138 and 142).  
      The allelic ratios for all 20 patients were plotted on a scatter plot and a Mann-Whitney 
U test was performed to identify any possible correlation between the associated SNP 
genotypes and the level or direction of AEI as measured with rs7794598 (Figure 3.14). 
Since rs7794598 and rs3815148 are in perfect LD all patients were compound 
heterozygous, thus disallowing the ability to study genotype correlations for rs3815148. 
rs7794598 and rs4730250 are not in perfect LD and a correlation analysis could therefore 
be performed for this SNP, revealing a significant difference in the allelic ratios between 
individuals homozygous AA and heterozygous AG at rs4730250 (P = 0.008; Figure 3.14), 
highlighting that the HBP1 eQTL correlates with genotype at this associated SNP. 
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Figure 3.13 Allelic expression analysis of the transcript SNP rs7794598 in HBP1 using cDNA from joint tissues: Cn, cartilage; Sy, 
synovium; Fp, fat pad; Li, ligament; Me, meniscus. The genotypes of the patients for the two associated SNPs rs3815148 and 
rs4730250 are shown (the rs4730250 genotypes were undetermined for patients 128, 138 and 189). The cDNA allelic ratio in each 
sample was compared to the DNA ratio using a Mann-Whitney U test. *** P < 0.001, ** P <0.01 and * P < 0.05.  
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Table 3.2 The allelic ratios for the samples analysed for AEI at rs7794598. Allelic 
ratios are shown ± the standard error of the mean. P-values were calculated using a 
Mann-Whitney U test. P-values < 0.05 are highlighted in bold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fact that not all rs4730250 heterozygotes demonstrated a significant allelic imbalance 
in the same direction (patients 26, 28, 33, 82, 86, 92, 142, and 134 show an imbalance in 
the direction of the C allele of rs7794598 whereas patients 52 and 148 show an imbalance 
in the opposite direction), suggests that the correlation is not complete. This is supported by 
the fact that several rs4730250 AA homozygotes also demonstrate significant AEI, which 
may also be highlighting the existence of more than one eQTL operating on HBP1. One of 
the cartilage samples studied was derived from a NOF patient (patient 189). This patient 
also demonstrated significant HBP1 AEI (P < 0.001), highlighting that the eQTL is not 
dependent on OA status. 
 
HBP1 
rs7794598 
Patient Allelic ratio (C/T) P value 
26 0.53 ± 0.17 <0.01 
29 0.93 ± 0.02 0.39 
33 0.83 ± 0.03 <0.01 
45 1.78 ± 0.11 <0.01 
46 1.62 ± 0.05 <0.01 
55 1.36 ±0.06 <0.01 
82 0.68 ± 0.05 <0.01 
86 0.78 ± 0.08 0.01 
92 0.67 ± 0.05 <0.01 
189 1.62 ± 0.08 <0.01 
28 0.85 ± 0.02 <0.01 
50 1.13 ± 0.04 0.11 
52 1.29 ± 0.01 0.03 
142 0.86 ± 0.02 <0.01 
148 1.44 ± 0.04 < 0.01 
134 0.73 ± 0.01 <0.01 
135 0.90 ± 0.01 0.33 
62 1.13 ± 0.04 0.04 
128 1.28 ± 0.06 <0.01 
138 0.85 ± 0.01 <0.01 
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Figure 3.14. Scatter plots of the allelic ratios from AEI analysis of rs7794598 in HBP1 
stratified by genotype at the associated SNPs rs3815148 and rs4730250. TG is the single 
genotypic group at rs3815148, as the SNPs are in perfect LD, and AA and AG are the 
genotypic groups at rs4730250. n is the number of patients in each of the genotypic groups. 
P-values were calculated using a Mann-Whitney U test.  
 
 
DUS4L 
AEI analysis was carried out on a number of different joint tissues taken from eighteen OA 
patients (Table A1), eight of whom were heterozygous for rs3815148, whilst five were 
heterozygous for rs4730250. Nine of the eighteen patients demonstrated a significant AEI 
(P < 0.05; Figure 3.15 and Table 3.3). The majority of the imbalances observed operated in 
the same direction, with the C allele at rs711442 producing more transcript than the T 
allele. 
In the scatter plot analysis there was no significant evidence (P < 0.05) for a correlation 
between the associated SNP genotypes and the level or direction of AEI as measured with 
rs711442 (Figure 3.16), although rs4730250 approached significance (P = 0.07).
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Figure 3.15 Allelic expression analysis of the transcript SNP rs711442 in DUS4L using cDNA from joint tissues: Cn, cartilage; Sy, 
synovium; Fp, fat pad; Li, ligament; Me, meniscus; Bn, cancellous bone. The genotypes of the patients for the two associated SNPs 
rs3815148 and rs4730250 are shown (the rs4730250 genotype was undetermined for patient 61). The cDNA allelic ratio in each 
sample was compared to the DNA ratio using a Mann-Whitney U test. *** P < 0.001, ** P <0.01 and * P < 0.05.  
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Table 3.3 The allelic ratios for the samples analysed for AEI at rs711442. Allelic ratios 
are shown ± the standard error of the mean. P-values were calculated using a Mann-
Whitney U test. P-values < 0.05 are highlighted in bold. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Scatter plots of the allelic ratios from AEI analysis of rs711442 in DUS4L, 
stratified by genotype at the associated SNPs rs3815148 and rs4730250. TT and TG are the 
genotypic groups at rs3815148 and AA and AG are the genotypic groups at rs4730250. n is 
the number of patients in each of the genotypic groups. P-values were calculated using a 
Mann-Whitney U test.  
DUS4L 
rs711442 
Patient allelic ratio (G/A) P value 
19 1.66 ± 0.23 0.01 
24 1.61 ± 0.08 <0.01 
55 2.02 ± 0.11 <0.01 
77 2.95 ± 0.27 <0.01 
81 1.03 ± 0.20 0.89 
83 1.87 ± 0.49 0.05 
91 2.03 ± 0.24 <0.01 
129 0.79 ± 0.13 0.04 
188 1.09 ± 0.14 0.89 
71 0.97 ± 0.03 1.00 
127 2.93 ± 0.14 <0.01 
151 2.53 ± 0.34 <0.01 
70 0.94 ± 0.19 0.94 
128 1.03 ± 0.09 0.53 
61 1.04 ± 0.03 0.25 
68 0.87 ± 0.15 0.60 
52 1.53 ± 0.23 0.03 
143 2.22 ± 0.29 0.02 
 81 
3.4 Discussion 
This expression analysis of the six genes that map to the chromosome 7q22 OA 
association signal has revealed that: 1) PRKAR2B, HBP1, COG5, DUS4L and BCAP29 are 
expressed in joint tissues and that all five are expressed at a significantly lower level in OA 
cartilage compared to control cartilage, 2) carriage of the OA associated alleles at 
rs3815148 and rs4730250 correlates significantly with reduced HBP1 expression in 
cartilage 3) this correlation is particularly pronounced in knee cartilage, the joint most 
relevant to the association signal 4) reduced HBP1 expression in OA synovium correlates 
with carriage of the OA associated allele at rs3815148 5) reduced DUS4L expression in OA 
fat pad correlates with carriage of the OA associated allele at rs4730250 and 6) all the 
correlations seen can be directly observed at an allelic level. These results therefore indicate 
that HBP1 should be prioritised from amongst the six as being the target of the OA 
susceptibility that maps to chromosome 7q22. 
      As previously mentioned, HBP1 codes for HMG-box transcription factor 1, which has 
been implicated in Wnt signaling suppression, premature cellular senescence, and 
superoxide production, but most research to date has focused on the transcriptions factor’s 
activity in a variety of human cancers (181-183). There have been no functional studies yet 
reported on the role of the transcription factor in arthritis. However the Wnt pathway, 
cellular senescence and oxidative stress are known to be contributors to OA etiology (184-
186).  
Wnt pathway activation is initiated by Wnt protein binding to frizzled-receptors and low-
density lipoprotein receptor 5/6 co-receptors. In the canonical Wnt pathway this binding 
inhibits the phosphorylation of β-catenin. This stabilizes the β-catenin and allows it to 
accumulate and translocate to the nucleus to interact with LEF/TCF transcription factors, 
which in turn activate Wnt target genes (187). Numerous Wnt factors have been shown to 
be upregulated in OA: Wnts 2b, 4, 6, 7a, 7b, 9b, 10a, 16 and particularly 3a, which, when 
used to stimulate chondrocytes, upregulated MMP3 and a disintegrin and metalloproteinase 
with thrombospondin motifs-4 (ADAMTS4; 188). Furthermore an experiment activating 
the Wnt/β-catenin pathway in chick embryos triggered expression of MMP13 leading to 
degradation of the proteoglycan matrix with subsequent loss of tissue structure and function 
(189) indicating that induction of the pathway reprogrammes chondrocytes towards a 
catabolic phenotype (184, 187). Therefore a low level of β-catenin is necessary for the 
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maintenance of the differentiated chondrocyte phenotype (190) preventing this stimulation 
of chondrocyte catabolic action (187). Since HBP1 has been shown to be an efficient 
repressor of Wnt/β-catenin signaling (158), altered HBP1 expression could therefore have a 
role in OA aetiology.  
         Price et al. showed that osteoarthritic chondrocytes expressed the marker of 
senescence, β-galactosidase, whereas non-osteoarthritic chondrocytes from the same donor 
did not express markers of cellular senescence (191). HBP1 is essential for initiation of 
premature cellular senescence as part of both the retinoblastoma and MAPK pathways 
(159), so again, it can be concluded that HBP1-mediated cellular senescence may 
contribute to OA aetiology.  
 
       Since adult articular cartilage is avascular, the mature chondrocytes must survive in a 
relatively hypoxic environment (192). Chondrocytes express NADPH oxidase, nitrogen 
oxide synthase (NOS) family members and oxygenases that generate reactive oxygen 
species (ROS), NO and the superoxide anion. ROS cause cartilage damage by cleaving 
collagen and aggrecan or by modulating the redox-sensitive pathways that control MMP 
expression (186). As discussed previously, HBP1 represses the p47phox subunit of 
NADPH oxidase (164), which is essential for the regulation of ROS and is therefore 
another possible mechanism by which altered expression of HBP1 could contribute to OA.  
 
Since the HBP1 expression data highlights that reduced expression of the gene correlates 
with OA susceptibility, then activation of the Wnt pathway, attenuation of senescence and 
repression of NADPH oxidase could all be risk factors for OA.   
The prioritisation of HBP1 means that this gene, and its encoded protein, merits 
particularly detailed investigation in the context of OA and joint tissues. The results of the 
AEI, showing an incomplete correlation between genotype and AEI suggests that there may 
be multiple cis-acting regulatory polymorphisms interacting to modulate the expression of 
HBP1. Other examples of this have been reported. For instance, in their investigation of the 
gene PYDN Babbitt et al. (193) demonstrated that the expression of PYDN was under the 
regulation of at least six cis-acting variants. These results also emphasise that it is important 
not to limit a functional investigation of OA genetic susceptibility solely to cartilage; HBP1 
demonstrated significant expression effects in a variety of non-cartilaginous joint tissues, 
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including the synovium, which plays a key role in the disease (194). Furthermore, this 
investigation highlighted a second gene, DUS4L, as harbouring an eQTL that correlated 
with the 7q22 association signal at rs4730250 in fat pad, albeit not as compelling as that 
seen for HBP1. This signal would not have been detected had cartilage been the sole tissue 
investigated. IPFP has been hypothesised to have a role in the development and progression 
of OA (57) as it can secrete inflammatory mediators, such as TNFα and IL-6, which 
exacerbate the OA disease process (56).  
In addition to this, one of the patients studied was a control sample taken from a 
patient undergoing surgery for NOF fracture. This patient also demonstrated significant 
AEI and so the HBP1 eQTL is therefore acting in the manner of a DNA change that leads 
to an amino acid substitution; so long as the individual carries the allele, the amino acid 
will be substituted/the eQTL will mediate allelic imbalance, irrespective of the individuals 
case or control status. It is the fact that the allele is more prevalent in a case cohort versus a 
control cohort that matters, namely the standard polygenic model. 
 
Overall, the data reported in this chapter clearly demonstrates the need for a 
comprehensive molecular analysis of potential cis-acting regulatory elements of HBP1 in 
order to identify the actual functional variant(s) and to elucidate their haplotypic 
relationship with rs7794598 and with the OA-associated SNPs rs4730250 and rs3815148. 
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Chapter 4: Identification and Analysis of a SMAD3 cis-acting eQTL Operating in 
Primary Osteoarthritis 
 
 
4.1 Introduction 
Mothers against decapentaplegic homologue 3 (SMAD3) is member of the TGF-β 
superfamily (195). The TGF-β signalling pathway plays a critical role in joint 
development and joint maintenance; TGFβ initiates chondrogenesis through stimulation 
of mitogen-activated protein (MAP) kinase and wnt pathways (196), the proliferation of 
the chondroblasts and the subsequent synthesis of the components of the ECM such as 
aggrecan and type II collagen. During the formation of articular cartilage, the terminal 
differentiation of the chondrocyte is inhibited by TGF-β and the prehypertrophic 
phenotype is stabilised by TGF-β, which results in permanent cartilage residing at the 
end of the long bones. However during OA the chondrocytes undergo phenotypic 
changes that resemble terminally differentiating chondrocytes (196). SMAD2 and 3 
signalling is essential for the inhibitory effect of TGF-β on the terminal differentiation 
of chondrocytes; without SMAD2/3 signalling chondrocytes leave their quiescent state 
and undergo premature terminal differentiation (196,197). SMAD2 and 3 are therefore 
essential for cartilage maintenance (198).  
 
TGF-β is secreted as an inactive complex, which once activated, binds to its cell 
surface type II receptor (TGFβRII; 197, 199). TGFβRII then activates and recruits the 
type I receptor (TGFβRI), which phosphorylates the receptor-activated SMADs (R-
SMADs) SMAD2 and SMAD3 (199). The phosphorylated SMADs form complexes 
with the co-mediator SMAD (Co-SMAD) SMAD4 (SMAD2/4 or SMAD3/4), which 
translocate to the nucleus where they regulate transcription (199, 200).  
 
The SMAD family has eight members; two TGFβ R-SMADs (SMAD2 and 
SMAD3), three bone morphogenic protein (BMP) R-SMADs (SMAD1, SMAD5 and 
SMAD8), one Co-SMAD (SMAD4) and two inhibitor-SMADs (I-SMADs; SMAD6 
and SMAD7; 201).  
There is accumulating evidence from mouse models with disrupted TGF-β 
signalling that demonstrate joint abnormalities, of the involvement of the TGF-β 
pathway in OA aetiology. For example, mice overexpressing a dominant negative form 
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of TGF-β type II receptor in skeletal tissue develop progressive skeletal degeneration 
that strongly resembles human OA (202), mice lacking latent TGF-β binding protein 3, 
a structural component of the ECM that regulated TGF-β availability, show altered 
chondrocyte differentiation and early-onset OA (203), and overexpression of Smurf2 in 
transgenic mice, an E3 ubiquitin ligase and negative regulator of TGFβ, causes articular 
cartilage fibrillation, osteophyte formation and increased expression of type X collagen 
and MMP13, all of which are observed in OA (204). In addition to these models, 
Smad3-knockout mice have been created by targeted disruption of Smad3 exon 8. These 
Smad3ex8/ex8 mice are characterised by hypertrophic chondrocytes expressing type X 
collagen, progressive loss of cartilage and formation of large osteophytes, much like 
human OA (198).  
Based on evidence linking the TGF-β pathway to joint abnormalities, a study was 
performed to investigate the role of common genetic variation in SMAD3 to the risk of 
large joint OA in humans (205). The study was performed on 313 TKR and 214 THR 
cases and 520 controls, then replicated in 2,537 knee cases, 1,074 hip cases and 1,221 
controls. All cases and controls were European. It was reported that the SNP 
rs12901499, which is located in intron 1 of SMAD3, was associated with both hip (OR 
1.22, P < 4x10-4) and knee OA (OR 1.22, P < 7.5x10-6;8). Since rs12901499 is not in 
LD with a non-synonymous polymorphism, this association may be operating on gene 
expression rather than having an effect on the protein. 
 
4.2 Aim 
The aim of this chapter is to test whether this OA association is marking a cis-eQTL 
that operates on SMAD3.  
 
4.3 Results 
4.3.1 Expression of SMAD3 in Human Synovial Joint Tissues. SMAD3 was initially 
assessed for expression by Real-Time qPCR (Chapter 2, section 2.6) in eight joint 
tissues collected from three OA patients who had undergone joint replacement surgery 
and in control cartilage from three non-OA patients who had undergone hip joint 
replacement due to a NOF fracture (Figure 4.1). SMAD3 demonstrated expression in all 
joint tissues tested.  
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Figure 4.1 Column graph of the levels of expression of SMAD3 by Real-Time qPCR in 
tissue from three patients and three controls who had undergone total joint replacement. 
The tissues used were: neck of femur fracture (NOF), OA cartilage (Cn), synovium 
(Sy), fat pad (Fp), meniscus (Me), ligament (Li), tendon (Te), osteophyte (Os) and 
cancellous bone (Bn). The reactions were carried out in triplicate using cDNA from 
three different individuals. The results were normalised against the mean Ct values of 
the HPRT1, GAPDH and 18S housekeeping genes. The error bars represent the standard 
error of the mean. 
 
 
4.3.2 Quantitative Comparison of SMAD3 Expression between Cartilage from OA 
and NOF Patients. Expression of SMAD3 was then compared between hip cartilage 
from 44 patients who had undergone THR for OA and hip cartilage from 16 NOF 
patients (Figure 4.2), revealing a significantly lower level of SMAD3 expression in OA 
hip cartilage (P = 0.005). SMAD3 expression was then compared between knee cartilage 
from OA patients who had undergone TKR and hip cartilage from OA patients who had 
undergone THR  (Figure 4.3). This revealed a significantly lower level of SMAD3 
expression in knee cartilage (P = 0.0008). Overall, SMAD3 showed a lower level of 
expression in OA versus NOF cartilage, and in knee versus hip cartilage. Having shown 
that SMAD3 demonstrates significantly different expression levels between OA and 
NOF and between OA hip cartilage and OA knee cartilage, the samples were analysed 
for a correlation between expression levels and genotype at rs12901499.  
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Figure 4.2 Columnar scatter plot of the quantitative expression of SMAD3 between 
cDNA from OA hip cartilage and cDNA from control hip cartilage. The control 
cartilage was collected from patients who had undergone surgery for a neck of femur 
(NOF) fracture. n is the number of patients studied. The results were normalised against 
the mean Ct values of the HPRT1, GAPDH and 18S housekeeping genes. The horizontal 
lines in each plot represent the mean and the standard error of the mean. The P-value 
was calculated using a Mann-Whitney U test. 
 
 
 
Figure 4.3. Columnar scatter plot of the quantitative expression of SMAD3 between 
cDNA from OA hip cartilage and cDNA from OA knee cartilage. n is the number of 
patients studied. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The horizontal lines in each plot represent the 
mean and the standard error of the mean. The P-value was calculated using a Mann-
Whitney U test. 
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4.3.3 Quantitative Expression of SMAD3 in Cartilage, Fat Pad and Synovium 
Stratified by Genotype at rs12901499. SMAD3 expression levels were quantified in the 
OA cartilage samples using Real-Time qPCR (Chapter 2, section 2.6) and then the data 
were stratified by genotype at rs12902499 (Chapter 2, section 2.8, Figure 4.4).  
 
Figure 4.4 Columnar scatter plots of the quantitative gene expression of SMAD3, with 
patients stratified by genotype at the associated SNP rs12901499. n is the number of 
patients studied. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The horizontal lines in each plot represent the 
mean and the standard error of the mean. The P-value was calculated using a Kruskal-
Wallis test.  
 
There was no correlation between genotype and expression (P = 0.9). The analysis was 
subsequently repeated after separating the knee and hip cases (Figure 4.5).  Again there 
was no correlation in either the knee cartilage (P = 0.44) or the hip cartilage (P = 0.31). 
As part of this study, fat pad and synovial tissue were also collected from several of the 
OA knee patients, providing the opportunity to assess whether SMAD3 expression in 
these two tissues correlated with genotype at rs12901499 (Figure 4.6). Once again there 
was no correlation between genotype and SMAD3 expression in either fat pad (P = 0.67) 
or synovium (P = 0.23). 
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Figure 4.5 Columnar scatter plots of the quantitative gene expression of SMAD3 in 
cDNA from OA hip and OA knee cartilage, with patients stratified by genotype at the 
associated SNP rs12901499. n is the number of patients studied. Due to the low 
frequency of AA homozygotes at rs12901499 in the hip cohort, the analysis was 
between GG homozygotes and A-allele carriers (AG and AA). The results were 
normalised against the mean Ct values of the HPRT1, GAPDH and 18S housekeeping 
genes. The horizontal lines in each plot represent the mean and the standard error of the 
mean. The P-value was calculated using a Kruskal-Wallis test for the knees and a 
Mann-Whitney U test for the hips. 
 
 
 
 
 
Figure 4.6 Columnar scatter plots of the quantitative expression of SMAD3 in fat pad 
and synovium from OA knees. Patients were stratified by genotype at the associated 
SNP rs12901499. n is the number of patients studied. The results were normalised 
against the mean Ct values of the HPRT1, GAPDH and 18S housekeeping genes. The 
horizontal lines in each plot represent the mean and the standard error of the mean. P-
values were calculated using a Kruskal-Wallis test.  
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The above analysis did not provide evidence for a correlation between SMAD3 
expression and genotype at rs12901499 in any of the tissues studied. However this 
technique is vulnerable to the natural fluctuation in gene expression, which can decrease 
its sensitivity and accuracy (206). An alternative method for correlating genotype with 
expression levels that is not vulnerable to such fluctuation is AEI.  
 
4.3.4 AEI Analysis in Joint Tissues. Since rs12901499 is not a transcript SNP it could 
not itself be used in the AEI analysis. Therefore patients who were heterozygous for 
rs12901499 and for the common SMAD3 3"UTR SNP rs8031440 were studied, enabling 
the indirect testing of allelic output that may correlate with rs12901499, since if this 
were occurring, AEI would be observed in a high proportion of these compound 
heterozygotes. rs8031440 was chosen because it has a reasonably high minor allele 
frequency (0.26; Table 4.1) ensuring that a large proportion of our patients will be 
heterozygous and therefore suitable for the AEI analysis. Individuals who were 
homozygous for rs12901499 but heterozygous for rs8031440 were also studied. By 
doing this it could be assessed whether SMAD3 was subject to cis-eQTLs that were 
acting independently of the OA association signal marked by rs12901499.     
 
 
 
Table 4.1 The two transcript SNPs used in the AEI analysis, the associated SNP, and 
their pair-wise D" and r2 values. 
 
 
 
 
 
 
 
 
1Minor allele frequency in Europeans (HapMap CEU) 
 
Fourteen OA patients were analysed (patient details can be found in Table A1); 
eight were patients in whom knee cartilage was studied, two were patients in whom 
knee fat pad was studied, two were patients in whom knee synovium was studied, and 
two were patients in whom knee meniscus was studied. AEI was performed as 
described in Chapter 2, section 2.11. All 8 of the cartilage samples demonstrated 
significant AEI (P < 0.05) and for each patient the AEI was in the same direction, with 
decreased expression of the G allele of rs8031440 (Figure 4.7 and Table 4.2). 
SNPs Alleles MAF1 Pairwise linkage disequilibrium relative to  
rs12901499 rs8031440 rs1052488 
r2 D" r2 D" r2 D" 
rs12901499 G/A 0.443 - - 0.01 0.21 < 0.01 0.03 
rs8031440 G/A 0.260 0.01 0.21 - - 0.10 1.00 
rs1052488 T/C 0.324 < 0.01 0.03 0.10 1.00 - - 
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Figure 4.7 Allelic expression analysis of the 3!UTR transcript SNP rs8031440 using cDNA from knee joint tissues. Cn, cartilage; Fp, infrapatellar fat 
pad; Sy, synovium; Me, meniscus. The genotypes of the patients for the associated SNP rs12901499 are shown. The cDNA allelic ratio in each sample 
was compared to the DNA ratio using a Mann-Whitney U Test. The error bars represent the standard error of the mean. ** P <0.01 and * P < 0.05.
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Table 4.2 The allelic ratios for the samples analysed for AEI at rs8031440.  Allelic 
ratios are shown ± the standard error of the mean. P-values were calculated using a 
Mann-Whitney U Test. P-values ≤ 0.05 are highlighted in bold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant AEI was also observed in a fat pad, a synovium and a meniscus sample; the 
observed AEI is not therefore cartilage-specific. Seven of the 14 patients were also 
heterozygous for rs12901499 whilst 7 were not. The most likely explanation for this 
AEI result is that the 3!UTR SNP rs8031440 is functional and mediating AEI or that it 
is in very high LD with the functional SNP. It is unlikely that the OA associated SNP 
rs12901499 is responsible (either directly or indirectly) for the AEI observed. However, 
since the rs12901499-rs8031440 compound heterozygotes demonstrated AEI, this 
possibility could not be excluded based on the rs8031440 AEI data alone. Therefore 
AEI analysis was performed using a second SMAD3 3!UTR SNP, rs1052488, which has 
an r2 of 0.1 with rs8031440 (Table 4.1). Eight new patients were investigated (five 
cartilage and three fat pad; patient details can be found in Table A1), seven of who were 
compound heterozygous for rs1052488 and rs12901499 but homozygous for rs8031440, 
and one who was heterozygous for all three SNPs (Figure 4.8). None of the seven 
patients homozygous for rs8031440 demonstrated significant SMAD3 AEI (all P-values 
> 0.05) but the patient that was heterozygous for this SNP did (patient 104, P = 0.03; 
Table 4.3).  
rs8031440 
Patient Allelic ratio (G/A) P value 
7 1.15 ± 0.05 0.05 
50 1.26 ± 0.06 <0.01 
74 1.28 ± 0.04 <0.01 
76 1.69 ± 0.08 <0.01 
80 1.31 ± 0.05 <0.01 
94 1.33 ± 0.09 0.02 
101 1.27 ± 0.03 0.02 
104 1.23 ± 0.09 0.05 
51 1.25 ± 0.06 0.03 
128 1.02 ± 0.11 1.00 
28 1.04 ± 0.09 0.90 
78 1.29 ± 0.05 <0.01 
65 1.18 ± 0.05 <0.01 
68 1.11 ± 0.04 0.19 
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Figure 4.8 Allelic expression analysis of the 3!UTR SNP rs1052488 using cDNA from knee joint tissues. Cn, cartilage; Fp, infrapatellar fat pad. The 
genotypes of the patients for the transcript SNP rs8031440 and the associated SNP rs12901499 are shown. The cDNA allelic ratio in each sample was 
compared to the DNA ratio using a Mann-Whitney U Test. The error bars represent the standard error of the mean. * P < 0.05.
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Table 4.3 The allelic ratios for the samples analysed for AEI at rs1052488. Allelic 
ratios are shown ± the standard error of the mean. P-values were calculated using a 
Mann-Whitney U Test. P-values ≤ 0.05 are highlighted in bold. 
 
 
 
 
 
 
 
 
It can be concluded therefore that the OA associated SNP rs12901499 does not correlate 
with SMAD3 AEI and that the AEI observed is mediated by rs8031440, or by a SNP in 
high LD with it, rather than by rs12901499, or a SNP in high LD with it. Having 
established that rs8031440 correlates with AEI, and is therefore highlighting a SMAD3 
eQTL, the SMAD3 quantitative expression analysis was repeated, this time stratifying 
the data by genotype at rs8031440. 
 
4.3.5 Quantitative Expression of SMAD3 in Cartilage, Fat Pad and Synovium 
Stratified by Genotype at rs8031440. A significant correlation between SMAD3 
expression in cartilage and rs8031440 genotype was observed (Figure 4.9), with the G 
allele of the SNP correlating with reduced SMAD3 expression (P = 0.005). This G allele 
also correlated with reduced expression in the AEI analysis. 
       The OA patients were subsequently stratified into knee and hip cases 
(Figure 4.10) and a significant correlation between expression and genotype was 
observed for the knee cases (P = 0.0004). The P value for the hip cases was not 
significant (P = 0.31), however the number of hip cases was only 16, which may have 
limited the power to see an effect in this stratum.  No significant correlation was 
observed between SMAD3 expression and rs8031440 genotype in fat pad or synovium 
(Figure 4.11). This was surprising, as AEI of SMAD3 had previously been observed in 
these two tissues (Figure 4.7, patients 51 and 78).  
rs1052488 
Patient Allelic ratio (C/T) P value 
4 1.15 ± 0.25 0.84 
38 0.54 ± 0.15 0.06 
72 0.77 ± 0.05 0.1 
81 1.06 ± 0.10 0.69 
104 1.16 ± 0.06 0.03 
87 0.97 ± 0.07 1.0 
126 0.99 ± 0.20 1.0 
145 1.09 ± 0.08 0.69 
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       Figure 4.7 demonstrates a difference in the degree of AEI between tissues, with 
cartilage samples showing the largest average allelic imbalance (A/G ratio 1.31), 
followed by synovium and meniscus (average ratios of 1.18 and 1.15, respectively) with 
fat pad showing the smallest (ratio of 1.13). Therefore it is possible that the smaller 
number of samples used for analysing overall SMAD3 expression, together with the 
smaller allelic imbalances observed for fat pad and synovium, restricted the sensitivity 
of the quantitative expression assay to detect SMAD3 expression differences that 
correlated with rs8031440 genotype in these two tissues.  
 
 
 
 
 
Figure 4.9 Columnar scatter plots of the quantitative gene expression of SMAD3, with 
patients stratified by genotype at the 3!UTR SNP rs8031440. n is the number of patients 
studied. The results were normalised against the mean Ct values of the HPRT1, GAPDH 
and 18S housekeeping genes. The horizontal lines in each plot represent the mean and 
the standard error of the mean. The P-value was calculated using a Mann-Whitney U 
test.  
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Figure 4.10 Columnar scatter plots of the quantitative gene expression of SMAD3 in 
cDNA from OA hip and OA knee cartilage, with patients stratified by genotype at the 
3!UTR SNP rs8031440. n is the number of patients studied. Due to the low frequency of 
AA homozygotes at rs8031440 in the hip cohort, the analysis was between GG 
homozygotes and A-allele carriers (GA and AA). The results were normalised against 
the mean Ct values of the HPRT1, GAPDH and 18S housekeeping genes. The horizontal 
lines in each plot represent the mean and the standard error of the mean. The P-value 
was calculated using a Kruskal-Wallis test for the knees and a Mann-Whitney U test for 
the hips. 
 
 
 
Figure 4.11 Columnar scatter plots of the quantitative expression of SMAD3 in fat pad 
and synovium from OA knees. Patients were stratified by genotype at the 3!UTR SNP 
rs8031440. n is the number of patients studied. Due to the low frequency of AA 
homozygotes at rs8031440 for fat pad and synovium, the analysis was between GG 
homozygotes and A-allele carriers (GA and AA). The results were normalised against 
the mean Ct values of the HPRT1, GAPDH and 18S housekeeping genes. The 
horizontal lines in each plot represent the mean and the standard error of the mean. P-
values were calculated using a Mann-Whitney U test.  
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The above results confirm that rs8031440 or a SNP in high LD with it is modulating the 
expression of SMAD3. A database search (Chapter 2, section 2.9) of the SMAD3 3!UTR 
revealed that rs8031440 is in perfect LD (r2 =1, D! = 1) with five other 3!UTR SNPs: 
rs8025774, rs8031627, rs2278670, rs12595334 and rs3743342 (SNP details are listed in 
the appendix, Table A6). Subsequently these five SNPs were taken forward for 
functional analysis to identify which of them was modulating SMAD3 expression.  
 
4.3.6 Functional Analysis of Common SMAD3 3´UTR Variants. To directly assess 
whether rs8031440 or any of these five other SNPs were functional, fragments of the 
3!UTR were cloned into a luciferase plasmid (Chapter 2, section 2.13.1-2), and reporter 
gene expression assays were performed using the SW1353 human chondrosarcoma cell 
line and the MG63 human osteosarcoma cell line (Chapter 2, section 2.13.3-7). Three 
fragments were amplified: amplicon A, containing rs8025774; amplicon B, containing 
rs8031440, rs8031627 and rs2278670; and amplicon C, containing rs12595334 and 
rs3743342 (Figure 4.12).  For each amplicon both allelic forms were cloned, such that 
for amplicon A, the C and T alleles of rs8025774 were cloned, for amplicon B the 
naturally occurring GGC and AAT haplotypes for rs8031440-rs8031627-rs2278670 
were cloned, and for amplicon C the naturally occurring CC and TT haplotypes for 
rs12595334-rs3743342 were cloned. 
 
 
Figure 4.12 Diagram of the SMAD3 3!UTR showing the three amplicons used for 
cloning into a luciferase plasmid. The position of the six SNPs in perfect LD with one 
another and their alleles are also shown.  
 
No significant differences in luciferase gene expression between the C and T alleles of 
rs8025774 or between the GGC and AAT haplotypes of rs8031440-rs8031627-
rs2278670 were observed in either SW1353 (Figure 4.13) or MG63 (Figure 4.14) cells.  
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Figure 4.13 Functional analysis of the three amplicons (A B and C) containing the six 
SMAD3 3!UTR SNPs in SW1353 cells. Data are the fold expression relative to Renilla 
activity and are shown as the standard error of the mean from three biological repeats 
each with six technical replicates. P-values were calculated using a Mann-Whitney U 
Test. 
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Figure 4.14 Functional analysis of the three amplicons (A, B and C) containing the six 
SMAD3 3!UTR SNPs in MG63 cells. Data are the fold expression relative to Renilla 
activity and are shown as the standard error of the mean from three biological repeats 
each with six technical replicates. P-values were calculated using a Mann-Whitney U 
Test. 
 
However a significant difference between the TT and CC haplotypes of rs12595334-
rs3743342 (amplicon C) in both cell lines was observed (P = 0.0001 for SW1353; P = 
0.004 for MG63) indicating that one, or both, of these SNPs is a functional variant 
influencing gene expression. Using site-directed mutagenesis (Chapter 2, section 2.13.8) 
each allele of these two SNPs was mutated in turn to create the alternative rs12595334-
rs3743342 haplotypes CT and TC. The luciferase activity between these and the 
naturally occurring TT and CC haplotypes was then analysed. In SW1353 cells, 
mutating rs3743342 from a C to a T had no effect (P = 0.97, Figure 4.15) whereas 
mutating rs12595334 from a C to a T caused a significant increase in luciferase activity 
(P = 0.0003, Figure 4.15). In MG63 cells, mutating rs3743342 from a C to a T did have 
an effect (unlike in SW1353), leading to increased activity (P < 0.0001, Figure 4.15). 
Mutating rs12595334 from a C to a T also caused a significant increase in luciferase 
activity in the MG63 cells (P < 0.0001, Figure 4.15), replicating the effect observed in 
SW1353. Since the natural CC haplotype of rs12595334-rs3743342 is in LD with the 
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low expressing G allele of rs8031440, this luciferase data supports the patient tissue 
expression data. Both rs12595334 and rs3743342 are functional, with rs3743342 
appearing to have a more cell-restricted effect. 
 
Figure 4.15 Functional analysis of amplicon C containing the four possible haplotypes 
(CC, CT, TT, and TC) for rs12595334 and rs3743342 in SW1353 and MG63 cells. Data 
are the fold expression relative to Renilla activity and are shown as the standard error of 
the mean from three biological repeats each with six technical replicates. P-values were 
calculated using a Mann-Whitney U Test. 
 
4.3.7 Database Search of Potential miRNA Binding Sites in the SMAD3 3!UTR. 
3!UTRs can be the target site for gene expression regulation by microRNAs (207). For 
example miR-140 has been shown to suppress the TGF-β pathway through targeting 
SMAD3 (208). Therefore a database search of potential microRNA binding sites 
encompassing rs12595334 and rs3743342 (Chapter 2, section 2.14) was performed. 
However, no miRNAs were predicted to bind at either allelic form of the SNPs.  
  
4.3.8 Genetic Association of rs12529334 and rs3743342 with OA. Finally the eQTL 
marked by rs8031440, and potentially mediated by rs12595334 and rs3743342, was 
assessed for association to OA. To do this, the arcOGEN GWAS dataset, comprising 
5,804 OA cases that had undergone hip or knee joint replacement and 11,009 population 
controls, was utilised (135). Neither rs8031440, rs12595334 or rs3743342 are on the 
Illumina 610 Quad array used by arcOGEN, nor are any of the other SMAD3 3!UTRs 
SNPs that are in perfect LD with them. The SNP rs7166081, which is located 
downstream of SMAD3, is however on the array and is also in perfect LD with 
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rs8031440, rs12595334 and rs3743342. The association data generated for rs7166081 
was therefore used as a direct proxy. This revealed that the SMAD3 eQTL showed 
marginal evidence of associated with OA (P = 0.027; Table 4.4). Stratification of the 
arcOGEN dataset by sex, by site of OA (hip or knee), and by sex combined with site did 
not particularly enhance the association signal, with the most significant P-value being 
0.001 (OR = 0.915) for male knee cases. In all instances the C allele of rs7166081, 
which is equivalent to the G allele of rs8031440 that correlates with decreased SMAD3 
expression, was less common in OA cases.  
 
 
Table 4.4 Association analysis of rs7166081 with OA using the arcOGEN data. 
 
Stratum Cases   Controls   C-allele frequency   P Odds ratio1  
   cases controls value  
All 5804 11009 0.220 0.235 0.027 0.921 (0.857-0.991) 
Hips 3039 11009 0.214 0.233 0.002 0.896 (0.837-0.960) 
Knees 2164 11009 0.221 0.233 0.077 0.932 (0.862-1.008) 
Females 3363 5515 0.217 0.235 0.030 0.904 (0.826-0.991) 
Males 2441 5494 0.211 0.232 0.020 0.883 (0.794-0.980) 
Female hip  1769 5515 0.222 0.235 0.183 0.931 (0.838-1.034) 
Female knee 1217 5515 0.215 0.232 0.014 0.903 (0.832-0.980) 
Male hip  1270 5494 0.220 0.232 0.232 0.931 (0.828-1.047) 
Male knee  947 5494 0.218 0.233 0.001 0.915 (0.867-0.965) 
1(95% confidence intervals) 
 
4.4 Discussion  
 
The aim of this chapter was to assess whether the alleles of the OA associated SMAD3 
SNP rs12901499 correlated with differences in expression of the gene, using joint 
tissues from patients with primary OA, based on the hypothesis that this may be the 
mechanism through which the rs12901499 OA association is operating. There was no 
evidence of such a correlation, implying that this hypothesis is incorrect. It is possible 
however that the association marked by rs12901499 is operating during development 
and that an investigation of the joint tissues of young individuals may reveal a 
correlation between rs12901499 and SMAD3 expression. The collection of a sufficiently 
large number of such tissues is however prohibitive, since young individuals do not 
routinely present for joint replacement surgery. In this study a significantly lower level 
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of SMAD3 expression was detected in OA versus NOF cartilage. Whether this is a cause 
or a consequence of the OA, or of the NOF, disease process is not clear. Consistently 
lower allelic expression was seen for the G allele when AEI was studied using 
rs8031440 indicating that SMAD3 was subject to a cis-acting eQTL. A significant 
difference in the degree of this AEI was observed between different joint tissues, 
implying that there are a range of modulating factors acting on this SMAD3 eQTL, 
which may be tissue-specific. The 3!UTR SNPs rs12595334 and rs3743342 were then 
identified as potential mediators of this eQTL. Using the arcOGEN data it was observed 
that this eQTL demonstrated nominal association to OA. The allele that correlated with 
reduced expression of SMAD3, the G allele of rs8031440 (indirectly tested using the 
proxy SNP rs7166081), was less common in the arcOGEN cases versus the arcOGEN 
controls.  
    SMAD3 mediates TGF-β signalling, which as discussed in the introduction, has a 
pivotal role in joint development and maintenance (196, 198). The majority of the 
evidence to date indicates that decreased SMAD3 expression leads to an OA phenotype; 
SMAD3 knockout mice develop an OA-like phenotype and loss of SMAD3 enhances 
bone morphogenic protein signalling in the articular chondrocytes, leading to 
hypertrophy and OA-like changes (Valdes 2010). SMAD3 can form repressor 
complexes preventing the action of transcriptional activators that may be important in 
development or maintenance of articular cartilage (209). For example SMAD3 blocks 
RUNX2 function (210), which is required for chondrocyte maturation (211). If SMAD3 
levels are increased then RUNX2 action will be blocked and chondrocyte maturation 
will be affected, which could have consequences for the production of the cartilage 
ECM. It is the balance of SMAD2/3 and SMAD1/5/8 that controls RUNX2 function 
and terminal differentiation. Dominant SMAD1/5/8 signalling triggers the articular 
chondrocytes to terminally differentiate leading to a chondrocyte autolytic phenotype 
characterised by degradation of its surrounding cartilage matrix (197). If SMAD3 levels 
are increased, the balance shifts away from SMAD1/5/8 signalling and deletion of 
SMAD1/5/8 transcription factors has been shown to cause defects in the formation of 
chondrocyte condensations and on chondrocyte maturation (212).  
 
In conclusion, this chapter has demonstrated that SMAD3 is subject to cis-acting 
regulatory polymorphism in joint tissues, and the 3!UTR SNPs rs12595334 and 
rs3743342 were identified as potential mediators of this effect.  
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Chapter 5: A SMAD3 cis-acting eQTL Identified in Osteoarthritis is also 
Operating in Aneurysms and Osteoarthritis Syndrome.   
 
5.1 Introduction 
 
Aortic aneurysm is a common condition and the mortality rate from dissections or 
ruptures is high (213-215). Aneurysms can be inherited in an autosomal dominant 
manner as a disorder known as familial thoracic aortic aneurysms and dissections 
(FTAAD; 216). FTAAD can be subdivided into syndromic and non-syndromic forms. 
Non-syndromic FTAAD can be caused by mutations in genes encoding the contractile 
proteins of the VSMCs such as α-actin 2 and myosin-11. Syndromic FTAAD includes 
systemic tissue connective disorders such as Marfan syndrome, which is caused by 
mutations in FBN1, and Loeys-Dietz syndrome, which is caused by mutations in 
TGFBRI and TGFBRII. All syndromic FTAADs are characterised by increased TGF-β 
signalling in the arterial wall (213). In 2011 a new syndromic form of TAAD was 
described named aortic aneurysms and osteoarthritis (AOS), characterised by arterial 
aneurysms and tortuosity (twisting of the blood vessels), mild craniofacial features, 
skeletal and cutaneous abnormalities and early onset OA (214). Genome-wide linkage 
analysis was performed using a SNP array, and a signal was identified on chromosome 
15q. Fine mapping the 15q area mapped the locus to a 12.8Mb region containing 157 
genes. SMAD3 and SMAD6 were chosen for sequence analysis from this region due to 
their roles in the TGF-β signalling pathway (214). No mutations were detected in 
SMAD6 but three different mutations were discovered in SMAD3; two heterozygous 
missense mutations leading to amino acid substitutions and a deletion of two 
nucleotides in exon 6 leading to a frame shift and a premature stop codon in exon 7 
(214). Sequencing data of the cDNA from patients carrying the deletion revealed 
normal SMAD3 expression for the WT allele but very reduced expression for the 
mutated allele. When fibroblast cultures from the patients were treated with 
cycloheximide, which is an inhibitor of nonsense-mediated decay, there was increased 
expression from the mutant allele. This indicated that the abnormally truncated RNA, 
which is missing the Mad homology 2 (MH2) domain and the TGFβRI target site for 
SMAD phosphorylation, was subject to nonsense-mediated mRNA decay and that 
normal SMAD3 could not be formed by this allele (214). Both of the missense 
mutations affect highly conserved amino acids within the MH2 domain of SMAD3 and 
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the most likely effect of these is loss of function, with TGF-β signals not being 
propagated via SMAD3 (213). Although there is clear phenotypic overlap with 
syndromes such as Marfan and Loeys-Dietz the distinct difference between these 
syndromes and AOS is the invariable presence of early onset joint abnormalities 
including intervertebral disc degeneration and meniscal anomalies, in all cases with 
SMAD3 mutations (214).  
 
 
5.2 Aim 
The aim of this chapter is to assess whether the SMAD3 cis-eQTL identified in joint 
tissues in Chapter 4 is also operating in tissues of relevance to AOS, thus potentially 
providing a pathological link between common OA and the syndrome. To achieve this, 
cells were studied that were isolated from AOS patients who harbour one of the 
missense mutations, a heterozygous mutation leading to the substitution of arginine for 
tryptophan at amino acid position 287 of SMAD3 (Arg287Trp).  
 
 
5.3 Results 
 
5.3.1 Expression of SMAD3 in Human VSMCs Derived from Aortic Tissue. cDNA 
from cultured VSMCs (Chapter 2, section 2.15) collected from four patients with AOS 
and an unrelated control (Figure 5.1; patient details in Table A1), was analysed for 
SMAD3 expression by Real-Time qPCR (Chapter 2, section 2.6 - 7). All four patients 
and the control demonstrated expression of SMAD3 (Figure 5.2). Patients were then 
genotyped for rs8031440 (Chapter 2, Section 2.8) and the heterozygotes were taken 
forward for AEI analysis to investigate the SMAD3 3#UTR eQTL’s effect in aortic 
tissue.   
 
5.3.2 AEI Analysis of SMAD3 in AOS. The activity of the SMAD3 eQTL was analysed 
using cDNA from the VSMCs (Chapter 2, section 2.11). Two of the patients with AOS 
(C and D) and the control (E) were heterozygous for rs8031440 and were therefore 
eligible for AEI analysis using this SNP. The control, individual E (a male born in 
1955), and patient C (a male born in 1979), both demonstrated a significant AEI (P < 
0.01), whereas patient D (a male born in 1947) did not (Figure 5.3).
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Figure 5.1 Simplified family tree of a family with AOS. Squares indicate males, circles represent females. Black symbols indicate the presence of the 
signs of AOS. Crossed out symbols represent deceased individuals. The four patients studied in this chapter are highlighted (Patients A-D). Figure 
courtesy of Aida M. Bertoli-Avella.  
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Figure 5.2 Column graph of the level of expression of SMAD3 by Real-Time qPCR in 
vascular smooth muscle cells derived from aortic tissue from four patients (A, B, C, D) 
and an unrelated control (E). Reactions were carried out in triplicate and normalised 
against the mean Ct of HPRT1, GAPDH and 18S. The error bars represent the standard 
error of the mean.  
 
 
 
 
 
 
Figure 5.3 AEI analysis of the SMAD3 3!UTR SNP rs8031440 using cDNA from 
vascular smooth muscle cells. The cDNA allelic ratio in each sample was compared to 
the DNA ratio by a Mann-Whitney U Test. The error bars represent the standard error 
of the mean. ** P <0.01. 
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The AEI observed in the control and patient C was in the same direction as that 
observed in OA joint tissues, namely decreased expression of the G allele of rs8031440 
(Chapter 4, Figure 4.7).  The allelic ratios of 1.39 (control) and 1.25 (patient C) were 
also comparable to those seen in the OA patients (Table 4.2). Therefore it can be 
concluded that the SMAD3 eQTL is also active in a tissue that is of direct relevance to 
the aneurysm component of AOS. Next it was assessed which of the alleles, the 
mutation or the WT, the low expressing allele of the eQTL was present on, by 
molecular haplotyping of the AEI samples. 
  
 
5.3.3 Molecular Haplotyping of AOS Patients. Using cDNA as a template the 
molecular haplotypes for the Arg287Trp mutation and rs8031440 were assessed in 
patients C and D (Chapter 2, section 2.16). This revealed that in both patients the low-
expressing G-allele of rs8031440 was on the WT allele (Figure 5.4).  
 
 
 
 
 
Figure 5.4 The haplotypes of the patients C and D and the control E, at the Arg287Trp 
mutation and the 3!UTR SNP rs8031440. Wild-type and high expressing alleles are 
highlighted green and mutant and low expressing alleles are highlighted red.  
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5.4 Discussion 
 
As noted in the introduction, AOS arises from rare mutations of SMAD3 (213-
215). These mutations are heterozygous and appear to be loss-of-function. One mutation 
previously described involves a frame-shift mutation that results in nonsense-mediated 
mRNA decay leading to little or no detectable transcript from the mutant allele, whilst 
another leads to the substitution of arginine for tryptophan at position 287 of the gene. 
This Arg287Trp mutation creates a protein that is unable to form SMAD3 protein 
homomers or heteromers with SMAD4 (6), dysregulating TGF-β signalling. In this 
chapter it has been demonstrated that the SMAD3 eQTL that was discovered in OA joint 
tissues is also operating in the VSMCs derived from the aortic tissue of an AOS patient, 
who has the Arg287Trp mutation. It is therefore likely to be of direct relevance to this 
syndrome. There is a high degree of both intra and interfamilial phenotypic variation in 
patients with AOS. Differences range from age of onset to presence of clinical features 
that segregate with AOS, such as congenital defects like bicuspid aortic valve, and 
vascular diseases elsewhere in the body such as intracranial aneurysms (216). This high 
level of variability implies that it is likely to be influenced by the genetic background on 
which the WT SMAD3 allele is operating; if the WT allele happens to be on a low-
expressing rather than a high-expressing copy of the gene, as is seen with patient C, 
then this may lead to an even greater reduction in functional SMAD3 protein and 
therefore a more severe phenotype. On the other hand, this eQTL could have variable 
relevance on different tissues, and could explain phenotypic variability determining, for 
example, a predominantly vascular skeletal phenotype in patients with SMAD3 
mutations. Comparing the inheritance of the eQTL between families in which AOS is 
segregating may therefore be informative in accounting for some of the phenotypic 
variability observed.  
Patient C is the first cousin once removed of patient D and both have the heterozygous 
Arg287Trp mutation. The two patients have therefore inherited the G-allele of 
rs8031440 from a recent common ancestor. The fact that this G-allele shows reduced 
expression in patient C but not in patient D implies that its expression is likely to be 
modified by other cis-acting effects, which may be genetic or epigenetic.  
 
In conclusion, SMAD3 is subject to cis-acting regulatory polymorphism in the 
tissues of relevance to both primary osteoarthritis and the aneurysms-osteoarthritis 
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syndrome. Etiological insights from the common form of osteoarthritis are therefore 
informing a rare form of the disease and vice versa.  
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Chapter 6: Analysis of DOT1L, a Gene Associated with Hip OA. 
 
 
6.1 Introduction  
 
 
Disruptor of telomeric silencing 1-like (DOT1L) is a histone H3 methyltransferase 
(217). Histones are the protein core that forms the basis of the nucleosome, the most 
basic level of chromosome organisation (218). The nucleosome comprises 147bp of 
DNA wound round an octamer consisting of a histone H3/H4 heterotetramer and two 
H2A/H2B dimers (218-220). In order for differentiated cells to express genes in a 
tissue-specific manner, covalent modifications are utilised that allow only certain 
DNA sequences to be accessed by transcription factors and therefore specific genes to 
be expressed (221). Histone modifications include acetylation, phosphorylation, 
ubiquitylation and methylation (219). There are six lysine (K) residues in histones that 
are targeted for methylation (221). DOT1L is the only histone methyltransferase 
known to methylate K79 of histone H3 (H3K79; 220). Genome-wide studies have 
demonstrated that H3K79 methylation is enriched in gene coding regions (222), and 
in mammals DOT1L is found in a protein complex with RNA polymerase II (Barry 
2010) suggesting that DOT1L methylation of H3K79 has a role in initiating gene 
transcription (219, 223). DOT1L also has a role in haematopoiesis; Knockout of 
DOT1L in human bone marrow cells has been shown to deplete haematopoietic stem 
cells, various progenitor cell populations, and terminally differentiated blood cell 
lineages (224). In addition to this, DOT1L and methylation of H3K79 are important in 
leukaemias that are caused by chromosomal translocations of mixed-lineage 
leukaemia (MLL) an H3K4 methyltransferase (225, 226). Interaction between 
DOT1L and MLL fusion proteins causes mistargeting of DOT1L to MLL target genes 
such as the HOX transcription factors. Aberrant hypermethylation of H3K79 leads to 
constitutive transcriptional activation of these HOX genes promoting uncontrolled 
proliferation of leukaemia cells (227). 
 
A 2012 GWAS looking at the width of the joint space in the hips of 6523 participants 
from the Rotterdam study, identified a genome-wide significant signal in intron 1 of 
DOT1L (P = 4.5x10-10; 132). JSW is considered a proxy for cartilage thickness and a 
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reduction in the JSW is indicative of cartilage degradation (Auleley 1998). This study 
was then replicated in three UK populations totalling 4,442 cases and the two studies 
were combined in a meta-analysis. The meta-analysis showed that the minor G-allele 
of rs12982744 is associated with a 12% reduced risk of hip OA (OR = 0.88, P = 
1.5x10-4) and with an increased JSW of 0.09mm per copy of the G allele, implying 
that homozygote carriers of the G allele should have ~5% thicker cartilage than the 
control group (132). In a second GWAS totalling 9789 hip OA cases and 31873 
controls it was discovered that in male subjects the C-allele of rs12982744 was 
associated with a 17% increased risk of hip OA (OR 1.17, P = 7x10-9; 113).  
 
Having demonstrated that knockdown of Dot1l in the chondrogenic mouse 
cell line ATDC5 caused reduced synthesis of sulfated proteoglycan, reduced levels of 
type X collagen and aggrecan and increased expression of Mmp9, Castano Betancourt 
et al. hypothesised that DOT1L was the gene underlying the association signal by 
influencing chondrogenic differentiation. They also demonstrated that DOT1L 
physically interacts with TCF4 (132), a transcription factor interacting with β-catenin. 
As Wnt/β-catenin signalling is critical in the formation of cartilage and bone and in 
the development of the synovial joint (228) they investigated whether mRNA 
expression of Wnt target genes was affected in Dot1l- cells. They discovered that 
Tcf1, Axin2 and c-Myc levels were increased in controls but not in Dot1l- cells, and 
there was an increase in osteocalcin, which is negatively regulated by Wnt/β-catenin 
signalling (132). Together these results suggest a role for DOT1L in chondrocyte 
differentiation through its interaction with the Wnt/β-catenin pathway. 
 
6.2 Aim 
The aim of this chapter is to investigate whether the OA associated SNP rs12982744 
is influencing the expression of DOT1L.  
 
6.3 Results 
 
6.3.1 Quantitative Comparison of DOT1L Expression between Cartilage from OA 
and NOF Patients. DOT1L was analysed for expression by Real-Time qPCR 
(Chapter 2, section 2.6 -7) in cDNA from the hip cartilage of OA patients undergoing 
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THR and the hip cartilage of patients who had undergone surgery for NOF fracture 
(Figure 6.1).  A significant increase in the expression of DOT1L in control cartilage 
compared to OA cartilage was seen (P < 0.0001). As the DOT1L signal was 
associated with hip OA, the data were then assessed for a difference in DOT1L 
expression between OA hip and OA knee cartilage.  
 
 
Figure 6.1 Columnar scatter plot of the quantitative expression of DOT1lL between 
cDNA from OA hip cartilage and cDNA from control hip cartilage. The control 
cartilage was collected from patients who had undergone surgery for a neck of femur 
(NOF) fracture. n is the number of patients studied. The results were normalised 
against the mean Ct values of the HPRT1, GAPDH and 18S housekeeping genes. The 
horizontal lines in each plot represent the mean and the standard error of the mean. 
The P-value was calculated using a Mann-Whitney U test. 
 
 
6.3.2 Quantitative Comparison of DOT1L Expression between Cartilage from OA 
Hips and Cartilage from OA Knees.  DOT1L expression was then compared between 
knee cartilage from OA patients who had undergone TKR and hip cartilage from OA 
patients who had undergone THR (Figure 6.2). No significant difference in DOT1L 
expression was seen between cDNA from OA hip and cDNA from OA knee cartilage 
(P = 0.35). The data were then analysed for a correlation between DOT1L expression 
and genotype at rs12982744 to ascertain whether this signal could be modulating 
expression of DOT1L in cartilage from patients undergoing TJR for OA.  
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Figure 6.2 Columnar scatter plot of the quantitative expression of DOT1L between 
cDNA from OA hip cartilage and cDNA from OA knee cartilage. n is the number of 
patients studied. The results were normalised against the mean Ct values of the 
HPRT1, GAPDH and 18S housekeeping genes. The horizontal lines in each plot 
represent the mean and the standard error of the mean. The P-value was calculated 
using a Mann-Whitney U test. 
 
 
6.3.3 Quantitative Expression of DOT1L in Cartilage Stratified by Genotype at 
rs12982744.  To investigate DOT1L for cartilage eQTLs, patients already analysed 
for overall expression were genotyped for rs12982744 by RFLP (Chapter 2, section 
2.8) and the data were stratified by genotype at this SNP (Figure 6.3). No correlation 
was observed between the three genotypic groups for rs12982744 (P = 0.63). The 
analysis was then repeated after separating the hip and the knee cases (Figure 6.4). 
Again, no correlation was observed between DOT1L expression and the three 
different genotypic groups for rs12982744 for either hips or knees (P = 0.48 and 0.81 
respectively).  
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Figure 6.3 Columnar scatter plot of the quantitative expression of DOT1L, with 
patients stratified by genotype at the associated SNP rs12982744. n is the number of 
patients studied. The results were normalised against the mean Ct values of the 
HPRT1, GAPDH and 18S housekeeping genes. The horizontal lines in each plot 
represent the mean and the standard error of the mean. The P-value was calculated 
using a Kruskal-Wallis Test.  
 
Figure 6.4 Columnar scatter plots of the quantitative expression of DOT1L in cDNA 
from OA knee (left panel) and OA hip cartilage (right panel), with patients stratified 
by genotype at the OA-associated SNP rs12982744. n is the number of patients 
studied. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The horizontal lines in each plot represent the 
mean and the standard error of the mean. P-values were calculated using a Kruskal-
Wallis test.  
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As in Chapter 4, despite the lack of correlation between DOT1L expression and 
genotype the samples were investigated for AEI analysis, as stratification of overall 
expression by genotype could be vulnerable to natural fluctuation in gene expression 
and as such may not pick up any difference in expression levels between the two 
alleles. As rs12982744 is an intronic SNP, and therefore cannot itself be interrogated 
for AEI, a database search was carried out (Chapter 2, section 2.9). This revealed four 
possible transcript SNPs within DOT1L that could be utilised for AEI, none of which 
were in high LD with rs12982744 (Table 6.1).  
 
Table 6.1 The transcript SNPs identified for AEI and their pairwise D" and r2 values 
relative to the associated SNP rs12982744 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Minor allele frequency in Europeans (HapMap CEU). 
 
 
Taqman could not be used for AEI analysis as no ready-made genotyping assays were 
available for any of the transcript SNPs, and none of the custom genotyping assays 
passed Applied Biosystems internal quality control (QC). Two other methods were 
investigated as possible methods to analyse DOT1L for AEI: Sequenom and 
Pyrosequencing, however all assays designed for these two methods failed QC and so 
AEI could not be assessed.  
 
6.4 Discussion 
 
The aim of this chapter was to assess whether DOT1L expression correlated with 
genotype at rs12982744 using cartilage from patients who had undergone total joint 
replacement for primary OA. The results did not provide evidence for a correlation 
between the OA associated SNP rs12982744 and DOT1L expression. The lack of a 
correlation between rs12982744 and DOT1L expression implies that the association 
Transcript 
SNP  
Alleles MAF1 Pairwise linkage disequilibrium  
relative to rs12982744 
   
r2 D" 
rs3815308     0.462 0.889 
rs2302061 
  
0.084 1 
rs740404 
  
0.079 1 
rs1558118     0.051 1 
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marked by this SNP is operating by a route other than an effect on the expression of 
the gene. However DOT1L could not be successfully assessed for AEI so it cannot be 
conclusively said that rs12982744 is not regulating expression of DOT1L. Expression 
was very low in our cartilage samples, with Cts between 32-38, and it has been 
observed that DOT1L has a low abundance (229).  In addition to this, this chapter 
demonstrated that DOT1L expression decreases with chondrogenesis and that there is 
a significant decrease in DOT1L expression in OA cartilage compared to NOF 
cartilage. It is therefore possible that it was difficult to assess AEI in DOT1L due to its 
low expression in mature cartilage, particularly in OA.  
The association between the rs12982744 and cartilage thickness was also 
observed in controls without OA, indicating that the association with cartilage 
thickness is present before the onset of OA and implicating involvement of DOT1L in 
formation of the articular cartilage in skeletal development (132). In addition to this 
rs12982744 has been associated with height, further suggesting a role for DOT1L in 
skeletal development (230, 231).  This indicates that it is possible that rs12982744 is 
modulating the expression of DOT1L at time points not studied in this chapter, for 
example during skeletogenesis or in adolescent tissues. In the future it would be 
beneficial to investigate overall expression and perform AEI analysis of DOT1L in the 
joint tissues of young individuals to see if a correlation between rs12982744 and 
DOT1L expression is revealed. If there had been more time to further investigate 
DOT1L AEI it may have been beneficial to select OA individuals that demonstrated 
high levels of overall DOT1L expression to validate the AEI assays, as low levels of 
expression will affect the QC of an assay.  
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Chapter 7: Genetic and Functional Analysis of GNL3, a Gene at an OA 
Susceptibility Locus on Chromosome 3p.  
 
 
7.1 Introduction 
 
Guanine nucleotide binding protein-like 3 or nucleostemin, encoded by GNL3, is a 
GTP-binding nucleolar protein that is expressed at high levels in embryonic and adult 
stem cells and tumour cells (232-234), but not in terminally differentiated cells (235).  
During differentiation GNL3 levels are rapidly down-regulated immediately prior to 
exiting the cell cycle and siRNA-mediated depletion of GNL3 has been shown to cause 
defects in the transition from metaphase to anaphase in cultured cells leading to cell 
cycle arrest (236-238). This indicates that reduction of GNL3 has a role in cell cycle exit 
rather than being a consequence of differentiation (237-239). Knockout studies have 
also shown that GNL3 is essential for cell proliferation and embryogenesis (238-240), 
and complete loss of function of GNL3 causes early lethality of the embryo (233). In 
addition to depletion of GNL3, its overexpression also causes cell cycle arrest (237, 
238). GNL3 exerts these effects on the cell cycle via its interactions with the tumour-
suppressor p53. The unstable p53 protein is stabilised in order to activate transcription 
of genes that encode cell cycle proteins (238). In unstressed cells p53 is maintained at 
low levels by its inhibitor, mouse double minute-2 (MDM2), an E3 ubiquitin ligase. 
Knockdown of GNL3 by siRNA causes cell stress leading to inhibition of MDM2 
function and the subsequent stabilisation and activation of p53 (237). Overexpression of 
GNL3 also leads to p53 activation and therefore cell cycle arrest, via direct binding of 
the excess GNL3 to MDM2 (237, 238).  
        p53 activation can also occur as a result of the disruption of ribosomal biogenesis 
(237). Ribosomal biogenesis is the process by which the cellular machinery required for 
protein synthesis is made (238). Ribosomal biogenesis includes the synthesis and 
processing of rRNA and the formation of ribosomal subunits and the mature ribosome 
(241). Disturbance of any step in the process can trigger ribosomal stress releasing free 
ribosomal proteins into the nucleoplasm, which directly bind MDM2 (242). GNL3 is a 
component of the nucleolar protein complex critical for rRNA processing, and reduction 
of endogenous GNL3 levels reduces the number of mature rRNAs, which may lead to 
the release of free ribosomal proteins (238). 
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          GNL3 also binds and modulates telomeric repeat binding factor-1 (TRF1) a 
component of the telomere-capping complex, telosome (240). TRF1 prevents elongation 
of the telomeres, protecting continuously dividing cells from telomere degradation (233, 
236, 240). Overexpression of GNL3 causes a reduction in TRF1 (233), which in turn 
leads to telomere degradation causing cellular senescence (243). Deletion of TRF1 also 
causes early embryonic lethality in mice, suggesting that it has an essential function in 
early embryogenesis (233, 236). 
A large case-control GWAS was performed using 7410 unrelated OA patients and 
11009 unrelated controls. The most promising signals were replicated in an independent 
set of 7473 cases and 42938 controls (135). Five of the loci showed GWS (P = 5x10 -8) 
and the most significant of these was on chromosome 3, identified by two SNPs in 
perfect LD with each other: rs11177 (allele A, P = 1.25x10-10), a missense 
polymorphism within exon three of GNL3 causing an Arginine-Glutamine (Arg-Gln) 
substitution, and rs6976 (allele T, P = 7.24x10-11) situated in the 3!UTR of GLT8D1, 
both associated with hip and knee OA in patients who had undergone joint replacement 
surgery (135). The function of GNL3 in bone and cartilage is not known, with mice 
homozygous for deletion of GNL3 showing very early embryonic lethality (233). 
Immunohistochemical staining showed strong nucleolar expression of GNL3 in primary 
cultured chondrocytes from patients with OA but GNL3 was barely detectable in 
cultured chondrocytes from controls, raising the possibility that this gene might by 
functionally important in the pathogenesis of OA (135). 
 
7.2 Aim 
 
The aim of this chapter is to investigate whether GNL3 contributes functionally to the 
OA association signal marked by rs11177 and rs6976.  
 
7.3 Results 
 
7.3.1 Database Search of Amino Acid Prediction Websites. rs11177 is a missense 
polymorphism causing an Arg-Gln amino acid substitution, so a search of databases that 
predict the likelihood that an amino acid change will affect protein function was 
conducted (Chapter 2, section 2.17). All three databases predicted the substitution to be 
tolerated. According to PolyPhen, the tertiary protein structure had no homology to any 
known protein structures so the protein sequence was therefore sent for modelling, to 
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provide a clearer assessment of whether the substitution is likely to have a detrimental 
affect on the protein.  
 
7.3.2 Modelling the GNL3 Protein Structure. The GNL3 protein was modelled by 
Jeremy Lakey, Professor of Structural Biochemistry, Institute for Cell and Molecular 
Biosciences, Newcastle University. Due to the lack of homology of the GNL3 protein 
with any other proteins, only the Guanosine Triphosphate (GTP)-binding domain could 
be modelled. Next to the GTP binding domain is an acidic domain, a coiled coil and a 
basic domain, which may have DNA binding capabilities. The rs11177 Arg-Gln change 
does not lie in any of the domains but lies in the linker region between the coiled coil 
and the basic domains. This, together with the database search of the prediction 
websites strongly suggests that the amino acid change is tolerated and does not affect 
the protein. Having ruled out the possibility that the association signal is marking this 
substitution in GNL3, the next step was to look at the possibility that it could be 
marking a transcriptional effect on the genes expression. 
 
7.3.3 Quantitative Comparison of GNL3 Expression between Cartilage from OA and 
NOF Patients. Expression of GNL3 was performed by Real-Time qPCR (Chapter 2, 
section 2.6 - 7) using hip cartilage cDNA from OA patients who had undergone THR 
and control patients who had undergone surgery for NOF fracture (Figure 7.1). No 
significant difference in expression was observed between OA and NOF cartilage (P = 
0.76).   
 
7.3.4 Quantitative Comparison of GNL3 Expression between Cartilage from OA Hips 
and Cartilage from OA Knees. GNL3 expression in OA knee cartilage from patients 
who had undergone TKR was then compared to expression in OA hip cartilage from 
patients who had undergone THR (Figure 7.2). Again, no significant difference in 
GNL3 expression was observed (P = 0.35).  
 
7.3.5 Quantitative Expression of GNL3 in Cartilage Stratified by Genotype at the 
Associated SNP. To ascertain whether GNL3 harboured a cartilage eQTL that 
correlated with the OA association signal, rs11177 was genotyped by RFLP analysis 
(Chapter 2, section 2.8) in all the OA patients analysed for overall GNL3 expression and 
the expression data were then stratified by the genotype at this SNP (Figure 7.3).  
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Figure 7.1 Columnar scatter plot of the quantitative expression of GNL3 between 
cDNA from OA hip cartilage and cDNA from control hip cartilage. The control 
cartilage was collected from patients who had undergone surgery for a neck of femur 
fracture. n is the number of patients studied. The results were normalised against the 
mean Ct values of the HPRT1, GAPDH and 18S housekeeping genes. The horizontal 
lines in each plot represent the mean and the standard error of the mean. The P-value 
was calculated using a Mann-Whitney U test. 
 
 
 
Figure 7.2 Columnar scatter plot of the quantitative expression of GNL3 between 
cDNA from OA knee cartilage and OA hip cartilage. n is the number of patients 
studied. The results were normalised against the mean Ct values of the HPRT1, GAPDH 
and 18S housekeeping genes. The horizontal lines in each plot represent the mean and 
the standard error of the mean. The P-value was calculated using a Mann-Whitney U 
test. 
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Figure 7.3 Columnar scatter plot of the quantitative expression of GNL3 in cDNA from 
OA knee and hip cartilage, with patients stratified by genotype at the associated SNP 
rs11177. n is the number of patients studied. The results were normalised against the 
mean Ct values of the HPRT1, GAPDH and 18S housekeeping genes. The horizontal 
lines in each plot represent the mean and the standard error of the mean. The P-value 
was calculated using a Kruskal-Wallis test. 
 
 
No correlation was observed between GNL3 expression and genotype at rs11177. The 
analysis was then repeated after separating the knee and hip data (Figure 7.4).  
 
 
Figure 7.4 Columnar scatter plots of the quantitative expression of GNL3 in cDNA 
from OA knee (left plot) and OA hip (right plot) cartilage, with patients stratified by 
genotype at the associated SNP rs11177. n is the number of patients studied. The 
horizontal lines in each plot represent the mean and the standard error of the mean. P-
values were calculated using a Kruskal-Wallis test for the knees and a Mann-Whitney U 
test for the hips. 
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No correlation was seen between the expression and rs11177 genotype for either hips or 
knees (P = 0.32 and 0.31 respectively). However, this method is sensitive to natural 
variation in gene expression and can therefore be subject to false negatives, so the SNP 
was taken forward for AEI analysis.  
 
7.3.6 AEI analysis of rs11177 in joint tissues.  As rs11177 is a transcript SNP it could 
be directly interrogated for AEI. AEI analysis at rs11177 was carried out by Professor 
John Loughlin (Chapter 2, section 2.11). Of the 20 OA patients analysed (patient details 
are listed in Table A1), 11 showed significant AEI (Figure 7.5, Table 7.1). One of the 9 
cartilage samples was from a NOF fracture (patient 182), and this also demonstrated 
significant AEI (P = 0.03), indicating that AEI is not dependent on disease status. In 
addition to the 20 joint tissues, blood samples from three controls not suffering from 
OA were also analysed. None of the three samples demonstrated AEI (patients 193, 194 
and 195 in Table 7.1 and Figure 7.5). For all the joint tissues analysed the OA-
associated A allele showed decreased expression.  
 
 
Table 7.1 The allelic ratios for the samples analysed for AEI at rs11177.  Allelic ratios 
are shown ± the standard error of the mean. P-values were calculated using a Mann-
Whitney U Test. P-values ≤ 0.05 are highlighted in bold. 
 
 rs11177 
Patient Allelic ratio (A/G) P value 
27 0.75 ± 0.11 0.22 
37 0.73 ± 0.05 0.03 
39 0.67 ± 0.06 0.03 
54 0.74 ± 0.03 <0.01 
57 0.82 ± 0.01 <0.01 
63 0.61 ± 0.18 0.15 
131 0.81 ± 0.03 0.02 
69 0.70 ± 0.08 <0.01 
182 0.76 ± 0.08 0.03 
49 0.83 ± 0.03 0.03 
53 0.93 ± 0.02 0.22 
58 0.90 ± 0.03 0.22 
127 0.93 ± 0.02 0.06 
136 0.75 ± 0.01 0.10 
148 0.86 ± 0.04 0.15 
67 0.88 ± 0.05 0.22 
70 0.85 ± 0.03 <0.01 
139 0.66 ± 0.06 0.02 
60 0.87 ± 0.05 0.06 
66 0.81 ± 0.01 <0.01 
193 1.03 ± 0.03 0.69 
194 0.97 ± 0.04 0.55 
195 1.00 ± 0.06 0.84 
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Figure 7.5 Allelic expression analysis of the transcript SNP rs11177 using cDNA from joint tissues and blood. Cn, cartilage; Fp, infrapatellar fat pad; 
Sy, synovium; Li, ligament; Me, meniscus; Te, tendon; Bl, blood. The cDNA allelic ratio in each sample was compared to the DNA ratio using a 
Mann-Whitney U Test. The error bars represent the standard error of the mean. ** P <0.01 and * P < 0.05.
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7.3.7 siRNA-Mediated Knockdown of GNL3 in HACs. Since the AEI showed 
decreased expression of the OA-associated allele in joint tissues particularly cartilage, 
GNL3 expression was knocked down in cultured HACs (Chapter 2, section 2.18; Figure 
7.6). The knockdown of GNL3 protein was confirmed by western blotting (Chapter 2, 
section 2.19; Figure 7.6). 
 
 
Figure 7.6 siRNA-mediated knockdown of GNL3 in human articular chondrocytes. A, 
C and E, show Real-Time quantitative expression of GNL3 in HACs from three donors 
(patients 196, 197 and 198 respectively; patient details can be found in the appendix 
Table A1) after treatment with an siRNA specific for GNL3 (siGNL3) and a non-
targeting control (siCON). The results were normalised against the mean Ct values of 
the HPRT1, GAPDH and 18S housekeeping genes. The error bars represent the standard 
error of the mean. The P-values were calculated using two-tailed students t-tests. B, D 
and F show western blots of GNL3 and β-actin, the latter used as a loading control. 
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7.3.8 Real-Time Quantitative PCR Expression Analysis of a Panel of 12 Genes after 
GNL3 Knockdown in HACs. To investigate what effect GNL3 knockdown had on a 
panel of genes important in cartilage anabolism and catabolism (Table 7.2), Real-Time 
qPCR (Chapter 2, section 2.6) was performed on cDNA extracted from the HACs 
(Chapter 2, section 2.18.4).  
 
Table 7.2 The 12 genes analysed for expression following GNL3 knockdown. 
 
The results varied between the three patients analysed, with some genes showing a 
significant difference in expression in one patient but not others (Figures 7.7-7.9; Table 
7.3), including, ACAN (P = 0.0003) in patient 196; SOX9 (P = 0.004), MMP9 (P = 
0.03), TIMP1 (P = 0.01), and RUNX2 (P = 0.04), in patient 197; and MMP13 (P = 
0.003) in patient 198 (Figures 7. 8 - 7.10). Two genes showed a significant difference in 
expression in two patients but not the third, COL2A1 in patients 196 and 198 (P = 
0.006, 0.008 respectively), and COL10A1 in patients 196 and 197 (P = 0.04, 0.02 
respectively). COL1A1 showed a significant difference in expression in all three 
patients (P < 0.0001, P = 0.03, P = 0.003), however the expression levels were 
inconsistent, showing an increase in expression in patient 197 and a decrease in 
expression in patients 196 and 198 (Figures 7.7 - 7.9). The only genes to show a 
consistent significant difference in expression after GNL3 knockdown were ADAMTS4, 
which showed an increase in expression in all three patients (P < 0.0001), and 
ADAMTS5 which showed a decrease in expression in all three patients (P < 0.0001)  
 Gene Gene Product      Role in cartilage 
homeostasis 
ACAN Aggrecan  
Anabolism COL2A1 Type II collagen, α-1 chain 
SOX9 SRY-box 9 transcription factor 
MMP1 Matrix metalloproteinase 1 
Catabolism 
MMP9 Matrix metalloproteinase 9 
MMP13 Matrix metalloproteinase 13 
ADAMTS4 A disintegrin and metalloproteinase with thrombospondin motifs 4 
ADAMTS5 A disintegrin and metalloproteinase with thrombospondin motifs 5 
TIMP1 Tissue inhibitor of matrix metalloproteinase 1 Anti-catabolism 
RUNX2 Runt-related transcription factor 2 Osteogenesis 
COL1A1 Type I collagen, α-1 chain 
COL10A1 Type X collagen, α-1 chain Hypertrophy 
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Figure 7.7 Real-Time quantitative expression of the 12 genes in human articular 
chondrocytes from patient 196 after treatment with siRNA specific for GNL3 (siGNL3) 
and a non-targeting control (siCON). Each condition was performed with six technical 
replicates. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The error bars represent the standard error of the 
mean. P values were calculated using two-tailed students t-tests.  
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Figure 7.8 Real-Time quantitative expression of the 12 genes in human articular 
chondrocytes from patient 197 after treatment with siRNA specific for GNL3 (siGNL3) 
and a non-targeting control (siCON). Each condition was performed with six technical 
replicates. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The error bars represent the standard error of the 
mean. P values were calculated using two-tailed students t-tests.  
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Figure 7.9 Real-Time quantitative expression of the 12 genes in human articular 
chondrocytes from patient 198 after treatment with siRNA specific for GNL3 (siGNL3) 
and a non-targeting control (siCON). Each condition was performed with six technical 
replicates. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The error bars represent the standard error of the 
mean. P values were calculated using two-tailed students t-tests.  
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Table 7.3 P- values of the 12 genes analysed for expression in all HAC patients studied 
following GNL3 knockdown. The arrows indicate a significant increase or decrease in 
expression when GNL3 is knocked down. The means of the biological replicates were 
also pooled to give the P-value across the three patients. 
 
 
 
 
 
 
 
 
 
 
 
7.3.9 siRNA-Mediated Knockdown of GNL3 in MSCs. As GNL3 is expressed at high 
levels in both embryonic and adult stem cells (232, 233) siRNA-mediated knockdown 
of GNL3 was also performed in mesenchymal stem cells (Chapter 2, section 2.18.2). 
Successful knockdown of GNL3 mRNA was assessed using real-time quantitative PCR 
(Chapter 2, section 2.6) and successful knockdown of the GNL3 protein was confirmed 
by western blotting (Chapter 2, section 2.19, Figure 7.10).  
 
7.3.10 Real-Time qPCR Expression Analysis of a Panel of 12 Genes after GNL3 
Knockdown in MSCs. The cDNA extracted from the MSCs (Chapter 2, section 2.18.4) 
after siRNA-mediated GNL3 knockdown was tested for differences in expression of the 
same 12 genes analysed in HAC cDNA. Again the results varied between the three 
patients analysed, with some genes showing a significant difference in expression in 
one patient but not others, such as SOX9 (P < 0.0001) and MMP13 (P = 0.02) for patient 
199, and TIMP1 (P = 0.02) for patient 201 (Figures 7.11-7.13: Table 7.4).  
 
 
 Patient number  
Gene 196 197 198 Pooled 
ACAN 0.0003    ! 0.42 0.92 0.15 
COL2A1 0.006    ! 0.89 0.008  ! 0.31 
SOX9 0.59 0.01   ! 0.22 0.71 
MMP1 0.30 0.59 0.01   " 0.56 
MMP9 0.35 0.02   ! 0.42 0.23 
MMP13 0.37 0.06 0.003  " 0.68 
ADAMTS4 <0.0001    ! <0.0001  ! <0.0001  ! <0.0001   
ADAMTS5 <0.0001    " <0.0001  " <0.0001  " <0.0001   
TIMP1 0.20 0.003  ! 0.18        0.01 
RUNX2 0.36 0.03  ! 0.06 0.11 
COL1A1 <0.0001   " 0.03  ! 0.003  " 0.83 
COL10A1 0.04   " 0.02  " 0.28 0.19 
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Figure 7.10 siRNA-mediated knockdown of GNL3 in mesenchymal stem cells. A, C 
and E, show real time quantitative expression of GNL3 in MSCs from three donors 
(patient 199, 200 and 201 respectively; patient details can be found in the appendix 
Table A1) after treatment with an siRNA specific for GNL3 (siGNL3) and a non-
targeting control (siCON). The results were normalised against the mean Ct values of 
the HPRT1, GAPDH and 18S housekeeping genes. The error bars represent the standard 
error of the mean. The P values were calculated using two-tailed students t-tests. B, D 
and F show western blots of GNL3 and β-actin, the latter used as a loading control.  
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Figure 7.11 Real-Time quantitative expression of the 12 genes in mesenchymal stem 
cells from patient 199 after treatment with siRNA specific for GNL3 (siGNL3) and a 
non-targeting control (siCON). Each condition was performed with six technical 
replicates. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The error bars represent the standard error of the 
mean. P values were calculated using two-tailed students t-tests.  
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Figure 7.12 Real-Time quantitative expression of the 12 genes in mesenchymal stem 
cells from patient 200 after treatment with siRNA specific for GNL3 (siGNL3) and a 
non-targeting control (siCON). Each condition was performed with six technical 
replicates. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The error bars represent the standard error of the 
mean. P values were calculated using two-tailed students t-tests.  
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Figure 7.13 Real-Time quantitative expression of the 12 genes in mesenchymal stem 
cells from patient 201 after treatment with siRNA specific for GNL3 (siGNL3) and a 
non-targeting control (siCON). Each condition was performed with six technical 
replicates. The results were normalised against the mean Ct values of the HPRT1, 
GAPDH and 18S housekeeping genes. The error bars represent the standard error of the 
mean. P values were calculated using two-tailed students t-tests.  
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Table 7.4 P- values of the 12 genes analysed for expression in all MSC patients studied 
following GNL3 knockdown. The arrows indicate a significant increase or decrease in 
expression when GNL3 is knocked down. The means of the biological replicates were 
also pooled to give the P-value across the three patients. Genes that were not expressed 
in MSCs are marked as n/a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients 199 and 200, but not patient 201, showed a significant difference in expression 
in ACAN (P = 0.03, 0.0002 respectively), MMP1 (P < 0.0001 for both), RUNX2 (P < 
0.0001, 0.0002 respectively), and COL1A1 (P = 0.0001, 0.02 respectively), however the 
difference in COL1A1 expression was inconsistent, showing an increase in expression 
after GNL3 knockdown in patient 199 and a decrease in expression in patient 200 
(Figures 7.11, 7.12). None of the three patients expressed either COL2A1 or COL10A1. 
Interestingly, as was observed in HACs, the only genes to show a consistent significant 
difference in expression after knockdown of GNL3 were ADAMTS4, which showed an 
increase in expression in all three patients (P ≤ 0.0001), and ADAMTS5 which showed a 
decrease in expression in all three patients (P ≤ 0.0001 patients 199 and 200, P = 0.02 in 
patient 201; Figures 7.11 - 7.13).  
 
  
 
 
 
 
 Patient number  
Gene 199 200 201 Pooled 
ACAN 0.03    " 0.0002     " 0.95 0.06 
COL2A1 n/a n/a n/a n/a 
SOX9 <0.0001    ! 0.85 0.25 0.41 
MMP1 <0.0001    " <0.0001    " 0.12 0.04 
MMP9 0.49 0.56 0.52 0.87 
MMP13 0.02    ! 0.07 0.25 0.45 
 
ADAMTS4 0.0001   ! <0.0001    ! 0.0001    ! 0.04 
ADAMTS5 <0.0001   " <0.0001    " 0.02    " 0.04 
TIMP1 0.07 0.03    " 0.79 0.87 
RUNX2 <0.0001    ! 0.0002    ! 0.13 0.20 
COL1A1 0.0001    ! 0.02    " 0.25 0.78 
COL10A1 n/a n/a n/a n/a 
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7.4 Discussion 
 
The aim of this chapter was to assess whether the association signal at chromosome 3p 
marked by a missense polymorphism, rs11177, correlated with expression of GNL3 
using joint tissues from patients who had undergone joint replacement for primary OA.  
Mutations that effect GNL3 protein conformation can have an effect on the ability 
of its coiled coil domain to bind to MDM2, and mutations in the GTP-binding region of 
GNL3, which is responsible for its localisation in the nucleolus, causes it to be 
redistributed to the nucleoplasm (238), where is exists in a protein complex with p53, 
inhibiting its effects (235). The rs11177 SNP confers an Arg-Gln substitution at 
position 39 in the amino acid sequence, however a database search of the effect the 
amino acid change has on GNL3, and modelling of the GTP-binding region suggested 
that there was no effect on the protein and therefore should have no effect on its ability 
to interact with MDM2 or p53.  
The results of AEI analysis demonstrated that there is consistently reduced 
expression of GNL3 for the risk allele (A) indicating that GNL3 is subject to a cis-acting 
eQTL mediated by rs11177 or a SNP in LD with it. Blood cDNA from three patients 
without any evidence of OA were also studied and showed no AEI however all the joint 
tissues studied did show AEI,  implying that this may be a joint specific effect. In 
addition to this the NOF cartilage sample assessed did demonstrate AEI, and there was 
no difference in expression of GNL3 between cartilage from OA and NOF patients, 
implying that this may not be OA-specific.  
The role of GNL3 in cellular homeostasis could make it important in OA 
pathogenesis. Maintaining a fine balance of GNL3 levels is essential for cellular 
homeostasis and when GNL3 levels become imbalanced p53 can be activated to halt cell 
growth and proliferation (238). If the number of stem cells and their decision to 
differentiate is disrupted either during embryonic development or in adults, premature 
senescence can occur (232).  Therefore, if there is reduced expression of GNL3, as with 
the OA risk allele, then this could have an impact on the number of MSCs and 
subsequently disrupt differentiation into chondrocytes.   
Of the 12 genes that were assessed for difference in expression following siRNA- 
mediated knockdown of GNL3, ADAMTS4 and 5 demonstrated consistent results for all 
human articular chondrocyte (HAC) and  mesenchymal stem cell (MSC) patients.  
Expression of ADAMTS4 was significantly increased in all patients and expression of 
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ADAMTS5 was significantly decreased.  ADAMTS 4 and 5 are members of the 
disintegrin and metalloproteinase with thrombospondin motifs family of aggrecanases, 
which have an important role in cartilage destruction in OA (244, 245). ADAMTS4 has 
been shown to be overexpressed both at the mRNA level in OA chondrocytes and at the 
protein level by immunohistochemistry in OA cartilage (246), supporting the results 
demonstrated in this chapter, namely, the risk allele of rs11177 (A) correlates with 
decreased expressed of GNL3 and when GNL3 is knocked down in both chondrocytes 
and MSCs ADAMTS4 expression is increased. However, ADAMTS5 expression was 
significantly decreased after GNL3 knockdown, and ADAMTS5-siRNA knockdown has 
been demonstrated to have a protective effect on cartilage degradation in human 
chondrocytes after aggrecan loss was significantly reduced (247). It is possible that the 
ADAMTS5 expression levels observed in the knockdown experiments in this chapter 
occur as a response to increased ADAMTS4 expression; Song et al. stated that the 
activity of ADAMTS5 may make aggrecan more susceptible to cleavage by ADAMTS4 
(247), so ADAMTS5 levels may be reduced in attempt to attenuate aggrecan 
degradation. Due to time constraints, the protein levels of ADAMTS4 and 5 were not 
assessed following GNL3 knockdown. In the future it would be beneficial to carry out 
western blotting to ascertain whether the significant difference in mRNA expression 
levels of ADAMTS4 and 5 was also demonstrated at the protein level, and to see if there 
is any affect on aggrecan levels. In addition, it would be worthwhile to differentiate the 
MSCs into chondrocytes following knockdown of GNL3, in order to see what effect 
reduced GNL3 may have on the cells ability to form cartilage. Unfortunately this was 
not possible due to the short amount of time remaining.  
As already mentioned, GNL3 overexpression also has effects on the cell cycle 
(237, 238) so the next logical step would be to overexpress GNL3 in HACs and 
differentiated MSCs and measure the expression of the same panel of 12 genes analysed 
for GNL3 knockdown, to observe the effects of GNL3 overexpression.  
 
In conclusion, the data reported in this chapter demonstrates that GNL3 is subject 
to a cis-acting eQTL potentially mediated by rs11177 and that GNL3 has a role in both 
chondrocytes and MSCs. There are two other genes at the 3p locus, GLT8D1 
harbouring the most significant signal (rs6976, P = 7.24x10-11) and a signal in TP63, 
(rs12107036, P = 6.71x10-8). This chapter has highlighted the need for further 
molecular analysis of these genes at the 3p locus to identify the variant responsible for 
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the observed AEI, and for further functional analysis of GNL3 in order to elucidate a 
possible role in the pathogenesis of OA.  
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Chapter 8: General Discussion 
 
        As more OA susceptibility loci are being identified it is becoming apparent that the 
majority of associated alleles are in non-coding regions and therefore contribute to risk 
by influencing gene expression (248). Recently, genetic research has shifted away from 
investigating protein structure altering polymorphisms, and most studies now focus on 
polymorphisms that regulate expression of genes, an excellent and well-characterised 
example of which is rs143383, a T-C transition in the 5´UTR of GDF5 (249). AEI 
analysis of rs143383 revealed that the OA-associated T allele showed lower GDF5 
expression in all joint tissues (250, 251) and four trans-acting factors (Sp1, Sp3, P15 
and DEAF-1) were later found to bind to the alleles of rs143383 and decrease 
expression of GDF5 (252).  
 
In this study, the expression patterns of genes at OA-associated loci have been analysed 
in joint tissues in order to identify potential eQTLs and regulatory variants.  
 
8.1 Key Results 
 
Chapter 3: Gene expression analysis of the osteoarthritis susceptibility locus 
mapping to chromosome 7q22 
 
The aim of chapter 3 was to use expression analysis to assess whether the six genes at 
the chromosome 7q22 OA susceptibility locus are subject to cis-acting regulatory 
polymorphisms that could contribute to the association signal. The key results of the 
expression analysis were:  
Five of the six genes at the locus, PRKAR2B, HBP1, COG5, DUS4L and 
BCAP29, are expressed at a significantly lower level in OA cartilage compared 
to control cartilage. 
Reduced HBP1 expression in cartilage correlates significantly with carriage of 
the OA associated alleles, particularly in knee cartilage, the joint most relevant 
to the association signal.  
Reduced HBP1 expression in OA synovium correlates with carriage of the OA 
associated allele.  
These observed correlations were also seen at the allelic level.  
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Together the results from chapter 3 indicate that among the six genes at the locus, HBP1 
can be prioritised as the potential target of the OA susceptibility at chromosome 7q22, 
but there is still a need for further study to elucidate the causal variant.  
      One key observation from the arcOGEN study was that OA associations are often to 
a particular joint rather than to several different joints therefore stratification by joint is 
critical in the discovery of association signals and is essential to avoid false negative 
associations (119). The results from chapter 3 emphasise this, as the significant 
difference in HBP1 expression was particularly pronounced in knee cartilage.  
 
Chapter 4: Identification and analysis of a SMAD3 cis-acting eQTL operating in 
primary osteoarthritis  
 
The aim of this chapter was to assess whether carriage of the alleles of the OA 
associated SMAD3 SNP correlated with differences in expression. The key results from 
this chapter were: 
There was no evidence of a correlation between the OA-associated SNP and 
SMAD3 expression, implying that this is not the mechanism through which the 
association is operating.  
Consistently lower allelic expression was seen for the OA-associated G allele 
when AEI was studied using a proxy SNP, indicating that SMAD3 was subject to 
a cis-acting eQTL. 
Two 3!UTR SNPs were identified as potential mediators of this eQTL.  
 
This complex cis-regulation of SMAD3 expression is also seen in the GDF5 promoter 
where the transcriptional effect on rs143383 is dependent on a second SNP, rs143384, 
with decreased expression of the T allele of rs143383 only observed in individuals that 
are compound heterozygous for both SNPs (251). The A allele of a third SNP -41bp 
from the transcription start site, can neutralise the effects mediated by rs143383 (253). 
The results observed for SMAD3, like GDF5, indicate that expression of each allele is 
highly context specific and that effects on gene expression mediated by cis-acting 
regulatory sites are potentially modifiable by targeting other cis sites within the gene 
(253).  
              SNPs in the 3!UTR, such as the two functional SNPs identified in chapter 4, 
can affect microRNA (miRNA) binding sites. The study of miRNA in OA is an 
expanding field that has produced many interesting results, such as the two miRNAs, 
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miR-199a and miR-101.3, which regulate the COX2 gene (254), and miR-101, which 
regulates SOX9 (255). In particular, miR-140, which targets SMAD3 (256), but was 
shown not to bind near the functional SNPs identified in chapter 4, has been identified 
as a critical miRNA in OA. This is due to its specific expression in cartilage, its 
important role in cartilage development, the lower levels observed in OA and the 
accelerated OA development in miR-140 knockout mice (257, 258). A recent study 
found opposing results, that levels of miR-140 in OA are increased (259). The 
difference in miR-140 levels in OA cartilage is unexplained but Swingler et al. used 
femoral heads and all other studies have used knees (260-262), once again highlighting 
the importance of stratification by joint in studies.  
 
The OA-associated SNP in SMAD3 did not show a correlation with expression in adult 
joint tissues but may show an effect in younger tissues. This highlights that future 
studies should not be confined to aged tissue samples but should also incorporate 
developmental tissues such as mesenchymal stem cells to identify possible eQTLs that 
are only operating during development.  
 
Chapter 5: A SMAD3 cis-acting eQTL identified in osteoarthritis is also operating 
in aneurysms and osteoarthritis syndrome  
 
In chapter 5 it was the aim to investigate the 3!UTR SNPs identified in chapter 4 as 
potential mediators of the cis-acting eQTL in OA joint tissues. The key result of this 
chapter was that the SMAD3 eQTL is also operating in VSMCs derived from the aortic 
tissue of an AOS patient. Despite the small number of patient samples studied in this 
chapter, AEI was detected in VSMCs and is therefore likely to be of direct relevance to 
this syndrome.  
Performing a comparison of the inheritance of the SMAD3 eQTL identified in chapter 4 
between AOS patients may establish whether the eQTL accounts for some of the 
phenotypic variability observed in AOS. 
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Chapter 6: Analysis of DOT1L, a gene associated with hip OA. 
 
As previously mentioned in the introduction, heterogeneity in case ascertainment can 
make association studies difficult. The study of endophenotypes, which are measurable 
intermediate phenotypes generally closer to the role of the gene product than the disease 
status (263), often provide much greater power to localise and identify disease-related 
eQTLs than disease status alone and are increasingly being used as endpoints for 
analyses to uncover OA susceptibility (129). The aim of this chapter was to assess 
whether expression of DOT1L, identified in a study of endophenotypes specifically 
analysing joint-space narrowing in OA patients (132), and found to be associated with 
OA at genome-wide significance in a subsequent study (113), correlated with genotype 
at the OA associated SNP in OA joint tissues. The key result of this chapter was that 
there was no evidence of a correlation between the OA-associated SNP and expression 
of DOT1L. 
  
 
Chapter 7: Genetic and functional analysis of GNL3, a gene at an OA susceptibility 
locus on chromosome 3p.  
 
The aim of this chapter was to assess whether the association signal at chromosome 3p 
marked by a missense polymorphism, correlated with expression of GNL3. Following 
this, GNL3 was knocked down in human cells and expression levels of a panel of genes 
were tested to see what affect the reduction in GNL3 had. The key results of this chapter 
were: 
AEI analysis demonstrated a consistently reduced expression of GNL3 for the 
risk allele indicating that GNL3 is subject to a cis-acting eQTL mediated by the 
OA-associated SNP, or a SNP in LD with it.  
Of the 12 genes that were assessed for difference in expression following 
siRNA- mediated knockdown of GNL3, ADAMTS4 demonstrated a consistent 
significant increase in expression for all patients, and ADAMTS5 demonstrated a 
consistent significant decrease in expression for all patients.  
 
The data reported in this chapter demonstrates that GNL3 is subject to a cis-acting 
eQTL, correlating with genotype at the OA-associated SNP, and that GNL3 has a role in 
both chondrocytes and MSCs. 
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There has been much interest in the role of ADAMTS4 and 5 as therapeutic targets in 
OA (264), as the ADAMTSs are responsible for most of the aggrecan degradation in 
cartilage (265) and are 1000 times more efficient at cleaving aggrecan than any other 
enzyme (Gilbert 2007). Mice whose specific aggrecanase cleavage site in aggrecan was 
mutated to resist ADAMTS5 activity demonstrated diminished aggrecan loss and 
cartilage erosion in mice, and cartilage repair appeared to be stimulated (266). This has 
implications for ADAMTS5 as a therapeutic target for OA treatment however, due to 
the differences in expression and regulation of ADAMTS5 in humans compared to mice, 
blocking ADAMTS5 action may not have the same protective effect in humans. A 
better understanding of human ADAMTS4 and 5 regulation is required in order to 
further investigate their potential therapeutic use, and the effect GNL3 knockdown has 
on ADAMTS4 and 5 expression may give some insight into elucidating their regulation.  
         AEI at the OA-associated SNP consistently demonstrated reduced expression for 
the risk allele, however overall GNL3 expression showed no correlation with carriage of 
this allele. This effect has also been demonstrated for COL11A1 (267), and highlights 
that overall expression studies may not be sensitive enough to pick up slight differences 
in expression between the two alleles and should not be solely relied upon to indicate 
the presence of an eQTL. 
     Due to time constraints, western blotting to determine the protein levels of 
ADAMTS4 and 5 were not performed following GNL3 knockdown to confirm that the 
expression differences were also observed at the protein level. 
 
 
 
8.2 Future work 
 
Overall, the data reported in chapter 3 clearly demonstrates the need for a 
comprehensive molecular analysis of potential cis-acting regulatory elements of HBP1 
in order to identify the actual functional variant(s) and to elucidate their haplotypic 
relationship to both the OA-associated SNPs. The fact that the results of the AEI 
analysis show an incomplete correlation between genotype suggests that there may be 
multiple cis-acting regulatory polymorphisms interacting to modulate the expression of 
HBP1. In the future, SNPs in HBP1 in high LD with the OA-associated SNPs should be 
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subject to haplotype analysis, as was carried out for SMAD3 SNPs in chapter 4, in order 
to identify the causal variant.  
GPR22 was not expressed in any of the OA joint tissues investigated in chapter 
3. This may be because it is expressed earlier in development and so it would be 
beneficial to assess whether there is a correlation between the OA-associated alleles and 
GPR22 expression in a developmental tissue such as MSCs.  
This approach would also be useful for further investigation of SMAD3 and DOT1L. 
Since there was no evidence of a correlation between the OA-associated alleles and 
SMAD3 or DOT1L expression in adult OA joint tissues it is possible that the 
associations are operating during development.  
          In addition to ascertaining whether the significant difference in mRNA expression 
levels of ADAMTS4 and 5 was also demonstrated at the protein level, it would be 
informative to see if there is any effect on aggrecan protein levels. It would also be 
worthwhile to differentiate the MSCs into chondrocytes following knockdown of 
GNL3, in order to see what effect reduced GNL3 may have on the cells ability to form 
cartilage.  
GNL3 overexpression also has effects on the cell cycle (237, 238) so the next 
logical step would be to overexpress GNL3 in HACs and differentiated MSCs and 
measure the expression of the same panel of 12 genes analysed for GNL3 knockdown, 
to observe the effects of GNL3 overexpression.  
 
For both HBP1 and GNL3 further investigation is required to identify which of 
the potential SNPs is causing the observed AEI at these loci. The next step would be to 
identify SNPs in perfect LD with the HBP1 and GNL3 SNPs that could be regulating 
the eQTLs and carry out functional investigations such as were used in the investigation 
of the SMAD3 eQTL (Chapter 4). If there are many potential SNPs the search can be 
narrowed to likely candidates with databases such as ENCODE and RegulomeDB, or if 
like 7q22 there is a region of high LD, trans-ethnic fine-mapping can be utilised to 
narrow the search for functional variants. Patterns of LD vary across ancestry groups 
due to divergent evolutionary and migratory histories (268). This difference in LD 
structure between ethnic groups can be exploited to fine-map functional variants. For 
example, in a study of cholesterol levels, six variants in high LD with one another in 
European and Asian cohorts were narrowed to one functional variant after an African 
American cohort was found to have no other SNPs in high LD with it (268).  
! 144!
Standard methods to investigate functionality of a SNP, such as luciferase 
reporter assays and electrophoretic mobility shift assays (EMSAs), as used to identify 
trans-acting factors for GDF5 (252), only give us an idea of how the polymorphisms 
behave in vitro. As mentioned previously, with regard to polymorphisms in the SMAD3 
3!UTR and the GDF5 promoter, the cellular context of a polymorphism is paramount. 
This is demonstrated by the SMAD3 luciferase reporter assays, which revealed that the 
3!UTR SNPs behave differently in the two immortalised cell lines analysed. The next 
challenge in genetic research, after confirming functionality of variants in vitro, is 
performing allele editing on the whole genome to see what a variants actual effect on a 
human somatic cell is. This introduction of targeted genome sequence changes into 
living cells and organisms is a potential avenue for therapy of genetic diseases (269). 
One way to achieve genome editing is by using nucleases, composed of a customisable 
sequence-specific DNA-binding domain fused to a nuclease that cleaves DNA inducing 
double strand breaks (DSBs) into specific DNA sites. The DSBs are repaired by 
mechanisms that can be exploited to create sequence alterations at the cleavage site 
(270). Normal cellular repair of DSBs by non-homologous end joining (NHEJ) or 
homology-directed repair (HDR) can be exploited to introduce several types of genomic 
alterations including point mutations, deletions, insertions, duplications and 
translocations (270). NHEJ repair rapidly and efficiently ligates the two broken ends, 
but because it is an error prone pathway that often results in small insertions or 
deletions, it can be harnessed to knock out genes by creating a DSB in a coding exon 
and hence disrupting the open reading frame (271, 272). HDR is a more accurate repair 
pathway, and by providing donor DNA that shares homologous sequence to the target 
gene, the cellular repair machinery will use this template for HDR, permitting the 
transfer of sequence information from the donor to the gene of interest (272). The vast 
majority of targeted genome editing has been performed using zinc finger nucleases 
(ZFNs) but transcription activator-like effector nucleases (TALENs) have rapidly 
emerged as an alternative to ZFNs (270).  TALENs have been successfully used to 
induce gene editing in C-C chemokine receptor 5 (CCR5), used by HIV to infect T-
cells, in a mammalian cell line (273). TALENs have also been successfully transfected 
into human CD4+ T cells to edit IL2Rγ mutations, which cause severe combined 
immunodeficiency (SCID; 274). However the use of TALENS is limited by the need to 
engineer specific proteins for each target site (275). A more versatile system for genome 
editing is clustered, regularly interspaced, short palindromic repeats (CRISPRs) and 
CRISPR-associated (Cas) nucleases, which are essential components of nucleic acid-
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based adaptive immune systems that are widespread in bacteria (275, 276). CRISPR 
systems consist of a series of short repeats separated by sequences that are incorporated 
from invading DNA elements. These CRISPR loci are transcribed and the transcripts 
are processed into a library of small CRISPR RNAS (crRNAs), each containing a guide 
sequence complementary to a fragment of incorporated foreign DNA (269, 276). Each 
crRNA hybridises with a second RNA, known as the trans-activating crRNA 
(tracrRNA), and these two RNAs complex with the one or more Cas proteins. The 
resulting ribonucleoprotein complex patrols the intracellular environment for targets 
that are complementary to the crRNA-guide sequence (276). In the simplest of these 
systems the ribonucleoprotein complex contains only one Cas protein, Cas9 (269), and 
the DNA-cleaving activity of CRISPR-Cas9 is programmed with a single guide RNA 
(sgRNA) that recognises specific DNA sequences (275). CRISPR RNA-guided 
nucleases are easier to use than TALENs or ZFNs as they rely on Watson-Crick base 
pairing therefore eliminating the need for protein engineering (276). 
        These approaches can be used to create entire human cell lines bearing specific 
single-nucleotide changes identified by large scale GWAS, ENCODE or other 
sequencing projects, potentially enabling the study of gene function and/or the 
modelling of disease causing mutations through the creation of a point mutation that is 
characteristic, for example, of a known disease predisposing allele such as the ones 
investigated here (270, 271). Additionally, with the use of CRISPRs, multiple sgRNAs 
can be introduced simultaneously in order to edit multiple genes (275). This has been 
demonstrated successfully in cynomolgus monkeys, where Pparγ and Rag1 were 
simultaneous disrupted (277). This technique could be particularly useful for OA where 
the disease is caused by the carriage of multiple risk alleles in multiple genes.  
 
 
8.3 Summary 
 
Using a number of expression techniques, this study has: 
Identified HBP1 from six genes at the 7q22 locus as being the most likely gene 
harbouring the association. 
Identified cis-acting eQTLs in SMAD3 that are active in joint tissues and 
vascular cells. 
Discovered a role for GNL3 in chondrocytes and mesenchymal stem cells and a 
potential role in the regulation of ADAMTS4 and 5.    
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Despite the relative success of GWAS, there is a gap between the many associated 
sequence variants and our understanding of how most of these variants contribute to 
complex trait biology (278). 
 
This is due in part to three main issues complicating the functional translation of GWAS 
signals: 
 
1) SNPs, either individually or in combination explain only a small fraction of the 
genetic variance of most complex traits and the phenotypic effects caused by the trait-
associated SNPs are subtle meaning that large numbers of independent studies are 
required to estimate the impact of each individual genetic variant (278); 2) Many signals 
identified are in loci containing a number of genes, often in a region of high LD, such as 
the 7q22 OA locus. This means that the signal could be marking one of many 
polymorphisms in any of the genes at the locus, making identification of the causal 
variant very difficult; 3) 74-95% of GWAS hits are in non-coding regions (279), 
preventing the direct interpretation of their functional effects (278). 
     Therefore the variants are likely to be involved in regulation of gene expression, 
which is dependent on cell type, developmental stage and environmental factors (278). 
SNPs that are associated with gene expression in disease-relevant tissues are more 
likely to be functionally relevant and the genes containing these SNPs are good 
candidates for the underlying pathological process (280, 281).  
 
     In addition to the issues surrounding further investigation of GWAS signals, 
associated loci are typically characterised by many common SNPs each of modest 
effect, which when considered together account for only a small proportion of the 
genetic variance of the trait (282). Low frequency and rare genetic variants not captured 
by GWAS may explain a substantial fraction of this missing genetic component of 
complex traits (278). Some of the missing heritability has also been attributed to 
imperfect tagging, for example, a weak GWAS signal might be indicating a variant that 
is much more strongly associated but which lies at some genomic distance (283).  
         Missing heritability, which is reflected in the small odds ratios and limited 
predictive value of these variants has raised questions about the ultimate applicability of 
GWAS findings to risk prediction and to potential therapies (283). 
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           The ultimate goal of performing genetic and genomic studies of any human 
disease is to identify and understand its pathogenesis (284). Yet despite the 
identification of over 2000 associations for over 300 complex traits and diseases, only a 
negligible fraction of discovered GWAS loci have been followed up in experimental 
studies (283). There needs to be an increase in the number of investigations into the 
molecular mechanisms of confirmed associations (278), and data from such studies will 
improve our interpretation of GWAS findings and their relation to specific cell 
populations (284). The technique of combining eQTL data with GWAS data 
significantly facilitates identification of potential causal variants (285), and has been 
applied to studies of other complex diseases, for example, autism in which expression 
of the SEMA5A gene was shown to correlate with disease-associated SNPs (286).  
Studies such as this have demonstrated the practicality and efficiency of eQTLs as a 
screening tool for candidate regulatory variants, and use of this expression information 
should move us closer to developing a more comprehensive understanding of the 
genetic basis for complex traits (287), and these new insights about the pathogenesis of 
complex diseases will help in the identification of novel therapeutic strategies to treat 
human disease (284). 
 
As discussed in section 8.2 there is a need for the SNPs identified in this thesis as 
modulating gene expression levels, to be further investigated using genome-editing 
techniques. For such techniques, specificity and delivery is paramount (278). 
The desired genome modification should occur with high frequency in the cell 
population, with no detectable off-target effects (278). Light inducible transcriptional 
effectors (LITEs) offer exciting possibilities for studying the function and regulation of 
mammalian genomes (288). LITEs consist of the light sensitive photoreceptor 
cryptochrome 2 (CRY2) fused to a customisable DNA-binding domain i.e TALENs or 
CRISPR/Cas9 systems. Illumination with blue light triggers a conformational change in 
CRY2 and subsequently recruits an effector to the target locus to mediate transcriptional 
modulation (288).  Importantly, the construct allows spatially and temporally precise, 
reversible and non-invasive modulation of gene transcription (278). Multiple implicated 
GWAS signals, such as the many OA-associated SNPs, can potentially be disrupted in 
combination to examine their interaction or synergistic effects (278). 
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Overall, this thesis has demonstrated that OA tissues are subject to a range of regulatory 
elements that can influence disease, and that by combining GWAS and expression data 
the search for causal variants can be narrowed.  
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Chapter 9: Appendix  
 
9.1 Tables 
 
 
Table A1: The 201 patients used in this study.  
Patient Sex Age at 
surgery 
(years)  
Joint 
replaced at 
surgery 
Tissue 
extracted 
1 F 75 H Cn 
2 F 67 K Cn 
3 M 69 K Cn 
4 F 77 H Cn 
5 F 73 K Cn 
6 M 71 K Cn 
7 F 73 K Cn 
8 F 64 H Cn 
9 F 80 H Cn 
10 F 51 H Cn 
11 M 71 H Cn 
12 F 56 H Cn 
13 F 67 H Cn 
14 F 83 H Cn 
15 F 60 K Cn 
16 F 67 K Cn 
17 F 78 H Cn 
18 M 62 K Cn 
19 F 72 K Cn 
20 M 74 K Cn 
21 F 83 H Cn 
22 M 50 K Cn 
23 F 76 H Cn 
24 M 79 K Cn 
25 F 60 H Cn 
26 M 67 K Cn 
27 M 85 H Cn 
28 M 79 K Sy 
29 M 76 K Cn 
30 F 82 H Cn 
31 F 71 K Cn, Sy 
32 F 72 H Cn 
33 F 42 K Cn 
34 F 72 H Cn 
35 F 67 H Cn 
36 F 70 H Cn 
37 F 70 H Cn 
38 F 60 H Cn 
39 F 74 H Cn 
40 M 53 K Fp, Sy 
41 F 50 H Cn 
42 M 63 K Cn, Fp 
43 F 78 H Cn 
44 F 81 K Cn 
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45 F 50 K Cn 
46 M 76 K Cn 
47 M 69 K Cn, Fp 
48 M 76 K Cn, Fp 
49 M 82 K Cn, Fp 
50 F 55 K Cn, Sy 
51 F 68 K Fp 
52 M 75 K Sy 
53 M 63 K Fp 
54 F 81 K Cn, Sy 
55 F 68 K Cn 
56 F 65 K Fp 
57 F 63 K Cn 
58 M 98 K Fp 
59 M 75 K Sy 
60 F 79 K Me 
61 F 69 K Me 
62 F 74 H Fp, Li 
63 M 57 K Cn 
64 M 85 K Fp 
65 F 64 K Fp, Sy, Me 
66 M 57 H Cn, Te 
67 F 78 K Fp, Sy, Li 
68 F 65 K Sy, Me 
69 M 72 K Cn 
70 M 65 H Li 
71 M 63 K Fp 
72 M 69 K Cn, Sy 
73 F 72 K Sy 
74 M 74 K Cn, Fp, Sy 
75 F 67 K Cn 
76 F 69 K Cn, Fp 
77 F 52 H Cn 
78 F  64 K Sy 
79 M 56 K Sy 
80 M 57 K Cn 
81 F 61 H Cn 
82 F 60 K Cn, Fp 
83 F 77 K Cn 
84 F 66 K Cn 
85 M 63 K Cn 
86 M 77 K Cn 
87 F 71 K Fp 
88 M 82 K Cn 
89 F 78 K Cn, Sy 
90 M 82 K Cn 
91 M 56 K Cn, Sy 
92 M 46 K Cn 
93 M 56 K Cn, Sy 
94 F 54 K Cn, Sy 
95 F 62 K Fp 
96 M 71 K Cn 
97 F 58 H Cn 
98 F 69 H Cn 
99 M 63 K Cn 
100 F 71 H Cn 
101 M 70 K Cn 
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102 M 67 K Cn, Sy 
103 F 80 K Cn 
104 F 67 K Cn, Fp 
105 M 71 K Fp 
106 F 46 K Cn 
107 F 62 K Cn 
108 F 58 K Cn 
109 F 59 K Cn 
110 M 64 K Cn 
111 F 81 K Cn 
112 F 80 K Cn 
113 F 64 K Cn 
114 F 78 K Cn 
115 F 61 K Cn 
116 F 82 K Cn 
117 F 80 K Cn 
118 F 59 K Cn 
119 F 71 H Cn 
120 M 74 K Cn 
121 F 74 H Cn 
122 M 72 K Cn 
123 M 72 K Cn 
124 M 68 H Cn 
125 F 72 H Cn 
126 M 69 K Fp 
127 M 68 K Fp 
128 M 58 K  Fp, Li 
129 M 75 K Cn, Fp, Sy 
130 F 60 K Fp 
131 M 76 H Cn 
132 M 71 K Fp 
133 F 73 K Sy 
134 M 66 K Fp 
135 F 58 K Fp 
136 F 69 K Sy 
137 F 82 K Fp 
138 F 81 K Fp, Me 
139 F 54 H Li 
140 M 68 H Sy 
141 M 72 K Sy 
142 M 85 H Sy 
143 F 72 H Bn 
144 F 70 K Fp, Li 
145 F 62 K Fp 
146 M 62 K Fp 
147 M 69 H Sy 
148 F 67 H Sy 
149 F 88 K Fp 
150 M 58 K Fp 
151 F 82 K Fp, Sy 
152 F 62 H Cn 
153 F 76 H Cn 
154 F 76 H Cn 
155 F 55 H Cn 
156 F 76 H Cn 
157 F 89 K Fp 
158 F 50 K Fp 
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F, female; M, male; K, knee; H, hip; Cn, articular cartilage; Fp, 
infrapatellar fat pad; Sy, synovium; Li, ligament; Me, meniscus;  
Bn, bone; HAC, Human articular chondrocytes; MSC, 
mesenchymal stem cells.  
159 M 79 H Cn 
160 F 72 H Cn 
161 M 71 K Ca 
162 F 86 K Fp 
163 M 59 K Me 
164 F 71 K Fp 
165 F 64 K Cn 
166 M 86 K Cn 
167 F 85 H Cn 
168 M 83 H Cn 
169 F 69 H Cn 
170 F 71 H Cn 
171 F 69 H Cn 
172 F 81 H Cn 
173 F 72 H Cn 
174 F 84 H Cn 
175 M 78 H Cn 
176 F 94 H Cn 
177 F 84 H Cn 
178 F 84 H Cn 
179 F 68 H Cn 
180 F 52 H Cn 
181 F 80 H Cn 
182 F 86 H Cn 
183 F 52 H Cn 
184 F 73 H Cn 
185 F 89 H Cn 
186 F 82 H Cn 
187 F 82 H Cn 
188 F 91 H Cn 
189 M 79 H Cn 
190 M 84 H Cn 
191 F 82 H Cn 
192 F 91 H Cn 
193 F 42 / Blood 
194 F 25 / Blood 
195 F 28 / Blood 
196 F 68 K HAC 
197 M 54 K HAC 
198 M 65 K HAC 
199 F 22 / MSC 
200 M 26 / MSC 
201 F 24 / MSC 
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Table A2: Primers used to amplify cDNA for standard qualitative gene expression analysis. n/a denotes primers that do not amplify DNA fragments.  
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Forward primer 5!- 3! Reverse primer 5! - 3! MgCl2 Annealing 
temperature 
Fragment size 
 
     cDNA DNA 
PRKAR2B GATTCACAAGGCGTGCCTCAG CCTTGATCAATTACATGCTCCC 2 mM 60°C 232bp n/a 
HBP1 AATACCCAAGATCATCTTGG GAAGGCTGGTTCACTCTTCG 2 mM 60°C 152bp 570bp 
COG5 GGAGATGCAAGTCAGGTGATTGG ACAGAAGTGAGTAAGGGTTGCAC 2 mM 55°C 149bp n/a 
GPR22 GCATGCAGTTGAAGTATTGG GAGACACTTGAAAGCTTAACGG 2 mM 60°C 238bp n/a 
DUS4L AGCCAGTGCACTATGATTCC AACACATGTAAGGAGTCCCG 2 mM 55°C 249bp n/a 
BCAP29 GTCTGGGGTAAAATTGCAAC GTTTCATCTGTGTGTGTTCATAG 2 mM 55°C 172bp n/a 
HPRT1 CTGAACGTCTTGCTCGAGATG TGCGACCTTGACCASTCTTTGG 2 mM 60°C 247bp n/a 
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Table A3:  Real time PCR primer and probe sequences for quantitative gene expression analysis.  
 
Gene Forward primer 5!-3! Reverse primer 5!-3! Probe 5!-3! 
HPRT1 TGCTGAGGATTTGGAAAGGG ACAGAGGGCTACAATGTGATG AGGACTGAACGTCTTGCTCGAGATG 
GAPDH ACATCGCTCAGACACCATG TGTAGTTGAGGTCAATGAAGGG AAGGTCGGAGTCAACGGATTTGGTC 
18S CGAATGGCTCATTAAATCAGTTATGG TATTAGCTCTAGAATTACCACAGTTATCC TCCTTTGGTCGCTCGCTCCTCTCCC 
PRKAR2B TGATCAAGGTGACGATGGTG TGTACATTAAGGCCAGTTCGC TGTGATGGTGTTGGAAGATGTGTTGGT 
HBP1 ACACCAGTAAGACACGAAAGG ACAGTGCCAGACAGTTGAAG CCAGGAATTGCACCATCCCAAATCA 
COG5 TGGGATTGAGTCGTTGGAAG CTGAAGTCTTGCTAGTTGTGC CCCTGTAAAGCCCCAATTCTCGTCT 
GPR22 GAAATCCATCAGCCAACTAAATCTC CACATTCTTTTGGAGCAGTTGG TCCCTGACAACAGTGAAGTAGCTGTG 
DUS4L TGGTAAAAGTCTGTGCCCC TGGTAAATTCGCTGTCTCTGG ACCAATGATTGTTGCCGCTGATTTTGT 
BCAP29 TGGAACAAGGCTTTCCTTACC TGTGTTCATAGGCATCAGGTC TCATACCATTGAGAAGAGCTCCACCAG 
SMAD3 ACCAGTTGACCCGAATGTG CTTGTCAAGCCACTGCAAAG TCTGTCTCCTGTACTCCGCTCCC 
DOT1L CCAAGAAGAACCAAACTGCAC TCGGAGGTAGCTGGTAGAAC CCTCACCCCAGGATGCCTACAGA 
GNL3 AGCAGAAACTTGACAGGCAG GAATTCTGTTTGCCCGACTTG CCCAAACTCCTTTTCCATAGGTTCCACA 
ACAN TGTGGGACTGAAGTTCTTGG AGCGAGTTGTCATGGTCTG CTGGGTTTTCGTGACTCTGAGGGT 
COL2A1 AACCAGATTGAGAGCATCCG ACCTTCATGGCGTCCAAG AGACCTGAAACTCTGCCACCCTG 
SOX9 ACTTGCACAACGCCGAG CTGGTACTTGTAATCCGGGTG TCTGGAGACTTCTGAACGAGAGCGA 
MMP1 AAGATGAAAGGTGGACCAACAATT CCAAGAGAATGGCCGAGTTC CAGAGAGTACAACTTACATCGTGTTGCGGCTC 
MMP9 CGGCACTGAGGAATGATCTAAG CGAACTTTGACAGCGACAAG CCGCCACGAGGAACAAACTGTATCC 
MMP13 AAATTATGGAGGAGATGCCCATT TCCTTGGAGTGGTCAAGACCTAA CTACAACTTGTTTCTTGTTGCTGCGCATGA 
ADAMTS4 CTGGGTATGGCTGATGTGG TGGCTTGGAGTTGTCATGG TTCACTGCTGCTCATGAACTGGGT 
ADAMTS5 CAAGTGCGGAGTATGTGGAG GTCTTTGGCTTTGAACTGTCG TTTATGTGGGTTGCCCCTTCAGGA 
TIMP1 TTCTGCAATTCCGACCTCG TCATAACGCTGGTATAAGGTGG TTGACTTCTGGTGTCCCCACGAAC 
RUNX2 AGCAAGGTTCAACGATCTGAG TGAAGACGGTTATGGTCAAGG CGGAGTGGACGAGGCAAGAGTTTC 
COL1A1 CCCCTGGAAAGAATGGAGATG TCCAAACCACTGAAACCTCTG TTCCGGGCAATCCTCGAGCA 
COL10A1 CAAGGCACCATCTCCAGG TGGGCATTTGGTATCGTTCAG ACTCCCAGCACGCAGAATCCAT 
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 Table A4: Primers used to amplify fragments for RFLP.
Gene SNP Primers 5´ - 3´ MgCl2 Annealing 
temperature 
Fragment 
size 
 
HBP1 rs7794598 F R 
GCCTTCCCTCATCACCATTGGAAGGAGGAAACACCAGT 
GTGAGACTACTTCCTATGAGG 2 mM 55°C 136bp 
COG5 rs3815148 F R 
TGACCTGTTAGTTGGCATC 
TGTCTGAGGTAATTACAGG 2mM 59°C 308bp 
DUS4L rs711442 F R 
GACTAGACTTCCCAAATAATTTTAATGTA 
GATCAGGATGTTTGAACCACTGGG 2 mM 55°C 225bp 
DUS4L rs4730250 F R 
CAGCTGGTAAAAGTCTGTGCC 
CTTAGGACCCATAATTGCACTC 2 mM 55°C 378bp 
SMAD3 rs12901499 F R 
GAAAGCCACCACTCTATCGTTTC 
ATGGTGTTTTGTTCACTGTCAGGAGAGAAGAC 2 mM 55°C 185bp 
SMAD3 rs8031440 F R 
CTGAGTGAGACCCAGCAAC 
GAGCTAGATCATCTTATATC 2 mM 55°C 255bp 
SMAD3 rs1052488 F R 
GAGATGATGGGCTAAACAGG 
CTAGAGTATACATTACTTATGC 3 mM 55°C 141bp 
DOT1L rs12982744 F R 
GTAGAACCCAGTGCTTCCGGC 
CTGCGTGATTTGACTGCGTG 2 mM 55°C 245bp 
GNL3 rs11177 F R 
CAGTGACTAGTGTTGTTACC 
GTTTCTCACTTGAATTCTGC 2 mM 60°C 297bp 
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Table A5: Restriction enzymes, buffers and reaction conditions for RFLP.  
 
 
 
 
 
 
Table A6: The SNPs analysed in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*HapMap CEU 
 
 
 
 
 
 
 
 
 
Gene SNP Restriction  
endonuclease 
NEB 
buffer 
Temperature BSA Digested  
fragments 
HBP1 rs7794598 BspHI 4 37°C  94bp/42bp 
COG5 rs3815148 MboII 4 37°C  205bp/103bp 
DUS4L rs4730250 DraII 4 37°C  285bp/103bp 
DUS4L rs711442 RsaI 4 37°C  167bp/44bp/28bp 
SMAD3 rs12901499 BccI 1 37°C ! 147bp/38bp 
SMAD3 rs8031440 BstNI 2 60°C ! 130bp/73bp 
SMAD3 rs1052488 NsiI 3 37°C  121bp/19bp 
DOT1L rs12982744 MspI 4 37°C  144bp/101bp 
GNL3 rs11177 AciI 3 37°C ! 132bp/165bp 
Gene SNP Location Alleles Allele Frequency* 
   (major/minor) Major Minor 
COG5 rs3815148 Intronic A/C 0.783 0.217 
DUS4L rs4730250 Intronic A/G 0.827 0.173 
DUS4L rs711442 3!UTR C/T 0.531 0.469 
HBP1 rs7794598 Exon 7 C/T 0.781 0.219 
SMAD3 rs12901499 Intronic G/A 0.531 0.469 
SMAD3 rs8031440 3!UTR G/A 0.770 0.230 
SMAD3 rs1052488 3!UTR T/C 0.739 0.261 
SMAD3 rs8025774 3!UTR C/T 0.770 0.230 
SMAD3 rs8031627 3!UTR G/A 0.770 0.230 
SMAD3 rs2278670 3!UTR C/T 0.770 0.230 
SMAD3 rs12595334 3!UTR C/T 0.770 0.230 
SMAD3 rs3743342 3!UTR C/T 0.770 0.230 
DOT1L rs12982744 Intronic C/G 0.625 0.375 
GNL3 rs11177 Exon 3 G/A 0.664 0.336 
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Table A7:  Primers used for AEI with the SNaPshot multiplex kit 
 
 
 
Table A8: Single base extension primer sequences.  
 
 
 
 
 
 
 
Table A9: Primers used to amplify DNA fragments for vector construction including restriction sites (underlined). 
 
 
 
 
Gene SNP Template Forward primer 5!-3! Reverse primer 5!-3! MgCl2 
concentration 
Annealing 
temperature 
Fragment 
size 
HBP1 rs7794598 DNA TCGAAGAGTGAACCAGCCTT GTGAGACTACTTCCTATGAGG 2 mM 60°C 152bp 
HBP1 rs7794598 cDNA TCGAAGAGTGAACCAGCCTT GAAGGCCAGGAATTGCACCATCC 2 mM 60°C 152bp 
DUS4L rs711442 DNA and cDNA GGCCATGTTTGCTGGGATATGAGGAAACC GATCAGGATGTTTGAACCACTGGG 3 mM 68.9°C 434bp 
Gene SNP Primer sequence 5!-3! 
HBP1 rs7794598 GGAGGAAACACCAGTAAGACA 
DUS4L rs711442 CTGTGGTTTCACTGTGGGTCTAAAAGT 
Gene  Encompassing 
SNPs 
Forward primer 5!-3! Reverse primer 5!-3! Annealing 
temperature 
Fragment 
size 
Restriction 
enzymes 
SMAD3 rs8025774 GGGGACTAGTCTTAAGTGAGCAGAACAGGTAG GGGGAAGCTTCATCCCAAGTCTATCCAGCTCAC 70°C 310bp SpeI, 
HIndIII 
SMAD3 rs8031440 
rs8031627 
rs2278670 
GGGGGAGCTCCATTAAATCAACTTTATCATATG GGGGACGCGTCGTGGGATAGGTCATTTTATAC 65°C 570bp SacI 
 MluI 
SMAD3 rs12595334 
rs3743342 
GGGGACTAGTGATCTATGGAAGTCGTGTC GGGGAAGCTTGAAAGGGAATAAAAGTTGGCTC 65°C 700bp SpeI, 
HindIII 
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Table A10: Restriction enzymes used for vector construction. 
 
 
 
 
 
 
 
Table A11: Primers used to sequence vector constructs and haplotyping. 
 
 
 
 
 
 
Table A12: Primers used for mutagenesis of SMAD3-luciferase vectors. Mutated alleles are shown underlined.  
 
 
 
 
 
 
 
 
 
Gene Restriction endonuclease NEB buffer Temperature BSA 
SMAD3 SpeI 4 37°C ! 
SMAD3 HindIII 2 37°C  
SMAD3 MluI 3 37°C ! 
SMAD3 SacI 1 37°C ! 
Gene Vector Forward primer 5!-3! Reverse primer 5!-3! 
SMAD3 pMIR report  AGGCGATTAAGTTGGGTA  ATTGCAACGATTTAGGTG 
SMAD3 pCR4 M13 GTAAAACGACGGCCAG T7 TAATACGACTCACTATAGGG 
Gene  SNP Change Forward primer 5!-3! Reverse primer 5!-3! 
SMAD3 rs12595334 T"C ATGTGATGAAATGACACGTTTGGCTGCAT ATGCAGCCAAACGTGTCATTTCATCACAT 
SMAD3 rs12595334 C"T ATGTGATGAAATGATACGTTTGGCTGCAT ATGCAGCCAAACGTATCATTTCATCACAT 
SMAD3 rs3743342 T"C CATGACATCTTCACCTTGCAGCTTGTGCT AGCACAAGCTGCAAGGTGAAGATGTCATG 
SMAD3 rs3743342 C"T CATGACATCTTCACTTTGCAGCTTGTGCT AGCACAAGCTGCAAAGTGAAGATGTCATG 
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Table A13: Primers used for haplotyping of SMAD3 cDNA from aneurysms-OA patients. 
 
 
 
 
 
 
Table A14: siRNA sequences. 
 
 
 Sense 5!-3! Antisense 5!-3! 
GNL3 siRNA AAGCUGUACUGCCAAGAACdTdT GUUCUUGGCAGUACAGCUUdTdT 
Control siRNA AAGCGCGCTTTGTAGGATTCdTdT GAAUCCUACAAAGCGCGCUUdTdT 
 
 
 
 
 
 
 
Forward primer 5!-3! Reverse primer 5!-3! Annealing temperature MgCl2 concentration Fragment size 
CCTGCAGCCAGTTACCTACTG GCAGGGCCATGCAGACCTC 70°C 2 mM 1060bp 
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